1
Approved, Date: 3 November 2017Janssen Research & Development *
Clinical Protocol
A Randomized, Active -Controlled, Open- Label, Flexible -Dose Study to Assess the Safety 
and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as 
Monotherapy in Pediatric Subjects with New or Recent -Onset Epilepsy
Protocol TOPMATEPY4067; Phase 3
Amendment INT -6
RWJ -17021 -000 (topiramate)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen 
Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these 
various legal entitie s; the sponsor is identified on the Contact Information page that accompanies the 
protocol.  
EudraCT NUMBER :2012 -001552 -19
Status: Approved
Date: 3November 2017
Prepared by: Janssen Research & Development, LLC 
EDMS No & Version: EDMS -ERI-21111756 , 14.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential.
[STUDY_ID_REMOVED]
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
2
Approved, Date: 3 November 2017TABLE OF CONTENTS
TABLE OF CONTENTS ................................ ................................ ................................ ............................... 2
LIST OF A TTACHMENTS ................................ ................................ ................................ ............................ 5
LIST OF IN -TEXT T ABLES A ND FIGURES ................................ ................................ ................................ 5
PROTOCOL A MENDMENTS ................................ ................................ ................................ ....................... 6
SYNOPSIS ................................ ................................ ................................ ................................ .................. 19
TIME AND EVENTS SCHE DULE ................................ ................................ ................................ .............. 25
ABBREVIA TIONS ................................ ................................ ................................ ................................ ......29
1. INTRODUCTION ................................ ................................ ................................ ................................ 30
1.1. COM PARATOR A GENT ................................ ................................ ................................ ................... 36
1.2. OVER ALL RA TIONA LE FO R THE STUDY ................................ ................................ ...................... 39
2. OBJECTIVES A ND HYPOT HESIS ................................ ................................ ................................ ...40
2.1. OBJECTIVES ................................ ................................ ................................ ................................ ....40
2.2. HYPOTHESIS ................................ ................................ ................................ ................................ ....40
3. STUDY DESIGN A ND RA TIONA LE................................ ................................ ................................ .40
3.1. OVERVIEW OF STUDY DE SIGN ................................ ................................ ................................ ......40
3.2. STUDY DESIGN RA TIONA LE................................ ................................ ................................ .......... 44
3.2.1. Blinding ................................ ................................ ................................ ................................ .......... 45
3.2.2. Active Control ................................ ................................ ................................ ................................ .45
4. SUBJECT SELECTION ................................ ................................ ................................ ..................... 46
4.1. INCLUSION CRITERIA ................................ ................................ ................................ ..................... 46
4.2. EXCLUSION CRITERIA ................................ ................................ ................................ .................... 48
4.3. PROHIBITIONS A ND RES TRICTIONS ................................ ................................ ............................ 51
5. TREA TMENT A LLOCA TION AND BLINDING ................................ ................................ ................. 52
6. DOSA GE A ND A DMINISTR ATION................................ ................................ ................................ ..53
7. TREA TMENT COMPLIA NCE ................................ ................................ ................................ ............ 55
8. PRESTUDY A ND CONCOMI TANT THERA PY................................ ................................ ................ 55
9. STUDY EVA LUATIONS ................................ ................................ ................................ .................... 57
9.1. STUDY PROCEDURES ................................ ................................ ................................ .................... 57
9.1.1. Overview ................................ ................................ ................................ ................................ ........ 57
9.1.2. Screening Phase ................................ ................................ ................................ ............................ 58
9.1.3. Open -Label Treatment Phase ................................ ................................ ................................ ........ 58
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
3
Approved, Date: 3 November 20179.1.4. Posttreatment Phase (Follow -Up)................................ ................................ ................................ ..59
9.1.5. Post-Study  Phase (Follow -Up)................................ ................................ ................................ ....... 59
9.2. PHARM ACOKINETICS ................................ ................................ ................................ ..................... 60
9.2.1. Sample Collection and Handling ................................ ................................ ................................ ....60
9.2.2. Analytical Procedures ................................ ................................ ................................ .................... 60
9.2.3. Pharmacokinetic Parameters ................................ ................................ ................................ ......... 60
9.3. SAFETY EVA LUATIONS ................................ ................................ ................................ .................. 60
10. SUBJECT COMPLETION/W ITHDRA WAL................................ ................................ ....................... 71
10.1. COM PLETION ................................ ................................ ................................ ................................ ...71
10.2. WITHDRA WAL FROM THE STUDY ................................ ................................ ................................ .71
11. STATISTICA L METHODS ................................ ................................ ................................ ................. 72
11.1. SUBJECT INFORM ATION................................ ................................ ................................ ................ 72
11.2. SAMPLE SIZE DETERMIN ATION................................ ................................ ................................ ....72
11.3. PHARM ACOKINETIC A NALYSES ................................ ................................ ................................ ...73
11.4. SAFETY A NALYSES ................................ ................................ ................................ ........................ 73
11.5. DATA MONITORING COMM ITTEE ................................ ................................ ................................ ..76
12. ADVERSE EVENT REPORT ING................................ ................................ ................................ ......76
12.1. DEFINITIONS ................................ ................................ ................................ ................................ ....76
12.1.1. Adverse Event Definitions and Classifications ................................ ................................ ............... 76
12.1.2. Attribution Definitions ................................ ................................ ................................ ..................... 78
12.1.3. Severity Criteria ................................ ................................ ................................ .............................. 78
12.2. SPECIA L REPORTING SI TUATIONS ................................ ................................ .............................. 78
12.3. PROCEDURES ................................ ................................ ................................ ................................ ..79
12.3.1. All Adverse Events ................................ ................................ ................................ ......................... 79
12.3.2. Serious Adverse Events ................................ ................................ ................................ ................. 80
12.3.3. Pregnancy ................................ ................................ ................................ ................................ ......81
12.4. CONT ACTING SPONSOR R EGARDING SA FETY ................................ ................................ .......... 81
13. PRODUCT QUA LITY COMP LAINT HA NDLING ................................ ................................ .............. 81
13.1. PROCEDURES ................................ ................................ ................................ ................................ ..81
13.2. CONT ACTING SPONSOR R EGARDING PRODUCT QUA LITY ................................ ..................... 82
14. STUDY DRUG INFORM ATION................................ ................................ ................................ ......... 82
14.1. PHYSIC AL DESCRIPTION OF STUDY DRUGS ................................ ................................ .............. 82
14.2. PACKA GING ................................ ................................ ................................ ................................ .....83
14.3. LABELING ................................ ................................ ................................ ................................ ......... 83
14.4. PREPA RATION, HA NDLIN G, AND STORA GE................................ ................................ ............... 83
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
4
Approved, Date: 3 November 201714.5. DRUG A CCOUNT ABILITY ................................ ................................ ................................ ............... 83
15. STUDY -SPECIFIC M ATERIA LS................................ ................................ ................................ ....... 84
16. ETHICA L ASPECTS ................................ ................................ ................................ ......................... 85
16.1. STUDY -SPECIFIC DESIGN CONS IDERA TIONS ................................ ................................ ............ 85
16.2. REGUL ATORY ETHICS CO MPLIANCE ................................ ................................ .......................... 87
16.2.1. Investigator Responsibilities ................................ ................................ ................................ .......... 87
16.2.2. Independent Ethics Committee or Institutional Rev iew Board ................................ ....................... 87
16.2.3. Informed Consent ................................ ................................ ................................ ........................... 89
16.2.4. Privacy of Personal Data ................................ ................................ ................................ ................ 90
16.2.5. Countr y Selection ................................ ................................ ................................ ........................... 91
17. ADM INISTRA TIVE REQUI REM ENTS ................................ ................................ .............................. 91
17.1. PROTOCOL A MENDMENTS ................................ ................................ ................................ ............ 91
17.2. REGUL ATORY DOCUMENT ATION ................................ ................................ ................................ .91
17.2.1. Regulatory Approval/Notification ................................ ................................ ................................ ....91
17.2.2. Required Pres tudy Documentation ................................ ................................ ................................ 92
17.3. SUBJECT IDENTIFICA TION, ENROLLMENT, A ND SCREENING LOGS ................................ ......92
17.4. SOURCE DOCUMENT ATION................................ ................................ ................................ ........... 93
17.5. CASE REPORT FORM COM PLETION ................................ ................................ ............................ 94
17.6. DATA QUA LITY A SSURAN CE/QU ALITY CONTROL ................................ ................................ .....94
17.7. RECORD RETENTION ................................ ................................ ................................ ...................... 95
17.8. MONITORING ................................ ................................ ................................ ................................ ....95
17.9. STUDY COMPLETION/TER MINA TION ................................ ................................ ............................ 96
17.9.1. Study Com pletion ................................ ................................ ................................ ........................... 96
17.9.2. Study Termination ................................ ................................ ................................ .......................... 96
17.10. ON-SITE A UDITS ................................ ................................ ................................ ....................... 97
17.11. USE OF INFORM ATION A ND PUBLICA TION ................................ ................................ ......... 97
REFERENCES ................................ ................................ ................................ ................................ ............ 99
ATTACHMENTS ................................ ................................ ................................ ................................ ....... 102
INVESTIGA TOR A GREEME NT................................ ................................ ................................ ............... 126
LAST PA GE................................ ................................ ................................ ................................ .............. 126
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
5
Approved, Date: 3 November 2017LIST OF A TTACHMENTS
Attachment 1: Habitual Activity Estimation Scale ................................ ................................ ............ 102
Attachment 2: Titration Schedules for Topiramate and L evetiracetam ................................ ........... 109
Attachment 3: Pharmacokinetic Collection and Handling Procedure ................................ .............. 112
Attachment 4: Labeling Instructions for Pharmacokinetic Samples ................................ ................ 114
Attachment 5: Shipment of Pharmacokinetic Samples ................................ ................................ ....115
Attachment 6: CBCL -Preschool ................................ ................................ ................................ ....... 116
Attachment 7: CBCL School Age ................................ ................................ ................................ .....118
Attachment 8: Colum bia Suicide Severity Sc ale: Baseline Version ................................ ................ 120
Attachment 9: Colum bia Suicide Severity Scale: Since Last Visit Version ................................ .....123
LIST OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Topiramate Monotherapy Target Total Daily Maintenance Dosing for Subjects 2 to 
<10 Years of Age ................................ ................................ ................................ ...................... 54
Table 2:  Volume of Blood to be Collected From Each Subject (mL) ................................ ...................... 57
FIGURES
Figure 1: Study Diagram ................................ ................................ ................................ .......................... 44
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
6
Approved, Date: 3 November 2017PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 21 November 2013
Amendment INT -1 11March 2014
Amendment INT-2 23April 2014
Amendment INT -3 15October 2014
Amendment INT -4
Amendment INT-510July2015
24August 2017
Amendment INT -6 3November 2017
Amendments are listed beginning with the most recent amendment.
Amendment INT-6(03November 2017)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union ,in that it does not significantly 
impact the safety or physical/men tal integrity of subjects, nor th e scientific value of the study.
The overall reason for the amendm ent: The overall objective of this amendm ent is to include minor changes and 
corrections for consistency within the protocol, and to align the protocol with the sponsor’s current protocol 
template.
Applicable Section(s) Description of Change(s)
Rationale: To clarify that tapering off of treatment after study completion or at early  withdraw al is not 
mandatory linked to the use of study drug but is also possible w ith commercially available product.
6. Dosage and 
Administration; 9.1.1. 
Overvie wThe term “study drug” was replaced by the generic drug name “topiramate or 
levetiracetam” to allow  the use of commercially ava ilable drug for tapering off.
Rationale: To clarify that the decision regarding subects’ eligibility to participate in the optional Post Study 
Follow -up phase is based on local dual energy x-ray absorptiom etry (DEXA )scan results (change in Z-score of -
0.5 or greater). This is because the central DEXA scan results are available only with delay, and the decision 
should be made on the day of the regular M12 visit.
3.1Overview  of 
Study Design; 9.1.1. 
Overvie wThe statement “… based on local DEXA scan results …” was added.
Rationale: Changes were made to align the protocol text per the sponsor’s current protocol template.
17.11 .Use of 
Information and 
PublicationOutdated text regarding Authorship of publications resulting from this study was 
updated to reflect change sto the International Committee of Medical Journal Editors 
(ICMJE )Recommendations .
Rationale: Minor errors w ere noted .
Throughout the 
protocolAbbreviations were updated per the sponsor ’sstyle guide
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
7
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
Protocol amendment 
table , Amendment 
INT-5
(24August 2017)The 24-hour urine collection was moved from Baseline/W1 visit to Screening period . 
This change in timing of urine collection was made in the synopsis (safety evaluations ), 
but, it w asnot captured in amendment table of Amendment INT -5.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
8
Approved, Date: 3 November 2017Amendment INT-5(24August 2017 )
This a mend ment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does impact the scientific 
value of the trial .
The overall reason for the amendm ent: The overall objective of thisamendment is to improve a 
slow er-than-expected study enrollment . At the current rate of subject randomization, the previously agreed -upon 
milestone for the study completion will not be met. Two major revisions, which should lead to a higher enrollment 
rate w ithout impacting the overall study objectives and data analysis ,will be implemented inthis amendment: 
The inclusion criterion # 2 w ill be expanded to allow  a higher number of seizures within a longer period 
prior to subject enrollment –from “up to 2 seizures within the last 3 months” to “up to 10seizures within 
the last 5 months” –and
An optional use of local laboratory evaluations as basis for randomization (in addition to the mandatory 
central laboratory evaluation), although the central laboratory evaluation results will be used for 
change -from -baseline analyses. The optional use of a local lab for th e evaluation of 25 -hydroxy -vitamin 
D, 1,25 -dihydroxy -vitamin D, Parathyroid hormone (intact) and IGF -1 might significantly reduce the 
duration of the screening period and consequently might increase the enrollment rate . Investigators have 
objected that a s creening period of up to 28 days before initiating a drug treatment for new -onset, pediatric 
seizure disorder is not a reasonable w aiting period for the subjects, their parents, and treating/referring 
physicians. It is expected that a shorter minimum scree ning period w ill improve the enrollment rate.
In addition, minor changes were included to specify theuse of local DEXA scan results for deciding about the 
subject’s eligibility to participate in the optional Follow -Up phase, and a clarification that the screening period 
should start no more than 35 days before baseline ,instead of “28 ± 7 days”, and may be as short as possible if all 
appropriate screening assessments will have been completed .
Applicable Section(s) Description of Change(s)
Rationale: The expansion of inclusion criterion #2 increases the number of eligible study participants and might 
lead to an increased enrollment rate without hazarding the study objectives. By allowing subjects to have at least 
1seizure, but no more than 10seizures in 5months (that is, a seizure frequency of approximately no greater than 
2seizure episode sper month), the loss of prospective subjects will be reduced , while the expected efficacy of 
monotherapy, using either of the two study drugs, would not be adver sely affected. Moreover, this revision is 
expected not to change the treatment that each patient would otherw ise receive if the patient were to receive 
treatment outside of the study.
Synopsis ,Study Population;
3.1 Overview  of Study Design;
4.1Inclusion Criteria ,
Criterion #2Inclusion criterion #2 w as revised to specify that s ubjects should have at least 1, 
but no more than 10, unprovoked seizures during the 5 months prior to 
screening .
Rationale: To reduce the duration of the screening period and, in consequence, a potential reduction of the time 
before the study drug treatment can be initiated.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
9
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
Time and Events Schedule, 
footnote “ k”;
9.1.1 Study Procedures, 
Overvie w, Table 2, footnote “ a”, 
footnote “c”;
9.3 Safety Evaluations, Clinical 
Laboratory TestsAn optional use of a local laboratory is allowed at screening for the decision 
regarding subject randomization for the following parameter s:
25-hydroxy -vitamin D;1,25-dihydroxy -vitamin D;Parathyroid horm one 
(intact) ;and IGF -1.
To reduce the duration of the screening phase , oneor moreof these laboratory 
parameters may be evaluated at the local laboratory ,at the discretion of the 
investigator .In such instance, the local laboratory instructions should be 
followed and local reference ranges should be applied. The local laboratory 
results should be used for decision regarding randomization . The central 
laboratory evaluation results will still be obtained and will be used for change -
from -baseline analys es. The additional use of a local laboratory might lead to an 
increase in blood volume to be drawn from the subject at screening.
Rationale: To ensure that the initial 24-hour urine collection will be completed before initiation of study drug 
therapy and the 24 -hour urine collection at Month -12during study drug therapy .
Time and Events Schedule, 
footnote “m ”;
9.3 Safety Evaluations, Clinical 
Laboratory TestsThe 24-hour urine collection was movedfrom Baseline /W1 visit to Screening 
period. It should be ensured that the initial 24-hour urine collection is completed 
before study drug therapy is initiated. Additionally ,it is clarified that the 
24-hour urine collection at Month 12 should be comp leted before the Month -12 
visit as this evaluation should be obtained during study -drug therapy. 
Rationale: To clarify that tapering off of treatment after study completion or at early withdraw al is not mandatory 
linked to the use of study drug but is also possible with commercially available product.
3.1 Overview  of Study Design, 
Posttreatment Phase;
9.1.4 Posttreatment Phase 
(Follow  Up)The term “study drug” was replaced by the generic drug name “topiramate or 
levetiracetam” to allow  the use of commercially available drug for tapering off.
Rationale: To clarify that the screening phase is any period up to 35 days. The previous Time and Event Schedule 
described a screening phase of 21 to 35 days (28 ±7days ). A screening phase of less than 21 days is desirable and 
this is reflected in the updated Time and Event Schedule .
Time and Events Schedule
Synopsis, Overview of Design;
3.1 Overview  of Study Design;
9.1.1 Overview ;
9.1.2 Screening PhaseThe screening phase with study day -28 including a study day window  of 
±7days was changed to study day ≤-28 inc luding a study day window  of -
7days (ie, day -35).
Rationale: To clarify that the decision regarding subects’ eligibility to participate in the optional Post Study Follow -
up phase is based on local DEXA scan results ( change in Z -score of -0.5 or greater ). This is because the central 
DEXA scan results are available only with delay, and the decision should be made on the day of the regular M12 
visit.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
10
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
Synopsis, Overview of Study 
Design; Time and Events 
Schedule, footnote “b”;
3.1 Overview  of Study Design, 
Post Study Phase (Follow Up);
Figure 1: Study Diagram, 
footnote “a”;
9.1.5 Post Study Phase (Follow 
Up).The statement “ … based on local DEXA scan results …” was added .
Amendment INT -4(10July2015)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly 
impact the safety or physical/mental integrity of subjects, nor the scientific value of the study.
The overall reason for the amendment: The overall reason for the amendment is to respond to health authority 
feedback requesting a more specific definition of age at which to conduct Tanner staging. Also the eligibility 
criterion for vitamin D level at screening was revised , and textwas clarif iedfor other study eligibility criteria and 
procedures .
Applicable Section(s) Description of Change(s)
Rationale: Systematically conducting Tanner staging at a sufficiently early age ensure sthat all children who may be 
exhibiting pubertal changes earlier than expected willbe identified .This change was requested by the US health 
authority.
Synopsis ,Safety Evaluations; 
Time and Events Schedule 
footnote "n"; 
Sec. 9.3. Safety Evaluations ,
Physical Examination Text was added to clarify that Tanner staging is to beconducted uniformly in 
subjects ofage 8 years and above.
Rationale: To ensure consistency ofseizure counting for determin ation of study eligibility .
Sec. 4.1.,Inclusion Criteri a Inclusion criterion #2 was revised to specify thatunprovoked seizure clustering
that occurs within a 2 4 hour period is to be considered as a single unprovoked 
seizure . This is in accordance with International League Against Epilepsy (ILAE) 
clinical definitions.16
Rationale: To ensure correct units are applied to the collection of WBC and neutrophil counts for determin ation of 
study eligibility.
Sec. 4.2.,Exclusion Criteri a Exclusion criterion #17 w as correct ed to show  theunits for WBC count and 
neutrophil count to be per μL.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
11
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
Rationale: The threshold of clinical concern for 25-hydroxy -vitamin Dis the deficiency threshold (<12ng/mL 
[<30 nmol/L]).19,42
Sec. 4.2., Exclusion Criteri a Exclusion criterion #17 w as revised to define the threshold of clinical concern 
for 25-hydroxy -vitamin D.
Rationale: To clarify that the 7-day window  allowed for scheduling study visits applies to all visits . 
Time andEvents Schedule A row was added to depict that the “± 7day” window  applie stoall study visits.
Rationale: To ensure that source data is collected correctly and, w ith regard to height, to clarify the blinded manner
in which it is to be obtained .
Sec. 5.,Treatment Allocation 
and B linding; 
Sec 9.3.,Safety Evaluations ,
Physical Examination; 
Sec. 17.4. ,Source 
DocumentationText was edited to state th at the specified parameters would be recorded in 
source documents first and then entered into the CRF , and textwas added to 
clarify how how height measurements is to be obtained so as to remain blinded.
Rationale: To clarify that venous ammonia is to be analyzed by the central laboratory in countries where local 
testing is not available.
Sec. 9.1.1., Table 2, footnote 
"b"; Sec. 9.3., Safety 
Evaluations, Clinical 
Laboratory TestsThe clinical laboratory tests will be performed by the central laboratory, except 
venous ammonia, which will be evaluated locally (except in select countries 
where local testing is not possible, in which case the central laborat ory will also 
evaluate venous ammonia).
Rationale: To clarify and m aintain consistency with inthe protocol regarding the timing and volume of blood 
collection for venous ammonia.
Sec. 9.1.1. , Table 2 Table 2 (Volume of Blood to be Collected From Each Subject (m L)) was revised
to ref lect a blood draw  volum eof 1.2 mL for venous ammonia at Month 1 fora 
corresponding total blood volume of 7.2 mL collected during the study. 
Accordingly ,also in Table 2 , total blood volume swere revised at Month 1 and 
during the study to 4.7 mL and 45.8 mL, respectively.
Text in Sec. 9.1.1. w as revised to reflect a total blood volume of 44.7 mL 
collected during the study . For adolescent girls who require serum pregnancy 
test at screening , text was revised to reflect a total blood volume of 45.8 mL 
collected during the study .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
12
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
Rationale: To clarify and maintain consistency within the protocol regarding the timing of serum biochemical 
assessments of bone metabolism and DEXA scans.
Sec. 9.3., Safety Evaluations , 
Bone MineralizationText w as revised to reflect that serum biochemical assessments of bone 
metabolism are to be obtained at screening , Month 6 and Month 12/early 
withdrawal, and DEXA scans are to be obtained at baseline , Month 6 and 
Month 12/early withdrawal.
Rationale: To clarify that C -SSRS is to be administered for subjects 6 to 15 years of age.
Time and Events Schedule, 
footnote “x”; Sec. 9.3., Safety 
Evaluations, SuicidalityText w as revised in Sec. 9.3 to state that C-SSRS will be administered for 
subjects 6 to 15 years of age and a footnote was added to the Time and Events 
Schedule to clarify the ages for w hich to administer C -SSRS .
Rationale: Concern that , in certain countries, the current protocol language woulddisagree w ith local product 
handling instructions on the study drug label.
Sec. 14.4. ,Preparation, 
Handling and StorageRevised language to delete specific storage parameters and add "All study drug 
should be stored and handled per the labelled storage conditions."
Rationale: To clarify that ECG data w ould not be transmitted directly to the sponsor's database from a central 
laboratory.
Sec. 17.6, Data Quality 
Assurance/Quality Control and 
Sec. 17.11 ., Use of Information 
and PublicationText w as revised to remove that ECG data w ould be transmitted directly to the 
sponsor's database from a central laboratory.
Rationale: Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
Amendment INT-3(15October 2014)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly 
impact t he safety or physical/mental integrity of subjects, nor the scientific value of the study.
The overall reason for the amendment: The overall reason for the amendment is to change the phase of the study 
from Phase 4 to Phase 3 , due to investigational monotherapy dosing for study medications in some countries, and to 
add a subspecialty referral for clinically important reductions in bone mineral density Z -score.
Applicable Section(s) Description of Change(s)
Rationale: Since topiramate and levetiracetam are not approved in all pediatric age groups as monotherapy in all 
countries in which the study is being conducted, the study is being changed from Phase 4 to Phase 3.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
13
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
Title page Phase of the study changed from Phase 4 to Phase 3.
Rationale: For subjects w ith a clinically relevant drop in bone mineral density Z-score, a consultation may be 
recommended at the discretion of the investigator to assess the subject and guide potential management of the case.
Sec. 9.3, Safety 
Evaluations, Bone 
MineralizationLanguage added for the investigator to make an appropriate referral (ie, subspecialty 
consult) for further evaluation of subjects who develop treatment -emergent clinically 
significant bone mineral density Z -scores (at 6 month or 12 month measurement) .
Rationale: To provide consistent interpretation of all renal ultrasound results (ie, screening, 6 -and 12 -month 
results) in all patients across sites , central rather than local readings will be performed.
Time and Events Schedule; 
Sec. 9.3, Safety 
Evaluations, Renal Stone 
EvaluationText changed to indicate that renal ultrasounds will be read and interpreted centrally 
rather than locally (local reading at the screening visit is acceptable to determine 
eligibility fo r study enrollment) , and that both the technician administering the text 
and the central and local readers are blinded to study drug treatment .
Rationale: Clarified that subjects willnot be discontinued from the study for exceed ingcurrently labeled, 
maximum recommended doses if higher doses are required for optimal clinical effect ,as judged by the investigator . 
In the event a subject takes a higher -than-recommended dose, their data collected w hile receiving higher doses may 
be ana lyzed separately. Higher doses could possibly confound safety evaluations including DEXA scans, laboratory 
tests (eg, bicarbonate), and renal ultrasounds (eg, increased nephrolithiasis). 
Synopsis; 
Section 6, Dosage and 
AdministrationAdded language that subjects will not be discontinued from the study if 
recommended maximum doses of study medication are exceeded. For any subject 
that exceeds the maximum recommended daily dose, data collected subsequent to the 
use of higher doses may be analyzed in a secondary analysis for each safety outcome 
of interest. 
Rationale: Evaluation of concomitant medications at screening visit is needed to determine if subjects meet 
inclusion/ exclusion criteria regarding whether they are treatment naïve or have previous treatm ent with AEDs.
Time and Events Schedule Added evaluation of co ncomitant medications at screening visit.
Rationale: To provide flexibility in the Data Monitoring Committee (DMC) meeting frequency according to the 
needs of the study.
Sec. 11.5 Data Monitoring 
CommitteeChange DMC meetings from minimally on a quarterly basis to minimally on a 
semiannual basis .
Rationale: Updated versions of Habitual Activity Estimation Scale (HAES) and Child Behavior Checklist (CBCL) 
scales added to protocol .
Attachment 1 Replaced HAES with updated version available from vendor. 
Attachments 6 and 7 Replace dCBCL -Preschool and CBCL -School Age with updated versions (scales 
were edited to meet the needs of this study -revised to remove irrelevant sections and 
open -ended questions).
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
14
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
Rationale: Minor errors w ere noted.
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
15
Approved, Date: 3 November 2017Amendment INT -2(23 April 2014)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European U nion, in that it does not significantly 
impact the safety or physical/mental integrity of s ubjects, nor the scientific value of the study.
The overall reason for the amendment: The overall reason for the amendment is to revise the blood draw  volume 
to accommodate a larger volume required for 1,25 -dihydroxy -vitamin D; HIV and hepatitis serology at screening 
have been removed to keep blood volume at a minimum.
Applicable Section(s) Description of Change(s)
Rationale: Blood draw  volume revised to accommodate a larger volume required for 1,25 -dihydroxy -vitamin D; 
HIV and hepatitis serology at screening have been removed to keep blood volume at a minimum.
Time and Events Schedule ;
4.2. Exclusion Criteria;
9.3. Safety EvaluationsHIV and hepatitis serology at screening removed.
9.1.1. Overview Blood volume revised.
Rationale: Added description of visual field defects reported w ith topiramate.
1. Introduction, Safety 
Issues of Clinical Concern, 
Vision AbnormalitiesAdded description of visual field defects reported w ith topiramate.
Rationale: Study procedures clarified.
Time and Events Schedule;
3.1. Overview  of Study 
Design, Screening Phase;
9.1.3. Open -Label 
Treatment Phase;
9.3. Safety EvaluationsParents of each subject will record the description, rather than the type ,of seizure in 
the seizure diary .
3.2.Study Design Rationale Description of approved uses for levetiracetam revis ed for consistency with 
Section 1.1, Comparator Agent.
5. Treatment Allocation 
and Blinding;
15. Study -Specific 
MaterialsInteractive system will be web -based (IWRS), rather than IVRS.
9.1.1. Overview Clarification added that higher blood volume will be required for adolescent girls who 
require s erum pregnancy test at screening .
9.1.1. Overview;
9.3. Safety EvaluationsClarification added that venous ammonia will be evaluated locally.
9.1.3. Open -Label 
Treatment PhaseDeleted statement that investigator or study personnel will describe the different types 
of seizures to be recorded in the seizure diary; this is no longer applicable w ith the 
current setup of the diary.
15. Study -Specific 
MaterialsWorksheet for NEPSY II and other scales added.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
16
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
16.2.3. Informed Consent Language added that assent will be obtained from subjects typically 7 years and older, 
for consistency with language later in the section.
16.2.5. Country Se lection Clarification that the study will only be conducted in those countries where 
topiramate and levetiracetam are commercially available for the treatment of 
epilepsy.
17.4. Source 
DocumentationAdded C -SSRS to assessments that will be recorded separa tely from the CRF and be 
considered source data.
Rationale: Minor errors w ere noted.
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
17
Approved, Date: 3 November 2017Amendment INT -1(11March 2014 )
The overall reason for the amendment: The overall reason for the amendment is to clarify exclusion and 
withdrawal criteria for subjects with a history of or significant risk of suicidal or violent behavior.
Applicable Section(s) Description of Change(s)
Rationale: To clarify exclusion and withdraw al criteria for subjects w ithahistory of or significant risk of suicidal 
or violent behavior.
4.2. Exclusion Criteria Added exclusion criterion for subjects with a history of any suicidal behavior 
(attempt , interrupted, aborted , or preparatory) in the past 6 months prior to the 
screening visit.
10.2. Withdraw al From the 
StudyAdded w ithdrawal criterion if the investigator believes the subject to be at significant 
risk of suicidal or violent behavior.
Rationale: Study procedures clarified.
Synopsis Overview of 
Study Design;
Time and Events Schedule;
3.1. Overview  of Study 
Design;
3.2.1. Blinding;
5. Treatment Allocation 
and Blinding;
9.3. Safety Evaluations;
16.1. Study -Specific 
Design ConsiderationsRenal ultrasound will be obtained under b linded conditions after randomization; 
screening ultrasound will not be blinded.
Synopsis Dosage and 
Administration; 
6. Dosage and 
AdministrationMaximum recommended daily dosage for levetiracetam added , for consistency with 
approved labeling .
Synopsis Safety 
Evaluations;
Time and Events Schedule;Renal ultrasound changed from baseline to screening, for consistency with 
Section 9.3, Safety Evaluations, to ensure results are available prior to randomization.
Synopsis Safety 
Evaluations;
Time and Events S chedule;
9.3. Safety EvaluationsBMI will not be obtained by the site, but will be calculated during statistical analysis.
Time and Events Schedule Clarification added that seizure counts will be recorded in the seizure diary (in 
addition to the date and type of seizure)
9.3. Safety Evaluations Statement added that for all evaluations, if possible, the same individual should 
evaluate the subject at all visits.
Statement regarding shipment of ammonia samples deleted, since testing will be done 
locally.
“Bone Age Scan” changed to “Bone Age Radiograph” for accuracy ; clarification 
added that this will be obtained in the nondominant hand/wrist.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
18
Approved, Date: 3 November 2017Applicable Section(s) Description of Change(s)
Number of questions for CBCL -Preschool and CBCL -School Age revised to 
99questions and 112 questions, respective ly, for consistency with Attachments 6 and 
7.
Clarification added for who can administer the Columbia Suicide Severity Rating 
Scale ( C-SSRS ), and that subjects themselves will respond if cooperative, in all 
subjects 6 years of age and older . 
9.3. Safety Evaluations;
11.4. Safety AnalysesReference to vital signs obtained in a seated position deleted, since orthostatic vital 
signs will be measured supine then standing.
15. Study -Specific 
MaterialsAdded “refrigerated centrifuge, if not available lo cally ”.
Rationale: Minor errors w ere noted.
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
19
Approved, Date: 3 November 2017SYNOPSIS
A Randomized, Active -Controlled, Open -Label, Flexible -Dose Study to Assess the Safety and 
Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric 
Subjects With New or Recent -Onset Epilepsy
TOPAMAX® (topiramate) (2,3:4,5 -Di-O-isopropylidene -ß-D-fructopyranose sulfamate) is a structurally 
unique compound that is effective and well tolerated as an anticonvulsant after oral administration in 
animals and humans. Topiramate is approved as adjunctive treatment in adults and in pediatric patients 
(2to 16 years of age) with partial -onset seizures (POS) ,primary generalized tonic -clonic seizures
(PGTCS) , or seizures associated with Lennox -Gastaut syndrome. It is also approved for monotherapy 
treatment in adult and pediatric patients down to 2 years of age with newly or recently diagnosed POS or 
PGTCS ,and for the prophylaxis of migraine in adults and adolescents 12 years of age and older .
The effects of topiramate on growth, bone mineralization ,and kidney stone formation have not been fully  
and systematically evaluated or well characterized in pediatric populations. This study will systematically  
assess the long-term safety of topiramate monotherapy compared with levetiracetam monotherapy ;
specific emphasis will be on metabo lic acidosis related to topiramate therapy and its association with 
nephrolithiasis, bone mineral density (BMD) abnormalities ,and delayed growth in children (2 to 15 years 
of age).Levetiracetam is an appropriate comparator because of its established efficacy for target seizure 
types , relatively low toxicity, and lack of significant known risk of kidney stones or possible deleterious 
effects on bone or growth.
EudraCT NUMBER: 2012 -001552 -19
OBJECTIVE SAND HYPOTHESIS
Primary Objective
The primary objective is to evaluate the effects of topiramate monotherapy compared with levet iracetam, 
another standard antiepileptic drug (AED), as monotherapy for new-onset or recent -onset epilepsy on 
pediatric growth and maturation, bone mineralization, and kidne ystone formation in children 2to 
15years of age .
Secondary Objective
Overall safety will be assessed.
Hypothesis
The study will test the hypothesis that flexible dosage s of topiramate monotherapy have the same effect as 
flexible dosage s of levetiracetam monotherapy on pediatric growth, bone mineralization, and kidney stone 
formation in children 2 to 15years of age with new-onset or recent -onset epilepsy , versus the alternative 
hypothesis that the effect of topiramate is different from that of levetiracet am.
OVERVIEW OF STUDY DESIGN
This is a 1-year, active -controlled, randomized, outpatient, multicenter, open -label, 2-arm flexible -dose 
monotherapy study of topiramate compared with 1 other AED (levetiracetam) in pediatric subjects with 
epilepsy. Subjects will be required to have newly or recently diagnosed epilepsy characterized by POS
with or without secondary generalized tonic -clonic seizures or PGTCS .
The study wil l include the following 3 phases: a screening phase of up to 35days, an open -label treatment 
phase of 1 year's duration, and a posttreatment phase of 30 days’ duration. There may be an optional 
post-study follow -up phase to obtain dual energy x-ray absorp tiometry (DEXA) measurements in a 
subgroup of subjects who experience a clinically important reduction (change in Z-score of -0.5 or 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
20
Approved, Date: 3 November 2017greater) in BMD ,based on local DEXA scan results ,after 1 year of treatment with topiramate, to 
determine whether a decrea se in BMD after or during 1 year of treatment with topiramate is reversible. 
These subjects will have a repeat DEXA scan 6 months after discontinuation of study drug .
To m inimize any bias in measurement, after randomization 3 of the safety assessments will be obtained in 
a blinded fashion, including the DEXA scan, renal ultrasound, and height.
An external, independent Data Monitoring Committee will be commissioned for this study and will 
evaluate safety data periodically throughout the study . 
SUBJECT POPUL ATION
Approximately 282 male and female subjects ,2 to 15years of agewith newlyor recently diagnosed 
epilepsy ,will be randomly assigned toeither the topiramate or levetiracetam arm, in a 1:1 ratio. The 
randomization will be balanced using randomly permuted blocks and will be stratified by country and age 
group (2 to 5 years of age, 6 to 9 years of age, 10 to 12 years of age, and 13 to 15 years of age). The 
enrollment will be monitored throughout thestudy to ensure that subjects are enrolled for each integer 
year in each treatment group.
Subjects will be required to have newly or recently diagnosed epilepsy characterized by POS with or 
without secondary generaliz ation or PGTCS . The epilepsy diagnosis must be within the previous 2 years 
before screening and the subject must have at least 1, but not more than 10,unprovoked seizure sduring 
the 5months prior to screening . Subjects must have evidence of appropriate physical development (height 
and weight ), including weight and height values within the 5thto 95thpercentile for chronological age at 
study entry. Previous AED exposure is limited to no more than 31 days immediately preceding study  
enrollment or to a total of 6 months of previous AED exposure in the past if the AED has been 
discontinued for at least 1 year prior to study enrollment. If the subject is currently treated with an AED, 
inadequacy of current epilepsy treatment must be documented.
Subjects must not have nephrocalcinosis, renal stones of any type, hydronephrosis, a his tory of long bone 
fractures, indwelling hardware ,or abnormalities of the skeleton orspine .Subjects must not have 
congenital glaucoma, known ocular deficits ,or clinically relevant abnormalities on renal ultrasound or 
DEXA scans. Subjects must not have a known history of disturbances of autonomic function , inborn 
errors of metabolism, mitochondrial dysfunction, or prior evidence of hyperammonemia . Subjects must 
not have any clinically significant abnormality in laborator y tests at screening , including a bicarbonate 
level < 20mEq/L, have a diagnosis of metabolic aci dosis, or beon alkali therapy. 
Caregivers of the subjects must be able to accurately maintain the subject take-home record and seizure 
diary .
DOSA GE A ND A DMIN ISTRA TION
Subjects will be randomly assigned to receive unblinded, flexible dosage s of topiramate or levetiracetam 
as follows :
Topiramate: weight -based dosing for subjects 2 to <10 yearsof age,not to exceed 350 mg/day , as 
tolerated ; dosage for subjects 10 to 15 years of age not to exceed 400 mg/day , as tolerated
Levetiracetam: weight -based dosing for all subjects 2 to 15yearsof age,not to exceed 60 mg/kg/day , 
as tolerated . The maximum recommended daily dosage is 3,000 mg (1,500 mg BID).
Subjects will receive study drug in a twice -a-day regimen. After randomization, subjects will be titrated 
as tolerated to the maximum recommended dosage for optimal clinical effect over 6 to 8 weeks and will 
be maintained on that dosage through the open -label treatment phase ,with the option for dosage
adjustment as required for optimal clinical effect. Changes to this schedule will be based on a risk -benefit 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
21
Approved, Date: 3 November 2017assessment of the subject’s clinical condition by the investigator. All study drugswill be provided in 
child -resistant packaging during the study .
Subjects are recommended not to exceed maximum recommended maintenance dosages; however ,
subjects will not be discontinued from the study if higher dosages are required for optimal clinical effect 
as judged by the investigator. Data collected while on dosages that exceed maximal recommendations 
may be analyzed separately ,as appropriate.
Only AED monotherapy will be used for both treatment groups. However, subject s will not be 
discontinued from the studyif 1 or more concomitant AED s are added after initiating treatment with 
study drug.Data will be collected prior to the use of the concomitant AED(s) for the primary analysis. 
Data subsequently collected while on the concomitant AED(s) will be analyzed in a secondary analysis 
for each safety outcome of interest.
PHARM ACOKINETIC EVALUA TIONS
Blood samples (1 mL per sample) for the determination of plasma topiramate and levetiracetam 
concentrations will be obtained during clinic visits according to the Timeand Events schedule .If 
possible, blood samples for pharmacokinetic (PK) evaluations should be trough samples (ie, taken 
immediately before the morning dose) and coincide with samples drawn for clinical laboratory tests.
During each PKassessment, the dos ing regimen, dose administered ,time and date of dose administration, 
time of sample collection, and concomitant medications will be recorded in the case report form .
Pharmacokinetic parameters will not be estimated. Topiramate and levetiracetam plasma concentration 
data will be summarized.
SAFETY EVA LUATIONS
Safety evaluations will include:
12-lead electrocardiogram (screening only)
Vital signs (including orthostatic vital signs) ,body weight , and height (all visits except Month 2 )
Neurologic and physical examinations (all visits except Month 2 )
Physical activity evaluation (screening )
Clinical laboratory tests (screening, Month 1, Month 3, Month 6, Month 9, and Month 12/early 
withdrawal )
Pregnancy testing (for girls of childbearing potential ; serum at screening only; urine at all other visits)
24-hour urine collection ( Screening , Month 6, and Month 12/ early withdrawal )
Adverse event monitoring, concomitant medication monitoring (throughout)
Suicidality, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS; all visits except 
screening )
DEXA scan ( baseline , Month 6, and Month 12/ early withdrawal )
Renal ultrasound, b iochemical bone markers (screening, Month 6, and Month 12/early withdrawal)
Bone age, as determined by hand/wrist x -ray (baseline and Month 12/ early withdrawal )
Tanner staging of subjects ofage 8 years and above (baseline , Month 6,and Month 12 or early 
withdrawal )
Seizure count s recorded by parent/guardian in take-home seizure diary(all visits beginning at 
baseline )
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
22
Approved, Date: 3 November 2017Cognitive ,developmental ,and behavioral assessments, conducted as follows:
Cogstate Battery (2practice session s, 1at screening and 1 at baseline prior to the baseline 
assessment ; assess edat baseline, Month 6, and Month 12/early withdrawal ):
oFor subjects 6 to 15 years of age, the Detection Test, Identification Test, One Card 
Learning Test, One Back Test, and Groton Maze Learning Test will be administered.
oFor cooperative subjects 4 to 5 years of age, the Detection Test and the Identification Test 
will be administered.
Language function test (Animal Fluency NEPSY -II(A Developmental NEuroPSYchological 
Assessment) ; 1 practice session at screening; assessed at baseline, Month 6, and Month 
12/early withdrawal for subjects 6 to 15 years of age ) 
Vinelan d Adaptive Behavior Scale (to be completed by a parent or guardian for subjects 2 to 
5 years of age, assessed at baseline, Month 3, Month 6, and Month 12/ early withdrawal )
Child Behavior Checklist (CBCL ;assessed at baseline, Month 3, Month 6, and 
Month 12/early withdrawal )-Parent version (Achenbach System of Empirically Based 
Assessment)
oPreschool version –subjects 2 to 5 years of age
oSchool -ageversion -subjects 6 to 15 years of age
Note: For subjects who turn 6 years of age during the study, the Vineland Adaptive Behavior 
Scale and the preschool version of the CBCL will continue to be administered throughout the 
study.
STATISTICA L METHODS
Sample Size Determination
A total of 282 randomized subjects, 141 in each treatment group, will be enrolled inthe study. The 
sample size takes into account a1-year dropout rateof 29%, which is a conservative estimate based on 
the dropout rates was observed in a previous monotherapy study in the 6-to 15-year-oldage group ,Study 
TOPMAT -EPMN -106, including a dro pout rate of 22% in the study overall (both double -blind and open -
label phases) and a dropout rate of 35% for the double -blind phase. The sample size was estimated in 
order to achieve a sufficient precision for the estimates of the treatment effect on the key endpoints. The 
precision of the confidence interval ( CI)estimates for the key safety parameters are shown below:
Annual change in BMD (L1 -L4) Z-score: In the Bone Mineral Density in Childhood Study (BMDCS), 
mean annual change in BMD (L1-L4) Z-score in6-to 15-year-old healthy subjects was, as expected, 
minimal (0.01 -0.07). The standard deviation (SD) varied from 0.3 to 0.48 across sex and age groups. 
Assuming an SD of 0.4, with 100 completed subjects per group, the 95% CI for the treatment 
difference will have a precision of 0.12.
Annual change in height Z -score in the 2-to 9-year-old age group: In the monotherapy epilepsy study 
TOPMAT -EPMN -106, the observed change from baseline in mean height Z -score at 1 year among the 
2-to 9-year-old subjects trea ted with topiramate 400 mg/day was -0.18, with an SD of 0.28. Assuming 
that 53% of the subjects will be recruited in the 2 to 9-year-old age group, ie, 53completed subjects 
per treatment group, the 95% CI for the treatment difference will have a precision of 0.11.
Incidence of kidney stone formation: In the studies TOPMAT -PEP-3001 and TOPMAT -PEP-1002 in 
infants (1 month to 2 years of age), a 7% incidence of kidney stones was observed during the1-year 
topiramate adjunctive treatment period. A sample size of 100completed subjects per treatment group 
will provide a 95% CI (Wilson score CI) for the treatment difference with a width of 0.12, assuming 
that the incidence of kidney stone formation is 7% and near zero in the topiramate group and the 
levetiracetam group, respectively.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
23
Approved, Date: 3 November 2017Change in weight Z-score in the 2-to 15-year-old age group: In the monotherapy epilepsy study 
TOPMAT -EPMN -106, a -0.59 decrease from baseline in weight Z-score , with an SD of 0.43, was 
observed after 1 year of treatment with topiramate 400 mg/day .Assuming an SD of 0.43, a sample 
size of 100completed subjects per treatment group will provide a 95% CI with a precision of 0.12.
Safety A nalyses
The key safety endpoints will include:
Percent ageof subjects with kid ney stones 
Change from baseline in weight Z-score over time
The following height analyses will be conducted for prepubertal subjects 2 to 9 years of age, subjects 
10 to 15 years of age , and subjects 2 to 15 years of age :
Height at 1 year postbaseline
Heig ht change from baseline over time
Height Z -score at 1 year postbaseline
Change from baseline in height Z -score over time
Height velocity at 1 year postbaseline
Height velocity Z -score at 1 year postbaseline
Percentage of outlier subjects with height Z -score decrease of >0.5, >1.0, and >2.0 over time
The following BMD and bone mineral content (BMC) endpoints:
BMD and BMC over time
BMD and BMC change from baseline over time
Z-score for BMD and BMC over time
Change from baseline in Z-score for BMD and BMC over time
Percent change from baseline in BMD and BMC over time
Percentage of outlier subjects with BMD Z -score decrease of >0.5, >1.0, and >2.0 over time
Change from baseline in biochemical markers of bone mineralization including: serum levels of 
calcium, phosphorus, alkaline phosphatase, 25-hydroxy -vitamin D, 1,25-dihydroxy -vitamin D, 
insulin -like growth factor 1 ( IGF-1), and parathyroid hormone.
Change from baseline in serum and urine laboratory tests, eg, bicarbonate, ammonia, renal function 
tests,and liv er function tests 
Change from baseline in bone age
Longitudinal endpoints will be analyzed using a mixed -model repeated measures (MMRM) analysis .The 
MMRM model will include treatment group, age group, visit, treatment -by-visit interaction, baseline 
measure , and baseline -by-visit interaction . An unstructured covariance will be used. Other appropriate 
covariance structures will beexplored as needed. Confidence intervals with 95% confidence for the 
estimated treatment differences will be provided at each time point as appropriate. For proportion 
endpoints, 95% confidence intervals will be provided for the treatment difference. Each of the endpoints 
will also be summarized by age group.
Seizure counts and cognitive ,developmental ,and behavioral assessm ents will be summarized by 
treatment group and age group .The incidence of suicide -related thoughts and behaviors as determined by 
the C -SSRS will be summarized by treatment group and age group.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
24
Approved, Date: 3 November 2017In addition tothe above endpoints, other safety -related endp oints may be included in the analyses if 
deemed necessary .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
25
Approved, Date: 3 November 2017TIME A ND EVENTS SCHE DULE
Phase Screening Open -Label TreatmentaPosttreatm entb
End-of-
Study/Early 
WithdrawalFollow -up 
Telephone 
Contact
Week (W)/Month (M)Baseline/
W1 M1 M2 M3 M6 M9 M12 M13
Study Day ≤-28 1c30 60 90 180 270 360 390d
Study Day Window -7day s ±7days ±7days ±7days ±7days ±7days ±7days ±7days ±7days
Visite1 2 3 4 5 6 7 8 NA
Screening/Administrative 
Informed consent and assent X
Inclusion/exclusion criteria X X
Medical/seizure history X X
Physical activity evaluationfX
Prestudy AED and other therapygX
Randomization X
Study Drug
Dispense study drug X X X X X X
Study drug accountability X X X X X X
Pharm acokinetics
Blood sample collection for 
quantitation of study drughX X X X
Safety
Physical examination X X X X X X X
Neurologic examination X X X X X X X
12-lead ECG X
Height/weightiX X X X X X X
Vital signs (temperature, HR, RR, 
BP)jX X X X X X X
Clinical laboratory testskX X X X X X
Pregnancy testlX X X X X X X X
24-hour urine collectionmX X X
Tanner stagingnX X X
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
26
Approved, Date: 3 November 2017Phase Screening Open -Label TreatmentaPosttreatm entb
End-of-
Study/Early 
WithdrawalFollow -up 
Telephone 
Contact
Week (W)/Month (M)Baseline/
W1 M1 M2 M3 M6 M9 M12 M13
Study Day ≤-28 1c30 60 90 180 270 360 390d
Study Day Window -7day s ±7days ±7days ±7days ±7days ±7days ±7days ±7days ±7days
Visite1 2 3 4 5 6 7 8 NA
Renal ultrasoundoX X X
Biochemical bone markerspX X X
DEXA scanb,qX X X
Bone age x -rayrX X
Dispense seizure diary and take -
home recordsX X X X X X
Revie w seizure diary and take -
home recordX X X X X X
Cogstate BatterytX X X X
Animal Fluency Test NEPSY -IIuX X X X
Vineland Adaptive Behavior 
ScalevX X X X
CBCL –Parent VersionwX X X X
C-SSRSxX X X X X X X
Ongoing Review
Concomitant therapy X X X X X X X X X
Adverse event monitoring X X X X X X X X X
Footnotes appear on the following page .aIncludes a titration period of approximately 6 to 8 w eeks, follow ed by  a maintenance period.bThere may be an optional post -study follow -up phase to obtain DEXA measurements in a subgroup of subjects who experience a clinically important reduction
(chan ge in Z -score of -0.5 or greater) in BMD ,based on local DEXA scan results ,after 1 year of treatment with topiramate; these subjects will have a repeat DEXA 
scan 6 months after discontinuation of study drug.cThe Day 1 visit will serve as the baseline vi sit. All procedures on Day 1 (except dispensing of study drug) should be completed before randomization.dThe site w ill contact the subject via telephone at Month 13, to collect data on adverse events and concomitant medications.eWindow  for all visits w ill be ±7 days.fAdequacy of p hysical activity will be assessed with the Habitual Activity Estimation Scale .gInvestigator w ill document inadequacy of any epilepsy treatment that the subject is receiving at the time of screening. Infor mation regarding A ED use and other 
medications within 2 years prior to the study will also be collected.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
27
Approved, Date: 3 November 2017hIf possible, b lood samples for determination of plasma topiramate and levetiracetam concentrations should be trough samples (taken immediat ely before the
morning dose) and should coincide with samples drawn for clinical laboratory tests.iSubjects will be w eighed in examination gowns or in lightweight clothing and without shoes. 
Height will be assessed using a w all-mounted stadiometer. 
All study site personnel measuring height will be blinded to treatment to avoid/minimize bias. jOrthostatic vital signs will be obtained for all subjects pending cooperation of subjects. A set of 3 measurements will be ob tained at baseline only at intervals of 
10minutes. Thereafter, only 1 orthostatic vital sign measurement will be taken at all subsequent visits. The method for obtaining or thostatic vital signs w ill be as 
follows: subject w ill be supine for 5 minutes prior to measurement, and standing for 2 minutes pri or to measurement.kClinical laboratory tests (nonfasting) include serum chemistry, hematology, venous ammonia and urinalysis. Insulin -like grow th factor 1, 1,25 -dihydroxy -vitamin D, 
25-hydroxy -vitamin D, and parathyroid hormone will be measured at screen ingand at Months 6 and 12 /early withdrawal . The laboratory tests for 
25-hydroxy -vitamin D, 1,25 -dihydroxy -vitamin D, Parathyroid hormone (intact) and IGF -1 at screening will be evaluated centrally ,but additional evaluation at a 
local laboratory is allowe d in order to reduce the duration of the screening phase .lSerum pregnancy test at screening; urine pregnancy test at all other visits.mA 24 -hour urine collection will be analyzed for pH, calcium, citrate, phosphorus, and creatinine levels. Collection i nstructions and storage conditions will be 
specified in the laboratory manual. A 14 -day window on either side of the scheduled Month 6 visit will be allowed for 24 -hour urine collection. The coll ection at 
Month 12 should be completed before the Month –12 visit as this evaluation should be obtained while the subject is still receiving study –drug therapy.nTanner staging of subjects ofage 8 years and above will be conducted by a qualified pediatric endocrinologist or by a physician trained in the method.oRenal ultrasound will be obtained under blinded conditions after randomization and will be read/interpreted centrally (local reading at the screening visit is 
acceptable to determine eligibility for randomization ).Both the technicians administering the renal ultrasound scans and the local and central reader swill be blinded 
to the study treatment group. pBiochemical bone markers will include serum calcium, phosphorus, parathyroid hormone [intact], 25 -hydroxy -vitam in D, and 1,25 -dihydroxy-vitamin D .qDEXA measurements will include posterior -anterior spine (lumbar) and total body less head areal BMD and BMC. Short -term precision testing will be performed 
for DEXA measurements according to standard protocols. The sam e DEXA machine will be used at each site for all subjects and all measurements; only clinical 
sites using recent -generation Hologic or General Electric Lunar systems will participate in the study ; the GE/Lunar systems will only be used for subjects ≥5 years 
of age . If possible, t he same technician should acquire all scans for any particular subject.
Both the technicians administering the DEXA scans and the central reader w ill be blinded to the treatment group.
For each time point, up to 3 scan attemp ts will be performed all on the same day (with repositioning between each scan), with the goal of obtaining 2 complete, 
movement -free scans of both the spine and whole body at screening .rA hand/wrist x -ray (in the nondominant hand/wrist) will be used to determine bone age.sSubjects will be given a take -home record, to capture data on study drug administration, concomitant medications, and items of general health, and a seizur e diary 
with instructions to record seizure counts and the date and description of each seizure.tThe computerized Cog state Battery will be administered by non-expert (non-psychologist) study site personnel trained in the Cog state administration method , with 
2practice session s, 1at screening and 1 at baseline prior to the baseline assessment . For subjects 6 to 15 years of age, the Detection Test, Identification Test, One
Card Learning Test, One Back Test, and Groton Maze Learning Test will be administered. For cooperative subjects 4 to 5 years of age, the Detection Te st and 
Identif ication Test w ill be administered.uThe Animal Fluency Test NEPSY -II will be administered for subjects 6 to 15 years of age , with 1 practice session at screening .vThe Vineland Adaptive Behavior Checklist will be completed by a parent or guardian for subjects 2 to 5 years of age.wThe CBCL -Parent version will be used for all subjects. For subjects 2 to 5 years of age, the preschool version will be administered. F or subjects 6 to 15 years of age, 
the school -age version will be administered.xThe C-SSRS will be administered for subjects 6 to 15 years of age and will not be administered for subjects 2 to 5 years of age.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
28
Approved, Date: 3 November 2017AED=antiepileptic drug; BMC=bone mineral content; BMD=bone mineral density; BP=blood pressure; CBCL=Child Behavior Checklist; C-SSRS=C olumbia Suicide 
Severity Rating Scale; DEXA=dual energy x -ray absorptiometry; ECG=electrocardiogram; HR=heart rate; IGF-1=insulin -like growth factor 1; NEPSY = A 
Developmental NEuroPSYchological Assessment ; RR=respiratory rate.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
29
Approved, Date: 3 November 2017ABBREVIA TIONS
AED antiepileptic drug
ALT alanine aminotransferase
ASEBA Achenbach System of Empirically Based Assessment
AST aspartate aminotransferase
BID twice a day
BMC bone mineral content
BMD bone mineral density
BMDCS Bone Mineral Density in Childhood Study
BMI body mass index
CBCL Child Behavior Checklist 
CDC Centers for Disease Control
CRF case report form 
C-SSRS Columbia Suicide Severity Rating Scale
DEXA dual energy x -ray absorptiometry
DMC Data Monitoring Committee
ECG electrocardiogram
eCRF electronic case report form 
eDC electronic data capture
EEG electroencephalogram
GAB A γ-aminobutyrate
GCP Good Clinical Practice
GGT gamma -glutamyltransferase
HAES Habitual Activity Estimation Scale
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IGF-1 insulin -like growth factor 1
IRB Institutional Review Board
IWRS interactive web -based response system
JME juvenile myoclonic epilepsy
LFT liver function test
MedDRA Medical Dictionary for Regulatory Activities
MMRM mixed -model repeated measures
NEPSY A Developmental NEuroPSYchological Assessment
NSAID s nonsteroidal anti -inflammatory drug s
PGTCS primary generalized tonic -clonic seizures
PK pharmacokinetic (s)
POS partial -onset seizures
PQC product quality complaint
ULN upper limit of normal
WBC white blood cell
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
30
Approved, Date: 3 November 20171. INTRODUCTION
TOPAMAX® (topiramate) (2,3:4,5 -Di-O-isopropy lidene -ß-D-fructop yranose sulfamate) is a 
structurally  unique compound that is effective and well tolerated as an anticonvulsant after oral 
administration in animals and humans. Topiramate is approved as adjunctive treatment in adults 
and in pedia tric patients (2 to 16 years of age) with partial -onset seizures (POS) ,primary 
generalized tonic -clonic seizures (PGTCS) , or seizures associated with Lennox -Gastaut 
syndrome . It is also approved for monotherap y treatment in adult and pediatric patients down to 
2 years of age with newly  or recentl y diagnosed POS or PGTCS ,and for the prophy laxis of 
migraine in adults and adolescents 12 years of age and older .
Background information on nonclinical and clinical studies with topiramate is provided below.
For the most comprehensive nonclinical and clinical information regarding the efficacy  and 
safet y of topiramate, refer to the latest version of the Investigator's Brochure for topiramate.33
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
Nonclinical Studies
Pharmacologic Profile
Pharmacologic effects that may contribute to the anticonvulsant activity  of topiramate include 
inhibition of some voltage -activated sodium channels; potentiation of the ability  of 
γ-aminobuty rate (GABA) to activate some GABA Areceptors; inhibition of the kainate or 
∝-amino -3-hydroxy-5-methy lisoxazole -4-propionic acid subty pe but not the N-
methy l-D-aspartate subtype of glutamate receptors; and a modest negative modulatory  effect on 
L-type and R-type voltage -activated calcium channels. Some studies suggest topiramate has an 
activating effect on some types of potassium channels, but this may be secondary  to effects on 
calcium channels. These pharmacod ynamic properties are observed at therapeutically  relevant 
concentrations (1 to 100 μM) and may have a common molecular mecha nism that affects the 
phosphory lation state of these complex membrane proteins. Topiramate also inhibits some 
carbonic anhydrase isozy mes, particularl y carbonic anhydrase -II and carbonic anhydrase -IV 
(Ki∼1 μM). The possible role of carbonic anhydrase inhibitory  activity  in the AED efficacy  of 
topiramate is not definitively  established, but there is clear evidence that carbonic anhydrase 
inhibition causes or contributes to metabolic acidosis and nephrolithiasis.33
Toxicology
Acute and long-term oral exposure to topiramate is generall y well tolerated. Topiramate is 
teratogenic in animals, does not affect the fertility  of male or female rats, and exhibi ts no 
genotoxic potential.33
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
31
Approved, Date: 3 November 2017In juvenile rats, findings were similar to those in adults, with no unique toxicities and no effect 
on memory  and learning, mating and fertility , or hysterotomy  parameters (numbers of corpora 
lutea, implantations, conceptuses or implantation losses) . Males had decreased serum inorganic 
phosphate levels, and both males and females had increased urine inorganic phosphate levels at 
dosages of 300 mg/kg/day . There were no effects on mean long bone (tibia) growth; global left 
femoral bone mineral density (BMD) was minimally  lower in juvenile rats given 300mg/kg/day 
compared with controls. Lower (around -20%) mean total height (thickness) of the growth plate 
and mean height of the proliferative or hypertrophic zones taken separately  were observed in 
males given 300 mg/kg/day  in comparison with controls. Individual values were below or within 
the lower part of the control range. However, there was an opposite trend in females given the 
same dosage ,where marginall y higher (+3%) mean total height was noted. Individu al values in 
females were within the control range.28
Pharmacokinetic Profile
In studies evaluating the pharmacokinetic (PK) profile and metabolism of topiramate in animals, 
oral doses of topiramate were rapidl y and almost completely  absorbed, rapidly  distributed to the 
tissues, poorly  bound to plasma protein, and eliminated primarily  via the kidney s. The metabolic 
pathway s for topiramate are qualita tively similar in the mouse, rat, rabbit, dog, and human.33
Clinical Studies
Human Pharmacokinetics
Topiramate exhibits linear PK,with no evidence of auto -induction or inhibition of metabolism. I t 
is rapidly  absorbed and not extensively  metabolized. Its absolute bioavailability  is 81% to 95% 
and its metabolism is not affected significantly  by food. The major elimination route of 
unchanged topiramate and its metabolites is renal.
The PKof topiramate were evaluated in pediatric subjects with epilepsy  (4to17years of age) 
receiving 1 or 2 other AEDs .32Pharmacokinetic profiles were obtained after 1week, at dosages 
of 1, 3, and 9 mg/kg/day . The PKof topiramate were linear, with clearance independent of 
dosage and stead y-state plasma concentrations increasing in proportion to dosage. Pediatric 
subjects (4to17years of age) had a 50% higher clearance, and consequently  a shorter 
elimination half -life, compared with adults. Consequently , the plasma concentration for the same 
milligram -per-kilogram dosage may be lower in pediatric subjects than in adults. As in adults, 
hepatic enz yme-inducing AEDs decreased the steady -state plasma concentrations of topiramate.
In a separate study , unchanged topiramate and 6 metabolites were quantified from the urine of 
children with infantile spasms who were between the ages of 9 and 43 months and receiving 
topiramate dosages of 7 to 10 mg/kg /day.14The relative amounts of topiramate and its 
metabolites found in the urine of subjects with infantile spasms were simil ar to those observed in 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
32
Approved, Date: 3 November 2017adults.14Both infants and adults receiving topiramate adjunctive to hepatic enzy me-inducing 
AEDs had a higher proportion of metabolites than of parent topiramate in the urine. Two 
metabolites, topiram ate-N-glucuronide and hydroxy topiramate sulfate, were identified in trace 
amounts (≤8%) in infants but were not detected in adults. The results of this study  indicate that 
topiramate does not appear to be metabolized significantly  differently  in infants oryoung 
children compared with adults.
Efficacy /Safet y Studies
Clinical studies have shown that topiramate is effective as an adjunctive treatment in adults and 
in pediatric subjects (2 to 16 years of age) with POS or PGTC S, and in pediatric subjects 
(≥2years of age) with seizures associated with Lennox -Gastaut syndrome . In the controlled 
adjunctive therap y studies ,which included pediatric subjects, target topiramate dosages were 
based on weight and ranged from approximately  5 to 9 mg/kg/day, administered in 2 divided 
doses. Topiramate was superior to placebo with regard to percent reduction in average monthly 
seizure rate, percent age oftreatment responders, and global assessments made by investigators 
and subjects. Dosages above 400mg/day  (600, 800, or 1,000 mg/day ) have not been shown to 
improve responses in dose -response studies in adults with POS.33
Topiramate has also been shown to be effective as monotherap y in adult and pediatric subjects
with refractory  epileps y or newl y or recentl y diagnosed epileps y. In monotherap y studies, 
topiramate was administered at dosage sranging from 25 to 400 mg/day  in children (≥6 years of 
age) and 50 to 500 mg/day in adults ( ≥16 y ears of age), and was effective in reducing the number 
of seizures experience d.7,8,9In particular, comparison of Kaplan -Meier survival curves for time 
to first seizure (primary  efficacy  endpoint) in the double -blind monotherapy  study 
TOPMAT -EPMN -106 (n=487; age ranging from 6 to 83 years) favored a higher dosage of 
topiramate over a lower dosage (400 mg/day vs. 50 mg/day ; p=0.0002 [log-rank test]). The 
separation between the groups in favor of the high-dosage group occurred early in the titration 
phase and was statistically  significant as early as 2 weeks after randomization (p=0.046), when, 
by following the weekly  titration schedule, subjects in the high-dosage group achieved a 
maximum topiramate dosage of 100 mg/day . The high-dosage group was also superior to the 
low-dosage group with respect to proportion of subjects remaining seizure -free, based on the 
Kaplan -Meier estimates, for at least 6 months (82.9% vs. 71.4%; p=0.005) and for at least 1 year 
(75.7% vs. 58.8%; p=0.001). The treatment effects, with respect to time to first seizure, were 
consistent across subgroups defined by age, sex, geographic region, baseline body  weight, 
baseline seizure t ype, time since diag nosis, and baseline AED use.33
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
33
Approved, Date: 3 November 2017Pharmacokinetic -pharmacody namic modeling and simulation bridging was used to identify  and 
validate the efficacious monotherap y dosing regimen for topiramate in children 2 to <10 years of 
age with newl y diagnosed epilepsy.17
Topiramate appears to be well tolerated; neuropsychiatric events of mild or moderate severity  are 
the most common treatment -emergent adverse events across subject populations. In general, 
there were no noteworthy  changes in clinical laboratory  analytes other than the expected 
decreases in serum bicarbonate/CO 2levels in topiramate clinical studies. Metabolic acidosis, 
considered to be possibly  related to the carbonic anhy drase -inhibiting effect of topiramate, has 
been reported less frequently  in adults compared with children but was most common ininfants
(1 to 24 months of age). In adolescents with migraine, there was no clinically  significant effect 
on serum CO 2.Overall , the incidence of adverse events and abnormal laboratory  findings are not 
notably  different for pediatric and adult subjects. 
Several issues of special interest have emerged during the development of topiramate, including 
effects on liver function; metabolic acidosis; effects on growth and maturation; vision 
abnormalities (acute myopia and secondary  angle-closure glaucoma); oligo hidrosis, 
hyperthermia, and secondary  rash; hyperammonemia and encephalopathy , and kidney  stones. 
These are discussed in brief below, and are described in further detail in the Investigator’s 
Brochure . 
Safety Issues of Clinical Concern
Effects on Liver Function
Comprehensive review of clinical study  and postmarketing data revealed no evidence of direct or 
cumulative hepatotoxicity  by topiramate. Across study  populations (adjunctive epileps y, 
monotherap y epileps y, and migraine), hepatic event rates and la boratory  liver function test (LFT) 
values for topiramate -treated subjects were similar to those of placebo -treated subjects and, 
generall y, better than those of subjects treated with comparator medications (carbamazepine, 
valproate, and lithium). Spontaneo usly reported hepatic events are very rare (<1/10,000 
patient -years). Based collectively  on clinical study  and postmarketing data, the majorit y of 
hepatic events are transient and mild tomoderate in severity . Moreover, hepatic adverse events 
that were considered serious, led to discontinuation, or involved markedl y abnormal LFT values 
often were confounded by  concomitant medications or intercurrent illness.33
Metabolic Acidosis
Hyperchloremic, non-anion gap, metabolic acidosis (ie,decreased serum bicarbonate below the 
normal reference range in the absence of chronic respiratory  alkalosis) is associated with 
topiramate treatment. This metabolic acido sis is caused by renal bicarbonate loss due to the 
inhibitory  effect of topiramate on carbonic anhy drase. Such electrol yte imbalance has been 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
34
Approved, Date: 3 November 2017observed with the use of topiramate in placebo -controlled clinical studies and in the 
post-marketing period. Gener ally, topiramate -induced metabolic acidosis occurs early in 
treatment, although cases can occur at any time during treatment. Bicarbonate decreases are 
usually  mild to moderate (average decrease of 4mEq/L  at daily  dosages of 400mg/day  in adults 
and at approximately  6mg/kg/day  in children); rarely, subjects can experience severe decreases, 
to values 10mEq/L .33
Some manifestations of acute or chronic metabolic acidosis may include hyperventilation, 
nonspecific symptoms such as fatigue and anorexia, or more severe sequelae, including cardiac 
arrhythmias or stupor. Chronic, untreated metabolic acidosis may increase the risk for 
nephrolithiasis or nephrocalcinosis, and may also result in osteopenia or osteoporosis, with an 
increased risk for fractures. Chronic metabolic acidosis in pediatric subjects may also reduce 
growth rates. A reduction in growth rate may eventually  decrease the maximum height achieved. 
The effect of topiramate on growth and bone -related sequelae has not been systematicall y 
investigated.
Growth and Maturation
Reports have suggested that certain AEDs may adversel y affect growth and maturation in some 
children. Body weight was evalu ated among pediatric subjects 6 to 15 years of age in clinical 
studies with topiramate monotherap y, and in 1 of these studies (study  TOPMAT -EPMN -106) 
body  mass index (BMI) was evaluated according to Centers for Disease Control (CDC) criteria. 
Among pediatr ic subjects administered topiramate monotherapy in studies 
TOPMAT -EPMN -104, TOPMAT -EPMN -105, and TOPMAT -EPMN -106, mean body  weight 
increased in the double -blind treatment phase; most subjects experienced an increase or no 
change in body  weight. Of those with weight loss, most exhibited decreases of 1% to 9%. 
Adverse events of weight loss were reported in 21% of pediatric subjects but none was serious or 
treatment -limiting. In the open -label extension of monotherapy  treatment studies
TOPMAT -EPMN -104and TOPMAT -EPMN -106, mean body  weight of pediatric subjects also 
increased . 
During the double -blind phase of study  TOPMAT -EPMN -106, mean BMI decreases were 
observed for approximately  half of the pediatric subjects in the topiramate 50-/400-mg/day  group 
and topiramate 400-/400-mg/day  group, with most of the remaining subjects showing no change 
in BMI. Larger BMI decreases followed 400 mg/day  topiramate than followed 50 mg/day . Based 
on CDC criteria, topiramate treatment rarely resulted in underweight BMI among pediatric 
subjects with normal BMI values at baseline. Mean BMI decreases ( -1.3kg/m2) were observed at 
6 months among pediatric subjects whose dosage increased from 50 to 400 mg/day  during this 
study 's open -label extension .39
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
35
Approved, Date: 3 November 2017Weight, height ,and BMI Z-score s decreased from baseline to endpoint in pediatric subjects in 
monotherap y studies . These results indicate that,in general, children continue to grow while 
receiving topiramate monotherapy  treatment, although at a rate slower than their normal healthy  
counterparts.33
Vision Abnormalities (Acute My opia and Se condary  Angle -Closure Glaucoma)
A medical condition consisting of sudden worsening of vision and an elevation of fluid pressure 
in the eyes (secondary  glaucoma) has been described in clinical studies and post-marketing 
reports in subjects taking topiramate, usuall y at the beginning of their treatment. In contrast to 
primary  narrow -angle glaucoma, which is rare under 40 years of age, secondary  angle-closure 
glaucoma associated with topiramate has been report ed in pediatric as well as adult subjects. 
Symptoms include acute onset (within 1 month of initiating topiramate therapy ) of decreased 
visual acuit y and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber 
shallowing, ocular hyperem ia (redness) ,and increased intraocular pressure. Mydriasis may or 
may not be present. The primary  treatment to reverse symptoms is discontinuation of topiramate 
as rapidl y as possible according to the judgment of the treating ph ysician.33
Visual field defects have been reported in subjects receiving topiramate independent of elevated 
intraocular pressure. In clinical studies, most of these events were reversible after topiramate 
discontinuation. If visual problems occur at any time during topiramate treatment, consideration 
should be given to discontinuing the drug .
Oligohidrosis, Hy perthermia, and Secondary  Rash 
Oligohidrosis (decreased sweating) and hyperthermia , infrequently  resulting in hospitalization, 
has been reported in clinical studies and post-marketing reports in association with the use of 
topiramate. These cases were characterized by decreased sweating and an elevation in body  
temperatu re above normal. Some of the cases were reported after exposure to elevated 
environmental temperatures. The majority  of the reports have been in children. Skin erythema 
has been reported secondary  to the hyperthermia and oligohidrosis and should be monitor ed; 
adequate h ydration is encouraged . 
Hyperammonemia and Encephalopathy  
In clinical studies and post-marketing reports, concomitant administration of topiramate and 
valproic acid has been associated with hyperammonemia with or without encephalopath y in 
subjects who have tolerated either drug alone. In most cases, symptoms and signs abated with 
discontinuation of either drug. This adverse event is not due to a PKinteraction. 
Topiramate treatment has produced h yperammonemia (in some instances dose -related) in clinical 
studies in adolescents (12-16 yearsof age) who were treated with topiramate monotherap y for 
migraine proph ylaxis and in very young pediatric subjects (1-24 month sof age) who were 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
36
Approved, Date: 3 November 2017treated with adjunctive topiramate for POS. In some subjects , ammonia was markedl y increased
(defined in the clinical study  report as >50% increase from baseline and absolute value >2x 
upper limit of normal [ULN] ). In the adolescent subjects, the incidence of markedl y increased 
hyperammonemia was 3% (1 subject), 0%, and 9% (3 subjects) for the placebo, 50mg/day, and 
100mg/day groups ,respectivel y.10
The hyperammonemia associated with topiramate treatment occurred with and without 
encephalopath y in placebo -controlled studies , and in an open -label extension study  in infants . 
Dose -related hyperammonemia was also observed in the open -label extension study in pediatric 
subjects 1month to 2 years of age . Clinical sy mptoms of hy perammonemic encephalopathy  may 
include acute alterations in level of consciousness and/or cognitive function with lethargy  or 
vomiting. Hyperammonemia with and without encephalopath yhas also been observed in 
post-marketing reports in patients who were taking topiramate without concomitant valproic 
acid.38
Kidney  Stones
The occurrence of renal calculi (1.5% to 1.9% incidence) was observed in clinical studies and 
post-marketing reports of topiramate in adult and pediatric subjects ≥2 years of age with 
epilepsy . The majorit y of cases did not require surgical intervention. Kidney  stones have also 
been reported in infant subjects during long-term (up to 1 year) topiramate treatment .In an 
open -label extension study  (TOPMAT -PEP-1002_3001 OLE) of 284 pediatric subjects 1to 
24months old with epilepsy , 7% developed kidney  or bladder stones , which were primarily 
asymptomatic andwere assessed systematicall y by renal ultrasound . Topiramate is not approved 
forpediatric patients less than 2 years of age .38
The mechanism is believed to be associated with the carbonic anhydrase inhibitory  activit y of 
topiramate. Carbonic anhy drase inhibitors (eg, zonisa mide, acetazolamide ,or dichlorphenamide) 
can promote stone formation by reducing urinary  citrate excreti on and by increasing urinary 
pH.33
1.1. Comparator A gent 
Levetiracetam
Levetiracetam is indicated for use as an adjunctive therapy  for POS (adults and children 
≥1month of age with epilepsy ), PGTCS (adults and children ≥6 years of age with idiopathic 
generalized epileps y), and myoclonic seizures (adults and children ≥12 years of age with juvenile 
myoclonic epileps y[JME] ).24The safety  profile in pediatric subjects with epilepsy  is 
summarized below. 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
37
Approved, Date: 3 November 2017Subjects With Partial -Onset Seizures
In pediatric subjects experiencing POS, levetiracetam is associated with somnolence, fatigue, and 
behavioral abnormalities.24
In a double -blind, controlled study  in children with epilepsy  experiencing POS, 22.8% of 
levetiracetam -treated subjects experienced somnolence, compared with 11.3% of placebo 
subjects . The design of the study  prevented accurately  assessing dose-response effects. No 
subject discontinued treatment for somnolence. In about 3.0% of levetiracetam -treated subjects 
and in 3.1% of placebo subjects ,the dos age was reduced as a result of somnolence.24
Asthenia was reported in 8.9% of levetiracetam -treated subjects , compared with 3.1% of placebo 
subjects . No subject discontinued treatment for asthenia, but asthenia led to a dos age reduction in 
3.0% of levetiracetam -treated subjects compared with 0% of placebo subjects .24
A total of 37.6% of the levetiracetam -treated subjects experienced behavioral symptoms 
(reported as agitation, anxiety , apath y, depersonalization, depression, emotional lability , 
hostility , hyperkinesia, nervousness, neurosis, and pe rsonality  disorder), compared with 18.6% of 
placebo subjects . Hostility  was reported in 11.9% of levetiracetam -treated subjects , compared 
with 6.2% of placebo subjects . Nervousness was reported in 9.9% of levetiracetam -treated 
subjects , compared with 2.1% of placebo subjects . Depression was reported in 3.0% of 
levetiracetam -treated subjects , compared with 1.0% of placebo subjects .24
A total of 3.0% of levetiracetam -treated subjects discontinued treatment due to psychotic and 
nonpsy chotic adverse events, compared with 4.1% of placebo subjects . Overall, 10.9% of 
levetiracetam -treated subjects experienced behavioral symptoms associated with discontinuation 
or dosage reduction, compared with 6.2% of placebo subjects .24
Subjects With My oclonic Seizures
During clinical development, thenumber of subjects with myoclonic seizures exposed to 
levetiracetam was considerabl y smaller than the number with partial seizures. Therefore, 
underreporting of certain adverse events was more likely  to occur in the myoclonic seizure 
population. In adult and adolescent subjects experiencing myoclonic seizures, levetiracetam is 
associated with somnolence and behavioral abnormalities. It is expected that the events seen in 
POS subjects would occur in patients with JME. In a double -blind, controlled study in adults and 
adolescents with JME experiencing myoclonic seizures, 11.7% of levetiracetam -treated subjects
experienced somnolence compared with 1.7% of placebo subjects . In 1.7% of 
levetiracetam -treated subjects and in 0% of placebo subjects ,the dosage was reduced as a result 
of somnolence.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
38
Approved, Date: 3 November 2017Non-psychotic behavioral disorders (reported as aggression and irritability ) occurred in 5% of 
the levetiracetam -treated JME subjects compared with 0% of placebo subjects . Non-psychotic 
mood disorders (reported as depress ed mood, depression, and mood swings) occurred in 6.7% of 
levetiracetam -treated JME subjects compared with 3.3% of placebo subjects . A total of 5.0% of 
levetiracetam -treated subjects had a reduction in dosage or discontinued treatment due to 
behavioral or psychiatric events (reported as anxiety , depressed mood, depression, irritability , 
and nervousness), compared with 1.7% of placebo subjects .
In a well-controlled clinical study  that included both adolescent (12 to 16 years of age) and adult 
subjects with myoclonic seizures, the most frequently  reported adverse events associated with 
the use of adjunctive levetiracetam , not seen at an equivalent frequency  among placebo -treated 
subjects , were somnolence, neck pain, and pharyngitis. The different pattern of adverse events, 
as compared with subjects with POS, is likely  due to the much smaller number of subjects in the 
JME study .24
Subjects With Primary  Generalized Tonic -Clonic Seizures
During clinical development, the number of subjects 4 years of age and older with PGTCS 
exposed to levetiracetam was considerabl y small er than the number with POS. As in the POS 
subjects , behavioral symptoms appeared to be associated with levetiracetam treatment. Gait 
disorders and somnolence were also described in the study  in PGTCS, but with no difference 
between placebo and levetiracet amtreatment groups and no appreciable discontinuations. 
Although it may be expected that drug-related events seen in POS subjects would be seen in 
PGTCS subjects (eg, somnolence and gait disturbance), these events may not have been 
observed because of the smaller sample size .24
Discontinuation or Dosage Reduction in Well -Controlled Clinical Studies
The adverse events most commonly  associated (≥3% insubjects receiving levetiracetam) with 
discontinuation or dosage reduction in the well-controlled pediatric POS study  were asthenia, 
hostility , and somnolence. The adverse event most commonly  associated (≥3% in subjects
receiving levetiracetam) with disco ntinuation or dosage reduction in the well -controlled pediatric 
JME study  was anxiety (2 subjects, 3.3%), but the small study  size (a total of 113 subjects 
enrolled with JME) limits the conclusions that can be drawn. The PGTCS study  was too small to 
adequatel y characterize the adverse events leading to discontinuation or dosage reduction.24
Hematologic Abnormali ties
Levetiracetam -treated pediatric subjects with POS experienced small, but statistically  significant, 
decreases in white blood cell (WBC )and neutrophil counts and increases in lymphocy te counts, 
as compared with placebo. In awell-controlled study , more levetiracetam -treated pediatric 
subjects with POS had a possibly  clinicall y significant abnormally  low total WBC value (3.0% 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
39
Approved, Date: 3 November 2017levetirac etam -treated versus 0% placebo); however, there was no apparent difference between 
treatment groups with respect to neut rophil count . No subject was discontinued secondary  to low 
WBC or neutrophil counts. Although there were no obvious hematologic abnormalities observed 
in subjects with JME, the limited number of subjects limits the conclusions that can be drawn .24
Liver Function Test Abnormalities 
There were no meaningful changes in mean LFT values in controlled studies in adult or pediatric 
subjects ; LFT abnormalities were similar in drug-and placebo -treated subjects in controlled 
studie s (1.4%). No pediatric subjects were discontinued from controlled studies due to LFT 
abnormalities.24
Impaired Renal Function 
Levetiracetam is known to be substantiall y excreted by the kidney , and the risk of adverse 
reactions to this drug may  be greater in patients with impaired renal function.24
Post-Marketing Experience With Adjunctive Therapy
The following have been reported in patients receiving marketed levetiracetam worldwide
(alphabeti cal order): abnormal LFT values , choreoathetosis, dyskinesia, erythema multiforme, 
hepatic failure, hepatitis, leukopenia, neutropenia, pancreatitis, pancy topenia (with bone marrow 
suppression identified in some of these cases), Stevens -Johnson syndrome, thrombocy topenia, 
toxic epidermal necroly sis, and weight loss. Alopecia has been reported with levetiracetam use; 
recovery  was observed in the majority  of cases where levetiracetam was discontinued. 
Levetiracetam Monotherapy
Levetiracetam is not approved as monothera py for epilepsy ; however, investigator -initiated 
studies of children with epilepsy  support its use in this indication. These monotherap y studies 
used the same titration and maintenance dosing as pivotal adjunctive studies; overall efficacy  and 
safet y outco mes were similar in both treatment settings.21,24,29,43
1.2. Overall Rationale for the Study
Among its various pharmacologic actions, topiramate is a carbonic anhydrase inhibitor and may 
induce metabolic acidosis, and other changes (eg, hypocitraturia, hypercalciuria, and elevated 
urine pH) that may be associated with an increased tendency for kidney  stone formation.41
Chronic metabolic acidosis may be associated with abnormal bone mineralization and/or 
homeostasis of vitamin D, calcium, or phosphorus. Childhood is a critical period for bone 
mineralization and growth. The effects of topiramate on growth, bone mineralization ,and kidney 
stone formation have not been fully  and systematically  evaluated or well characterized in 
pediat ric populations. 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
40
Approved, Date: 3 November 2017Preclinical juvenile rat studies demonstrated various clinical chemistry  and bone findings 
(eg,changes in serum and urinary  phosphate, decreased global BMD , decreased growth plate 
thickness) with topiramate treatment that raise concerns about long-term toxicities in pediatric 
patients. 
This study  will systematically  assess the long-term safet y of topiramate monotherap y compared 
with levetiracetam monotherap y;specific emphasis will be on metabolic acidosis related to 
topiramate therap y anditsassociation with nephrolithiasis, BMD abnormalities ,and delay ed 
growth in children (2 to 15years of age ).
2. OBJECTIVES AND HYPOTHESIS
2.1. Objectives
Primary Objective
The primary  objective is to evaluate the effects of topiramate monotherap y compared with 
levetiracetam, another standard AED, as monotherapy  for new-onset or recent -onset epileps y on 
pediatric growth and maturation, bone mineralization, and kidney  stone formation in children 2 
to 15years of age .
Secondary Objective
Overall safet y will be assessed.
2.2. Hypothesis
The stud y will test the h ypothesis that flexible dosages of topiramate monotherapy  have the same 
effect as flexible dosages of levetiracetam monotherapy  on pediatric growth , bone 
mineralization, and kidney stone formation in children 2to 15years of agewith new-onset or 
recent -onset epileps y, versus the alternative hypothesis that the effect of topiramate is different 
from that of levetiracetam .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a 1-year, randomized, active -controlled, outpatient, multicenter, open -label, 2-arm 
flexible -dose monotherapy  study of topiramate compared with 1 other AED (levetiracetam) in 
pediatric subjects with epilepsy .Subjects will be required to have newl y or recentl y diagnosed 
epilepsy  (within the previous 2 years, with at least 1, but no more than 10, unprovoked seizures 
during the 5months prior to screening ) characterized by POS with or without secondary  
generalization or PGTCS. 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
41
Approved, Date: 3 November 2017Approximately  282 male and female subjects, 2 to 15 years ofage, with newly  or recently 
diagnosed epileps y, who meet the inclusion/exclusion criteria will be randomly  assigned to either 
the topiramate or levetiracetam arm, in a 1:1 ratio. The randomization will be balanced using 
randomly  permuted blocks and will b e stratified by country  and age group (2 to 5 years of age, 6 
to 9years of age, 10 to 12 years of age, and 13 to 15 years of age). The enrollment will be 
monitored throughout the study  to ensure that subjects are enrolled for each integer year in each 
treatment group.
For each subject, his or her parent(s) (preferably  both parents, if available) or a legally 
acceptable representative(s), as required by local regulations, must give written consent 
(permission) according to local requirements after the natur e of the study  has been fully 
explained and before the performance of any  study -related activity . Children (minors) or subjects 
who are unable to comprehend the information provided can be enrolled only after obtaining
consent from parents or a legally  acceptable representative. Assent must be obtained from 
children (minors) capable of understanding the nature of the study , typically  subjects 7 years of 
age and older, depending on the institutional policies. For the purposes of this study , all 
references to subjects who have provided informed assent/consent refers to the subject (assent as 
applicable) and his or her parent(s) or the subject's legal guardian(s) or legally  acceptable 
representative(s) who have provided consent according to this process. Minors who assent to a 
study  and later withdraw their assent should not be maintained in the study  against their will, 
even if their parents still want them to participate.
The study  will include the following 3 phases: a screening phase of up to 28 days, an open -label 
treatment phase of 1 year's duration, and a posttreatment phase of 30 days’ duration. There may 
be an optional post-study  follow -up phase to obtain dual energy  x-ray absorptiometry  (DEXA) 
measurements in a subg roup of subjects who experience a clinically  important reduction (change 
in Z-score of -0.5 or greater) in BMD, based on local DEXA scan results, after 1 year of 
treatment with topiramate, to determine whether a decrease in BMD after or during 1 year of 
treatment with topiramate is reversible. These subjects will have a repeat DEXA scan 6months 
after discontinuation of study  drug.
To minimize any bias in measurement, after randomization 3 of the safety  assessments will be 
obtained in a blinded fashion, inc luding the DEXA scan, renal ultrasound, and height.
Screening Phase:
Subjects meeting the inclusion/exclusion criteria (see Section 4, Subject Selection) will be eligible 
to enter into the study . They  (and/or their parents or legally  acceptable representatives) will sign an 
informed consent/assent form as appropriate (see Section 16.2.3 , Informed Consent) and enter a 
screening phase of up to 35days. During the screening phase, subjects will be assessed for study  
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
42
Approved, Date: 3 November 2017qualifications. Subjects (or their parents/guardians) will keep a seizure diary  (date of seizure and 
description). Information will be transcribed onto the case report form (CRF). Seizure diaries will 
be maintained with the source documents.
Open -Label Treatme nt Phase:
Immediately  following the Screening Phase, qualified subjects, based on inclusion/exclusion 
criteria, will be randomly  assigned to 1 of 2 treatment groups during the open -label treatment 
phase: topiramate (up to 350 mg/day  in subjects 2 to <10 years of age, and up to 400 mg/day  in 
subjects 10 to 15 years of age) or levetiracetam (up to 60 mg/kg/day ). Antiepileptic drug dosages 
may be adjusted for clinical effect (efficacy  and safet y) during the open -label treatment phase but 
may not exceed these m aximum dosages. 
Only  AED monotherapy will be used for both treatment groups. However, subjects will not be 
discontinued from the study  if 1 or more concomitant AEDs are added after initiating treatment 
with study  drug. Data will be collected prior to the use of the concomitant AED(s) for the 
primary  analysis. Data subsequently  collected while on the concomitant AED(s) will be anal yzed 
in a secondary  anal ysis for each safet y outcome of interest.
All subjects will enter a 30-day posttreatment phase after completing the open -label treatment 
phase.
The open -label treatment phase has 2 periods, titration and maintenance.
Titration Period
Randomization will take place on Day  1 (Visit 2). The Day  1 visit will serve as the baseline visit. 
All procedures on Day 1 (except dispensing of study  drug) should be completed before 
randomization.
Study  drug will be titrated as tolerated to the maximum recommended dosage for optimal clinical 
effect over approximately  6 to 8 weeks, based on titration guidelines according to clinical 
response (see Section 6, Dosage and Administration). For all subjects, at any  time, up -titration of 
open -label study  drug may be slowed down if clinically  indicated for tolerability , and may be 
accelerated if clinicall y indicated for seizure control. 
Subjects will return for a clinic visit at Month 1 and Month 2 for dispensing of study  medication. 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
43
Approved, Date: 3 November 2017Maintenance Period
Subjects should be mainta ined on the dosage achieved at the end of the titration period through 
the remainder of the open -label treatment phase, with the option for dosage adjustment as 
required for optimal clinical effect. Changes to this schedule will be based on a risk-benefit 
assessment of the subject’s clinical condition by  the investigator.
Clinic visits will be scheduled at Months 1, 2, 3, 6, 9, and 12/early  withdrawal. Extra visits may 
be scheduled at the discretion of the investigator. Blood samples for PK evaluations will be taken 
at Months 1, 3, 6, and 12/earl y withdrawal.
Posttreatment Phase
Subjects will be contacted by telephone 30 days after the last dose of study  drug to monitor 
adverse events and concomitant medications. Subjects who complete the study  or discontinu e 
early from the study  may, at the discretion of the investigator, either continue on commercially 
available topiramate or levetiracetam or taper off topiramate or levetiracetam over a period of up 
to 2 weeks during the posttreatment phase.
Post-Study Follow-up Phase
There may be an optional post-study  follow -up phase to obtain DEXA measurements in a 
subgroup of subjects who experience a clinically  important reduction (change in Z-score of -0.5 
or greater) in BMD ,based on local DEXA scan results ,after 1 year of treatment with topiramate, 
to determine whether a decrease in BMD after or during 1 year of treatment with topiramate is 
reversible. These subjects will have a repeat DEXA scan 6 months after discontinuation of study  
drug. During study  conduct, thesponsor will assess site/investigator interest for participation in 
this phase to determine if the follow -up phase will be included. An additional consent/assent will 
be required for this phase.
An external, independent Data Monitoring Committee (DMC) will be commissioned for this 
study . See Section 11.5,Data Monitoring Committee , for details.
A diagram of the stud y design is provided in Figure 1.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
44
Approved, Date: 3 November 2017Figure 1: Study Diagram
Levetiracetam
(n=141)Topiramate
(n=141)
Open -Labe l Maintenance Period
(304 to 318 day s)Titration Period
(6-8 weeks;
42-56 day s)
Month 3 Visit
Month 6  Visit
Month 9  Visit 
Post-
treatm ent 
phase 
(30 day s)Month 12  Visit 
Optional DEXA  
follow-up scan
(18 m onths from 
Random ization)aScreening 
phase 
(up to  28 
days)
Month 1 VisitBaseline/
Randomization (Day 1)
Month 13 Telephone ContactMonth 2 Visit
aOptional post -study follow -up phase to obtain DEXA measurements in a subgroup of subjects w ho experience a 
clinically important reduction (change in Z -score of -0.5 or greater) in BMD ,based on local DEXA scan results ,
after 1 year of treatment with topiramate; these subjects will have a repeat DEXA scan 6 months after 
discontinuation of study drug .
3.2. Study Design Rationale
A study  population from 2 to 15years of ageis appropriate for this study  because this is the 
approved pediatric age group for topiramate monotherap y.Levetiracetam is indicated as 
adjunctive therapy for POS in adults and children ≥1 month of age with epilepsy ),PGTCS 
(adults and children ≥6 years of age with idiopathic generalized epilepsy ), and myoclonic 
seizures (adults and children ≥12 years of age with JME). It has been studied as monotherap y in 
pediatric subjects down to neonates and has been demonstrated to be effective and safe in all 
treatment settings . Evaluation of this target age group will provi de long-term systematic 
assessments of important safety  issues ,eg,chronic metabolic acidosis and effects on growth, 
bone mineralization, and nephrolit hiasis. Subjects will be stratified by country  and by age (2 to 
5years of age, 6 to 9years of age, 10 to 12 years of age, and 13to 15years of age) in order to 
examine anydifferences in thesafet y profile between prepubescent children and postpubescent
adolescents . A study  duration of 1 year is appropriate in order to detect clinically  important 
treatment -related effects on key safety  parameters (growth retardation , bone mineralization ,or 
kidney  stone formation ). See also Section 16.1, Study -Specific Design Considerations .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
45
Approved, Date: 3 November 20173.2.1. Blinding
The stud y is designed as an open -label stud y to enhance subject participation and completion and 
to simulate a naturalistic treatment setting. Given the technical challenges regarding blinding of 
study  drug,along with the prolonged blinding required in young children and possible 
consequent impact on study  conduct and results (eg,difficult regimens requiring too many 
tablets may result in poor compliance, protocol violations ,or subjects prematurely dropping out 
of the study ), a double -blind approach is not optimal. An open -label study  is considered to be 
optimal given that the study  population will include pediatric subjects down to 2 y ears of age and 
the study  duration will be 1 y ear. An open -label design allow sflexibility  in dosing regimens .
To minimize any bias in measurement, after randomization 3 of the safety  assessments will be 
obtained in a blinded fashion, including the DEXA scan, renal ultrasound, and height. These are 
the key  assessments that are being evaluated on the basis of the biological effects associated with 
topiramate, and are necessary  for achieving the primary  objective .
3.2.2. Active Control
An active control will be used as opposed to a placebo control because of obvious ethical 
concerns of placebo treatment in along-term monotherap y treatment setting for epileps y,a 
chronic and potentially  life-threatening disorder. Randomization will be used to minimize bias in 
the assignm ent of subjects to treatment groups, to increase the likelihood that known and 
unknown subject attributes (eg, demographic and baseline characteristics) are evenl y balanced 
across treatment groups, and to enhance the validity  of statistical comparisons across treatment 
groups.
Levetiracetam is an appropriate comparator because of its established efficacy for target seizure 
types, relativel y low toxicity , and lack of significant known risk of kidney  stones or possible 
deleterious effects on bone or growth. Levetiracetam is not approved as monotherapy  for 
epilepsy ; however, studies of children with epilepsy  support its use in this indication. Notabl y, 
these monotherap y studies used the same titration and maint enance dosing as pivotal adjunctive 
studies; overal l efficacy  and safet y outcomes were similar in both treatment settings.21,24,29,43On 
this basis, the FDA -approved dosing recommendations for levetiracetam (titration schedule, 
dosing frequency ) will be used in this study . 
Study  drugwill be given as monotherapy  only, since use of any concomitant AED may
potentially  confound results. However, subjects will not be discontinued from the study  if 1 or 
more concomitant AEDs are added after initiating treatment with study  drug. Data will be 
collected prior to the use of the concomitant AED(s) for the primary  analysis. Data subsequently 
collected while on the concomitant AED(s) will be analy zed in a secondary  analysis for each 
safet y outcome of interest.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
46
Approved, Date: 3 November 20174. SUBJECT SELEC TION
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following 2 sub sections. If there is a question about the inclusion or exclusion criteria below, the 
investigator should consult with the appropriate sponsor rep resentative before enrolling asubject 
in the study . 
For a discussion of the statistical considerations of subject selection , refer to 
Section 11.2,Sample Size Determination.
4.1. Inclusion Criteria
Each p otential subject must satisfy  all of the following criteria to be enrolled in the study . 
1. Subject must be a child or adolescent (male orfemale) 2 to 15years of age with a 
clinical diagnosis of new-onset or recent -onset epilepsy  characterized by POS (with or 
without secondary  generalization) or PGTCS in accordance with criteria of the 
Interna tional League Against Epilepsy .12The epilepsy  diagnosis must be within the 
previous 2 y earsbefore screening .
2. Subject must h ave clinical or electroencephalogram (EEG) evidence of POS (simple or 
complex), with or without secondary  generalization, or PGTCS within 5 months prior to 
the first day  of screening. Subjects should have at least 1, but no more than 10, 
unprovoked seizure s during the 5 months prior to screening . Unprovoked seizure 
clustering within a 24 -hourperiod will be considered a s asingle unprovoked seizure for 
the purposes of counting seizures to determine eligibility .16
Acceptable evidence of POS includes 1 of the following:
Documented recurrent clinical seizures with asymmetric motor features or 
characteristic behavioral alterations. The interictal EEGs may be negative or 
inconclusive, provided that the clinical criterion for POS is met.
A routine EEG or video EEG showing focal or asymmetric EEG findings 
(epileptiform discharges, focal slowing, focal attenuation, or a combination), with or 
without secondary generalization. Clinical seizures with symmetric or behavioral 
features are acceptable in the presence of EEG evidence of an as ymmetric origin.
Acceptable evidence of PGTCS includes 1 of the following: 
Documented recurrent clinical seizures with seizures that are initially  generalized, 
associated with tonic co ntractions and clonic movements
EEG expression that is a generalized, s ynchronous, sy mmetrical discharge
Interictal EEGs may be normal or show generalized discharges such as spikes, 
polyspike, spike -wave, and poly spike wave.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
47
Approved, Date: 3 November 20173. At screening , subject must have weight and height values within the 5thto 95th
percentile for chronological age (based on standard Child Height and Weight Charts 
from the CDC ).25
4. Subject must n ever have been treated for epileps y (treatment -naïve) or have been treated 
with no more than 1 standard AED if temporary  or urgent AED use was necessary . 
Previous AED exposure must not exceed either of the following:
Thirty -onedays immediately  preceding enrollment ,or 
Atotal of 6 months of previous AED exposure in the past if the AED has been 
discontinued for at least 1 year prior to enrollment
5. If subject is currently  treated with an AED, inadequacy  of current epilepsy  treatment 
must be documented on a worksheet provided to the investigator. Criteria for 
inadequacy  include:
AED dosage is considered optimized (including, if clinicall y appropriate, recent 
demonstration of adequate blood levels) in the opinion of the investigator and 
unchanged for at least 5 half -lives prior to the first day  of screening and found to be :
Inadequate in control ling seizures in the opinion of the investigator, as 
shown in part by a retrospective history  of at least 1seizure in the 3months 
prior to screening ,or 
Not well tolerated
6. Parents (or legall y acceptable representatives) of the subject must sign an informed 
consent/permission document ,indicating that they understand the purpose of and 
procedures required for the study  and are willing to give permission for their child to 
participate in the study . Subjects 7 years of age and older , capable of understanding the 
nature of the study , must provide assent for their participation.
7. Caregivers (parents or legall y acceptable representatives) of the subject must be able to 
accuratel y maintain the subject take -home record and seizure diary .
8. Subject must h ave had a computerized tomography  or magnetic resonance imaging scan 
within 2 years prior to study  entry, to confirm the absence of a progressive lesion, such 
as a tumor, with the exception of lesions of tuberous sclerosis and Sturge -Weber 
syndrome, which are allowed. The report must be included in the source documents.
9. Subject must have an electrocardiogram (ECG )at screening with no “abnormal, 
clinically  significant” interpretations by  a local cardiologist .
10. Subject must be otherwise healt hy on the basis of physical examination, medical 
history , vital signs, clinical laboratory  tests, and 12 -lead ECG performed at screening. If 
there are abnormalities, they must be consistent with the underly ing illness in the study  
population. This determin ation must be recorded in the subject's source documents and 
initialed by  the investigator.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
48
Approved, Date: 3 November 201711. Subject must be ambulatory  and must have normal activity  levels based on the Habitual 
Activity  Estimation Scale (HAES; see Attachment 1) at screening , according to 
recommended levels .
12. Before randomization, a girl must be either :
Not of childbearing potential: premenarchal; permanentl y sterilized (eg, tubal 
occlusion, hysterectom y, bilateral salpingectomy); or otherwise be incapable of 
pregnancy
Of childbearing potential and practicing a highl y effective method of birth control 
consistent with local regulations regarding the use of birth control methods for 
subjects participating in clinical studies, eg, established use of oral, injected, or 
implanted hormonal methods of contraception; placement of anintrauterine device 
or intrauterine s ystem; male partner sterilization (the vasectomized partner should be 
the sole partn er for that subject); true abstinence (when this is in line with the 
preferred and usual lifesty le of the subject).
Note: Male partners must use a barrier method, such as a condom with spermicidal 
foam/gel/film/cream/suppository  or occlusive cap (diaphr agm or cervical/vault cap) 
with spermicidal foam/gel/film/cream/suppository . 
Note: If the childbearing potential changes after start of the study  (eg, girl who is not 
heterosexually  active becomes active, premenarchal girl experiences menarche), the 
subject must begin a highly  effective method of birth control, as described above.
13. Agirl of childbearing potential must have a negative serum -human chorionic 
gonadotropin pregnancy test at screening, and a negative urine pregnancy  test at 
randomizatio n/baseline and at all subsequent visits of the open -label treatment phase.
4.2. Exclusion Criteria
Any potential subject who meet sany of the following criteria will be excluded from participating 
in the study .
1. Subject h as a surgicall y implanted and functioning vagus nerve stimulator.
2. Subject has a history  of seizures as a result of a correctable medical condition, such as 
metabolic disturbance, toxic exposure, neoplasm, or active infection within 2 weeks 
prior to the first day  of screening.
3. Subject has had uncontrolled seizures while previously  taking either topiramate or 
levetiracetam.
4. Subject has a history  of nonepileptic seizures within 2 weeks prior to the first day of 
screening.
5. Subject h as my oclonic or absence seizures.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
49
Approved, Date: 3 November 20176. Subject has a history  of status epilepticus within 2 weeks prior to first day of screening. 
Status epilepticus is defined as 30 minutes of continuous motor seizures.
7. Subject h as had epileps y surgery  within 3 months prior to the first day  of screening.
8. Subject has any progressive neurologic disorder, including malignancy , brain tumor, 
active central nervous system infection, demyelinating disease, or degenerative or 
progressive central nervous sy stem disease, with the exception of tuberous sclerosis and 
Sturge Weber s yndrome.
9. Subject has any clinically  significant uncontrolled medical illness, including hepatic or 
renal failure, ischemic cardiac disease, bone disorders, growth and maturation disorders 
of any type, malignancy , physical impairments that prevent normal ambulation, or any 
disorder that, in the opinion of the investigator, places the subject at risk through 
participation in a clinical study .
10. Subject has nephrocalcinosis, renal stones of any type, or hydronephrosis, as evidenced 
bymedical history  or screening examination.
11. Subject has a history  of ≥2 long bone fractures if the subject is ≤10 yearsold; ≥3 long 
bone fractures if the subject is >10 years old, where at least 1 of the fractures was a low -
impact fracture, defined as slight trauma that may include:
Falling to the ground from <0.5 m (standing height)
Falling to a resilient surface (rubber or sand) from 0.5 to 3 m
Falling from a bed or cot
Playing injuries, including play ground scuffles
12. Subject has indwelling hardware, or has an abnormality  of the skeleton or spine, such as 
scoliosis of 20 degrees or more, ky phosis, or skeletal dy splasia.
13. Subject has clinically  relevant abnormalities noted on renal ultrasound or DEXA scans. 
Subjects with baseline BMD Z-score s≤-2, for either posterior -anterior lumbar spine 
(L1-L4) or total bod y less head, will not be enrolled.
14. Subject has congenital glaucoma or known ocular deficits, or is receiving any ocular 
medications except lubricating ey e drops or topical antibiotics.
15. Subject has a known history  of central hyperthermia, dysautonomia, or other 
disturbances of autonomic function.
16. Subject has a known history  of inborn errors of metabolism, mitochondrial dysfunction, 
or prior evidence of h yperammonemia .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
50
Approved, Date: 3 November 201717. Subject has any clinically  significant abnormality  in laboratory  tests at screening, 
including but not limited to:
WBC count < 3,000/μL  or absolute neutrophil count <1,000/μL  in the last 6 months 
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or 
gamma -glutamy ltransferase (GGT) 3 times the ULN
Total bilirubin 1.5 mg/dL or conjugated bilirubin 20% of total
Venous ammonia 2 times the ULN
25-hydroxy -vitamin D (level for clinicall y significant vitamin D deficiency  is 
<12.0 ng/mL, conventional units [<30 nmol/L , SI units])19,42
Parathy roid hormone (normal reference range is 14.0 to 72.0 pg/mL)
1,25-dihydroxy-vitamin D, as determined by the age-dependent reference ranges 
(see lab manual)
Insulin -like growth factor 1 (IGF-1), as determined by the age-dependent reference 
ranges (see lab manual)
18. Subject has a bicarbonate level <20mEq/L, has a diagnosis ofmetabolic acidosis, or is 
on alkali therap y.
19. Subject has refractory  epilepsy and requires adjunctiv e AED therap y or is receiving 
>1concurrent AED (including benzodiazepines, regardless of the reason for 
prescription).
20. Subject is being treated with furosemide, hydrochlorothiazide, vigabatrin, vitamin B6 
therap y for epileps y, monoamine oxidase (A or B) inhibitors, felbamate, zonisamide, or 
any other medication that is a potent carbonic anhy drase inhibitor (eg, acetazolamide). 
Past treatment with furosemide for more than 2 weeks must be discussed with the 
sponsor and the discussion documented .
21. Subject is being treated with other drugs that may affect bone metabolism ,eg,steroids
(intravenous or oral steroids ), growth hormone, antacids, or nonsteroidal 
anti-inflammatory  drugs (NSAIDs) for chronic or underl ying disorders for more than 
7consecutive day s at least 1 month prior to the first day  of screening .
22. Subject h as been treated with an investigational drug within 5 half -lives prior to the first 
day of screening.
23. Subject has used topiramate or levetiracetam within 1 month prior to the first day of 
screening.
24. Subject has a known allergy  or hypersensitivity  to formulations for either topiramate or 
levetiracetam.
25. Subject is on a ketogenic diet to control epilepsy  (eg, the ketogenic diet, the Atkins diet, 
the South Beach diet, or another low -carboh ydrate diet).
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
51
Approved, Date: 3 November 201726. Subjects with history  of poor dietary  intakes including requirements for special diets, 
inadequate caloric intake, inadequate nutrient intake, failure to thrive, growth 
abnormalities, poor weight gain, etc.
27. For subjects with at least 2 previous measurements available prior to the first day of 
screening, if the subject’s length or weight has crossed (in a decreasing direction) 
2major percentile lines on the standard CDC growth charts, enrollment must be 
discussed with the sponsor and the discussion must be documented . 
28. For all subjects, if the weight -versus -length plot at screening is lower than the 
3rdpercentile on the standard CDC chart, enrollment must be discussed with the sponsor
and the discussion must be documented . 
29. Subject has a history  of noncompliance with AEDs or clinic attendance that is 
sufficient, in the judgment of the investigator, to interfere with participation in this 
study .
30. Subject i s not reasonabl y expected to complete the study .
31. Subject is a child or other famil y member of the investigator or of an employ ee of the 
study  center, with direct involvement in theproposed study  or other studies under the 
direction of that investigator or stud y center.
32. Subject is pregnant, breast -feeding, or planning to become pregnant while enrolled in 
this study  or within 4 weeks after the last dose of study  drug .
33. Subject has a history  of any suicidal behavior (attempt , interrupted, aborted , or 
preparatory )in the past 6 months prior to the screening visit.
NOTE: Investigators should ensure that all randomization criteria have been met prior to 
baseline . If a subject 's status changes (including clinical laboratory  results or receipt of additional 
medical records ) after screening but before the first dose of study  drug is given such that he or 
she no longer meets all eligibility  criteri a, then the subject should be excluded from participation 
in the study .Section 17.4, Source Documentation, describes the required documentation to 
support meeting the enroll ment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1. Agirl of childbearing potential who ishetero sexually  active must remain on a highl y 
effective method of birth control (see Section 4.1, Inclusion Criteria) .
2. Subjects must refrain from using an y of the prohibited medications, including:
Ocular medications, except lubricating ey e drops or topical antibiotics
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
52
Approved, Date: 3 November 2017 Furosemide, hydrochlorothiazide, vigabatrin, vitamin B6therapy  for epilepsy , 
monoamine oxidase (A or B) inhibitors
Any other medication that is a potent carbonic anhydrase inhibitor (eg, 
acetazolamide, furosemide, zonisamide)
Citrate treatment
Medications that may affect bone metabolism if taken for more than a 10-day 
treatment course, including intravenous or oralsteroids, growth hormone, NSAIDs, 
or antacids
5. TREA TMENT ALLOCA TION AND BLINDING
Procedures for Ra ndomization and Stratification
Subjects will be randomly assigned to 1 of 2treatment groups based on a computer -generated 
randomization schedule prepared before the study  by or under the supervision of the sponsor. 
The randomization will be balanced using randomly  permuted blocks and will be stratified by 
coun try and agegroup (2 to 5years of age, 6 to 9 years of age, 10 to 12 years of age, and 13to 
15yearsof age). The enrollment will be monitored throughout the study  to ensure that subjects 
are enrolled for each integer year in each treatment group. 
Based on this information , the interactive web-based response system (IWRS) will assign a 
unique treatment code, which will dictate the treatment assignment and matching study  drug kit 
for the subject. As subjects are randoml y assigned to treatment, the IWRS will assign a study  
drug kit to be dispensed at that visit. New study  drug kits will be assigned each time the IWRS is 
accessed for dispensing additional study  drug.
Blinding
As this is an open -label study , blinding procedures are not applicable for tre atment assignment.
To minimize any bias in measurement, after randomization 3 of the safety  assessments will be 
obtained in a blinded fashion, including the DEXA scan, renal ultrasound, and height. The 
location for these data should be kept separate from the rest of the study  data. Procedures for 
main taining the blind will include the following (further details will be provided in a separate 
Blinding Plan for this study ):
Separate secure locations for blinded and unblinded study  documents
A separate office or ph ysical space for obtaining the height measurements
Blinded staff will not be permitted access to areas where unblinded activities are performed.
Measures will be required to ensure no overlap of equipment. Height will be measured by a 
trained individu al who is blinded (unaware of the treatment); blinded height measures are not 
to overlap assessments of unblinde d assess ments (weight and vital signs) .The same blinded 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
53
Approved, Date: 3 November 2017person should obtain height measurements using the same technique on the same stadiometer 
at a given center. It is also recommended that the stadiometer be calibrated at least monthly 
and that this be document ed. 
Blinded height measures are to be recorded in the source documents, or provided to the 
unblinded study  coordinator for entry into the source documents. The unblinded study  
coordinator will then enter this data, along with other visit data, into the CRF.
Documented measures will be required to ensure that no communication of blinded vs. 
unblinded data takes place in the same office suite.
6. DOSA GE A ND A DMINISTR ATION
Subjects will be randomly  assigned to receive unblinded, flexible dosages of topiramate or 
levetiracetam as follows:
Topiramate: weight -based dosing for subjects 2 to <10 years of age, not to exceed 
350mg/day , as tolerated ; not to exceed 400 mg/day in subjects 10 to 15years of age, as 
tolerated
Levetiracetam: weight -based dosing for all subjects 2 to 15years of age, not to exceed 
60mg/kg/day , as tolerated
Subjects will receive study  drugin a twice -a-day regimen (BID). The first dose of study  drug on 
Day 1 will be taken in the evening. After randomization, subjects will be titrated as tolerated to 
the maximum recommended dosage for optimal clinical effect over 6 to 8 weeks and will be 
maintained on that dosage through the open -label treatment phase ,with the option for dosage
adjustment as required for optimal clinical effect. Changes to this schedule will be based on a 
risk-benefit assessment of the subject’s clinical condition by  the investigator. 
Topiramate Ti tration in Subjects 2 to <10 Years of Age
Dosing in subjects 2 to <10 years of age is based on weight. During the titration period, the 
initial dosage of topiramate should be 25 mg/day,administered nightl y for the first week. Based 
upon tolerability , the dosage can be increased to 50 mg/day  (25 mg BID) in the second week (see 
Table s1 to 3 in the titration schedules in Attachment 2). Dosage can be increased by 25to 
50mg/day  each subsequent week as tolerated. Titration to the maximum recommended dosage
should be attempted over 6to 8weeks. Based upon tolerability  and seizure control, the rate of 
titration may be adjusted to achieve optimal clinical response . The total daily  dosage should not 
exceed the maximum maintenance dosage for each range of body  weight (Table 1).Subjects 
with a body  weight >38 kg will be assi gned to the titration schedule for subjects 10 to 15 y ears of 
age, as described below .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
54
Approved, Date: 3 November 2017Table 1: Topiramate Monotherapy Target Total Daily Maintenance 
Dosing for Subjects 2 to <10 Years of Age
Weight (kg)Total Daily Dosage (mg/day)a
Minimum Maintenance DosageTotal Daily Dosage (mg/day)a
Maximum Maintenance Dosage
Up to 11 150 250
12–22 200 300
23 –31 200 350
32 –38 250 350
a.Administered in 2 equally divided doses.
The topiramate sprinkle formulation will be provided for those subjects who cannot swallow 
tablets. Sprinkle capsules may  be swallowed whole or may  be administered by  carefull y opening 
the capsule and sprinkling the entire contents on a small amount (teaspoon) of soft food. This 
drug/food mixture should be swallowed immediately  and not chewed. It should not be stored for 
future use.
Topiramate Titration in Subjects 10 to 15Years of Age 
The recommended dosage for topiramate monotherap y in adults and pediatric patients 10years 
of age and older is 400mg/day  in 2divided doses. The dosage should be achieved by titration 
according to the schedule shown in Table 4in the tit ration schedules in Attachment 2. 
Levetiracetam Titration in Subjects 2 to 15Years of Age
Treatment should be initiated with a daily  dosage of 20 mg/kg /day in 2 divided doses (10mg/kg 
BID). The daily  dosage may be increased every  2 weeks by increments of 20mg/kg /day to the 
recommended daily dosage of 60 mg/kg/day (30 mg/kg BID). The maximum recommended 
daily  dosage is 3,000 mg (1,500 mg BID). Subjects with a body  weight ≤20kg should be dosed 
with oral solution. Subjects with body  weight above 20 kg can be dosed with either tablets or 
oral solution. See Table s5, 6, and 7 in the tit ration schedules inAttachment 2for dosing for oral 
solution for subjects with a body  weight ≤20 kg, and Table 8in the titration schedules in 
Attachment 2for dosing for tablets for subjects with a body  weight >20 kg. 
The following calculation should be used to determine the appropriate daily  dosage of oral 
levetiracetam solution for pediatric subjects based on a daily  dosage of 20 mg/kg/day , 
40mg/kg/day ,or 60 mg/kg/day : 
Total daily  dosage (mL/day ) = Daily  dosage (mg/kg/day ) x subject weight (kg)
100 mg/mL
All study  drug swill be provided in child -resistant packaging during the study . It is recommended 
that tablets not be broken. Both topiramate and levetiracetam can be taken without regard to 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
55
Approved, Date: 3 November 2017meals. Study  staff will instruct subjects and/or parents/caregivers on how to store medication for 
at-home use as indicated for this study . If a subject vomits within 30 minutes of receiving a dose, 
the dose will be repeated. If a subject vomits a second time or more than 1 hour later, the dose 
will not be repeated. All cases of vomited doses and action taken must be recorded in the 
subject ’stake-home record. Subjects will be instructed to take any  missed doses of study  drug as 
soon as possible. However, if the subject is within 6 hours of taking the next scheduled dose, he 
or she should wait until then to take theusual dose of study  drug and skip the missed dose.
Subjects should not take a double dose in case of a missed dose.
Subjects should be titrated and maintained according to clinical response, eg,titration may be 
slowed on the basis of tolerability  and may be accelerated for the purposes of seizure control. 
Maint enance dosage s should be based on optimal clinical response and may be adjusted at any 
time during the open -label treatment phase. Subjects are recommended not to exceed maximum 
recommended maintenance dosages; however ,subjects will not be discontinued from the study  if 
higher doses are required for optimal clinical effect as judged by the investigator .Data collected 
while on dosages that exceed maximal recommendations may be analy zed separatel y,as 
appropriate.
Once a subject completes the study  ordiscontinues early from the study , at the discretion of the 
investigator , he or she will either continue on commerciall y available topiramate or levetiracetam 
orbe tapered off of topiramate or levetiracetam over a period of up to 2 weeks.
7. TREA TMENT COMPLIA NCE
The investigator or designated study  personnel will maintain a log of all drug dispensed and 
return ed. Drug supplies for each subject will be inventoried and accounted for throughout the 
study  (at each visit). Subjects will receive instructions on compliance with study  treatment at the 
screening visit (eg, subject take -home record). During the course of the study , the investigator or 
designated study  research staff will be responsible for providing additional instruction to 
reeducate an y subject who is not compliant with taking the stud y drug.
8. PRESTUDY AND CONCOMITA NT THERAPY
Prestudy  AEDs and other medications taken within 2 y ears prior to the study must be recorded at 
screening.
Concomitant therapies must be recorded throughout the study  beginning w ith the start of the first 
dose of study  drug.Concomitant therapies should also be recorded beyond 30 days after the last 
dose of study  drug,but only in conjunction with new or worsening adverse events or serious 
adverse events that meet the criteria outlined in Section 12.3.2 , Serious Adverse Events .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
56
Approved, Date: 3 November 2017All therapies (prescription or over-the-counter medications, including vaccines, vitamins ,herbal 
supplements; non-pharmacologic therapies such as electrical stimulation, acupuncture, specia l 
diets, exercise regimens) different from the study  drug must be recorded in the CRF. 
Modification of an effective preexisting therapy  should not be made for the explicit purpose of 
entering a subject into the study .
For subjects receiving an AED at basel ine, this AED should be tapered down and discontinued 
during the titration period. Concomitant AEDs at baseline used for any purpose will be 
withdrawn in one -third decrements during the 6-to 8-week titration period.
Only  AED monotherap y will be used for both treatment groups. In the event of insufficient 
seizure control or intolerability , it should be explored first if a dosage adjustment of the study  
drug might be useful before adding another AED . However, subjects will not be discontinued 
from the study  if 1 or more concomitant AEDs are added after initiating treatment with study  
drug. Data will be collected prior to the use of the concomitant AED (s)for the primary  analysis. 
Data subsequently  collected while on the concomitant AED (s)will be analy zed in a secondary 
analysis for each safet y outcome of interest.
Other prohibited concomitant medications include: 
Ocular medications ,except lubricating ey e drops or topical antibiotics
Furosemide, hydrochlorothiazide, vigabatrin, vitamin B6therapy  for epilepsy , monoamine 
oxidase (A or B) inhibitors , or felbamate
Any other medication that is a potent carbonic anhydrase inhibitor (eg, acetazolamide , 
furosemide, zonisamide )
Citrate treatment 
Medications that may  affect bone metabolism taken for more than a 10 -day treatment course, 
including intravenous or oral steroids, growth hormone, NSAIDs, antacids, calcium, 
vitamin D, or multivitamins
Subjects will be allowed to take calcium, vitamin D, and multivitamins as concomitant therap y 
provided the dosages fall within the range of recommended daily  allowances for the age of the 
subject. These agents will only be allowed as prophy laxis against a deficiency , and not as a 
treatment for a previously  diagnosed deficiency .
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
57
Approved, Date: 3 November 20179. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule that follows the synopsis summarizes the frequency  and timing 
of safet y, PK, and other measurements applicable to this study .
The study  includes 3 phases: a screening phase of up to 35days, an open -label treatment phase 
of 1 year'sduration (including titration andmaintenance ), and a posttreatment phase of 30 days, 
during which subjects will either continue on commerciall y available topiramate or levetiracetam
or will be tapered off of topiramate or levetiracetam over a period of up to 2 weeks. There may
be an optional post-study  follow -up phase to obtain DEXA  measurements in a subgroup of 
subjects who experience a clinically  important reduction (change in Z-score of -0.5 or greater) in 
BMD, based on local DEXA scan results, after 1year of treatment with topiramate, to determine 
whether a decrease in BMD after or during 1year of treatment with topiramate is reversible .
These subjects will have a repeat DEXA scan 6 months after discontinuation of study  drug.
The total blood volume to be collected from each subject will be approximately  44.7 mL 
(45.8 mL for adolescent girls who require serum pregnancy  test at screening ;Table 2).Blood 
samples for testing specific analytes are listed in order of priorit y, in the event of difficulties in 
obtaining the desired volume of blood for any reason at a specific visit. Repeat or unscheduled 
samples may  be taken for safet y reasons or for technical issues with the samples.
Table 2:  Volume of Blood to be Collected From Each Subject (mL)
Visits ScreeningaMonth 1 Month 3 Month 6 Month 9Month 
12Total 
Volume of 
Bloodb
Blood chemistry 
profile, including 
electrolytes1.1 1.1 1.1 1.1 1.1 1.1 6.6
CBC (EDTA whole 
blood)1.2 1.2 1.2 1.2 1.2 1.2 7.2
25-hydroxy -vitamin Dc1.1 1.1 1.1 3.3
IGF-1c1.1 1.1 1.1 3.3
Parathyroid hormone 
(intact)c1.1 1.1 1.1 3.3
1,25-dihydroxy -
vitamin Dc3.0 3.0 3.0 9.0
Ammonia, venousc1.2 1.2 1.2 1.2 1.2 1.2 7.2
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
58
Approved, Date: 3 November 2017Table 2:  Volume of Blood to be Collected From Each Subject (mL)
Visits ScreeningaMonth 1 Month 3 Month 6 Month 9Month 
12Total 
Volume of 
Bloodb
Pharm acokinetic 
samples ( plasma ; AED 
levels)1.2 1.2 1.2 1.2 4.8
Serum pregnancy test 1.1 1.1
Total 10.9 mL 4.7mL 4.7mL 11.0 mL 3.5 mL 11.0 mL 45.8 mL
a The optional use , during the screening period, of local laboratory evaluations for 25 -hydroxy -vitamin D, 1,25 -
dihydroxy -vitamin D, Parathyroid hormone (intact) and IGF -1 might lead to an increase in blood volume for the 
subject concerned. The total volume is dependent on the local laboratory requirements and on the number and 
type of individual assays.
bCalculated as number of samples multiplied by amount of blood per sample.
c All laboratory tests will be evaluated ce ntrally except for venous ammonia ,which will be evaluated locally 
(except in select countries where local testing is not possible, in which case the central laboratory will also 
evaluate venous ammonia) . The laboratory tests for 25 -hydroxy -vitamin D, 1,25 -dihydroxy -vitamin D , 
Parathyroid hormone (intact) and IGF -1 at screening will be evaluated centrally but additional evaluation at local 
laboratory is allowed to reduce the duration of the screening phase. At the dis cretion of the investigator, one, or 
moreof these laboratory parameters may be evaluated at the local laboratory. The volume of blood is based on 
reference laboratory minimal volumes.
AED=antiepileptic drug; CBC=complete blood count; EDTA= ethylene diamine tetra -acetic acid; IGF-1=insulin -
like growth factor 1 .
9.1.2. Screening Phase
The screening phase will last up to 35days, during which subjects will be assessed for study 
qualifications and other measures as listed in the Time and Events Schedule following the 
synopsis . 
9.1.3. Open -Label Treatment Phase
The open -label treatment phase includes randomization and distribution of study  drugand 
titration instructions (Visit 2; Day 1), a 6-to 8-week titration period, and a maintenance period ,
during which subjects will remain in the study  until they either complete 1 year of open -label 
treatment or withdraw from the study . 
Subject take -home records and seizure diaries will be given to parents/guardians at Visit 1 and at 
each subsequent visit. Each subject's parent will record in the seizure diary  the date, description , 
and number of seizures. The investigator or designated study  personnel will review the data to be 
recorded in the subject take-home record with the subject’s parents/legall y acceptable 
representatives at the beginning of the study. At each visit, the investigator will review the 
seizure data , and then transcribe the data onto the appropriate page of the CRF.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
59
Approved, Date: 3 November 2017Titration intervals and dosage s may be adjusted for individual subjects to achieve their optimal 
dosage . Subjects receiving 1concomitant AED at baseline for any purpose will have their AED
tapered down and discontinued in one -third decrements during the 6-to 8-week titration period.
At the end of the titration period ,the dosage of study  drugshould be maintained but may be 
adjusted at the investigator ’sdiscretion for optimal clinical effect . 
Subjects will return for a clinic visit at Months 2 and 3, with subsequent visits to occur every 
3months. 
9.1.4. Posttreatment Phase (Follow -Up)
Subjects who comp lete the study  or discontinue early  from the study  may at the discretion of the 
investigator either continue on commercially  available topiramate or levetiracetam or be tapered 
off of topiramate or levetiracetam over a period of up to 2 weeks during the posttreatment phase. 
A final visit will be performed at the end of the 1-year open -label treatment period or upon early 
withdrawal, including review of seizure frequencies from the subject seizure diary and review of 
safet y and adverse eve nts.
Telephone contact will be made to assess adverse events and concomitant medications 30 days
after the last dose of study  drug, unless the subject has died, is lost to follow -up, or has 
withdrawn consent /assent . If the information on adverse events andconcomitant medications is 
obtained via telephone contact, written documentation of the communication must be available 
for review in the source documents . If the subject has died, the date and cause of death must be 
collected and documented on the CRF.
9.1.5. Post-Study Phase (Follow -Up)
There may be an optional post-study  follow -up phase to obtain DEXA measurements in a 
subgroup of subjects who experience a clinically  important reduction (change in Z-score of -0.5 
or greater) in BMD ,based on local DEXA scan re sults,after 1 year of treatment with topiramate, 
to determine whether a decrease in BMD after or during 1 year of treatment with topiramate is 
reversible . These subjects will have a repeat DEXA scan 6 months after discontinuation of study  
drug.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
60
Approved, Date: 3 November 20179.2. Pharmacokinetic s
9.2.1. Sample Collection and Handling
Blood samples (1 mL per sample) for the determination of plasma topiramate and levetiracetam
concentrations will be obtained during clinic visits according to the Time and Events schedule. If 
possible, blood samples for PK evaluations should be trough samples (ie, taken immediatel y 
before the morning dose) and coincide with samples drawn for clinical laboratory  tests. During 
each PK assessment, the dosing regimen, dose administered, time and date of dose 
admin istration, time of sample collection, and concomitant medications will be recorded in the 
CRF .
Attachment 3,Attachment 4,andAttachment 5detail further information regarding handling and 
shipment of plasma samples.
9.2.2. Analytical Procedures
Pharmacokinetics
All PKsamples will be analyzed under the supervision of the sponsor’s Depar tment of 
Bioanal ysis. Plasma samples will be analyzed to determine concentrations of topiramate and 
levetiracetam using validated, specific and sensitive liquid chromatograph y-tandem mass 
spectrometry  methods.
9.2.3. Pharmacokinetic Parameters
Pharmacokinetic parameters will not be estimated. Topiramate and levetiracetam plasma 
concentration data will be determined b y a validated bioanal ytical method(s) and summarized. 
9.3. Safety  Evaluations
Details regarding the DMC are provided in Section 11.5.
Any clinically  significant abnormalities persisting at the end of the study /early withdrawal will 
be followed b y the investigator until resolution or until a clinically stable endpoint is reached. 
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule . For all evaluations, if possible, the same 
individual should evaluate the subje ct at all visits.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
61
Approved, Date: 3 November 2017Take -Home Record /Seizure Diary
Throughout the study , caregivers (parents or legally  acceptable representatives) of the subjects 
must maintain a subject take -home record and a seizure diary .The take -home record will include 
data on study  drug administration, concomitant medications, and items of general health . The 
seizure diary contains instructions to record the date and description of each seizure and will be 
reviewed by the investigator at each study  visit during the open -label treatment phase and at the 
end-of-study/early withdrawal visit. The information from thetake-home record and seizure 
diary  will be reviewed by the investigator and transcribed into theelectronic case report form
(eCRF ).
Adverse Events
Adverse events will be reported by the parent (or his or her legally  acceptable representative) for 
the duration of the study , from thetime of signing the consent/assent . Adverse events will be 
followed by the investigator as specified in Section 12, Adverse Event Reporting. Subjects will 
be monitored for signs of suicidal ideation and behavior with both adverse event reports and the 
C-SSRS (see below) , and they (or their caregivers, as appropriate) will be advised to seek 
immediate medical attention should signs of suicidal ideation or behavior emerge.
Clinical Laboratory Tests 
Blood samples for serum chemistry  (nonfasting) and hematology  and a random urine sample for 
urinaly sis will be collected. The investigator must review the laboratory  report, document this 
review, and record any clinically  relevant changes occurring during the study  in the adverse 
event section of the CRF. The following tests will be performed by the central laboratory except 
for venous ammonia, which will be evaluated locally (except in select countries where local 
testing is not possible, in which case the central labora tory will also evaluate venous ammonia) . 
The laboratory  tests for 25-hydroxy -vitamin D, 1,25-dihydroxy-vitamin D, Parathy roid hormone 
(intact) and IGF-1 at screening will be performed at a central laboratory ,but additional 
evaluation at local laboratory  is allowed in order to reduce the duration of the screening phase :
Hematology  Panel
-hemoglobin -WBC count with differential
-hematocrit -platelet count
-red blood cell count
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
62
Approved, Date: 3 November 2017Serum Chemistry  Panel
-sodium -creatine phosphokinase 
-potassium -lactic acid deh ydrogenase 
-chloride -uric acid
-bicarbonate -calcium
-blood urea nitrogen (BUN) -phosphorus
-creatinine -albumin
-glucose -total protein
-AST -cholesterol
-ALT -triglycerides
-GGT -magnesium
-total bilirubin -25-hydroxy-vitamin D*
-ammonia -1,25-dihydroxy -vitamin D*
-serum pregnancy  test (at screening, for girls 
of childbearing potential)-parath yroid hormone*
-alkaline phosphatase -IGF-1*
* Only measured at visits for screening, Month 6 ,and Month 12/early withdraw al(see Bone Mineralization 
section below ).
Special instructions for ammonia sample collection : Collect blood on ice, separate 
plasma from cells,and freeze ASAP (within 15 minutes of draw time). Specimens need 
to be spun in a refrigerated centrifuge and are unstable if thawed and refrozen. 
In addition to its routine assessment, free-flowing venous ammonia will be obtained on 
an immediate basis in the event of:
oClinical evidence of change in mental status consistent with a hyperammonemic 
encephalopath y (not seizures or post -ictal state)
oElevated hepatic enzy mes as follows, unless a routine ammonia done at the same 
time was normal:
oALT, AST, or GGT 3 times the ULN(or 2 times the ULN forsubjects 
taking valproic acid)
oTotal bilirubin 1.5 mg/dL
oConjugated bilirubin 20% of the total
oAny other appropriate clinical indication
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
63
Approved, Date: 3 November 201725-hydroxy -vitamin D, 1,25 -dihydroxy-vitamin D , Parathy roid hormone (intact) and IGF -1:
Atthe discretion of the investigator, oneor more of these laboratory  parameters may be 
evaluated at the local laboratory to reduce the duration of the screening phase .In such 
instance s, the local laboratory  instructions should be followed and local reference ranges 
should be applied. The local laboratory  results would be used for decision regarding 
randomization . The central laboratory  evaluation results will be used for study  data analysis. 
The additional use of a local laboratory  might lead to an addit ional amount of blood volume 
to be drawn from the subject at screening.
Urinaly sis will be performed by  the central laboratory , and will include dipstick and sediment 
as noted below. If dipstick result is abnormal, flow cytometry  will be used to measure 
sediment. In case of discordance between the dipstick results and the flow cytometric results, 
the sediment will be examined microscopicall y.
Dipstick Sediment
-specific gravit y -RBCs
-pH -WBCs
-glucose -epithelial cells
-protein -crystals
-blood -casts
-ketones -bacteria
-nitrite
Urine Pregnancy  Testing (for girls of childbearing potential only)to be obtained at all visits 
after screening during the open -label treatment phase . If a girl starts menstruating and 
becomes of childbearing potential during the study , urine pregnancy  testsshould be obtained 
at all subsequent visits during the open -label treatment phase.
24-Hour Urine Collection: A 24-hour urine collection will be analyzed for pH, calcium, 
citrate, phosphorus, and creatinine levels. Collection instructions and storage conditions will 
be specified in the laboratory  manual. A 14-day window on either side of the scheduled 
Month 6 visit will be allowed for 24 -hour urine collection. The collection at Month 12 should 
be completed before the Month –12 visit as this evaluation should be obtained while the 
subject is still receiving study –drug therap y.
Additional use of local laboratories is allowed in cases where safet y follow -up is time-critical 
and the central laboratory  results are not expected before the need to take actions for safety 
reasons.
After consultation with the medical monitor , investigators may obtain additional laboratory
assessments and/or advice from local medical consultants in the event of any  clinically  important 
safet y concern.
Bone Age Radiograph
A hand/wrist x-ray will be obtained in the nondominant hand/wrist to determine bone age at 
baseline and at Month 12 (or final study  visit if a subject discontinues prematurel y).20This will 
be read and interpreted locally .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
64
Approved, Date: 3 November 2017Electrocardiogram
A single 12-lead ECG willbe collected at screening only.To be enrolled, subjects must have an 
ECG at screening with no “abnormal, clinically significant” interpretations by a local 
cardiologist .
During the collection of ECGs, subjects should be in a quiet setting without distra ctions (eg, 
television, cell phones) . Subjects should rest in a supine position for at least 5minutes before 
ECG collection and should refrain from talking or moving arms or legs. If blood sampling or 
vital sign measurement is scheduled for the same time point as ECG recording, the procedures 
should be performed in the following order: ECG, vital signs, blood draw.
Vital Signs
Vital signs will be recorded at the times given in the Time and Events Schedule. Measurement of 
vital signs includes axillary  temperature, heart rate, respiratory  rate,and blood pressure .
Temperature will be assessed using anaxillary  thermometer; if temperature is ≥38.0 C, the 
temperature should be repeated immediatel y and both values recorded in the CRF. Respiration 
measurements will be assessed over at least 30 seconds. Blood pressure and heart rate 
measurements should be assessed with a completely  automated device (if available) consisting of 
an inflatable cuff and an oscillatory  detection system. All values will be registered ona built-in 
recorder so that measurements are observer -independent. If an automated device is not available, 
all manual heart rate measurements will be measured each time for a full minute to minimize the 
effects of heart rate variability . Blood pressure w ill be measured with t he cuff placed on the right 
arm. An appropriate size cuff has 1) an inflatable cuff bladder width that is at least 40% of the 
arm circumference (at a point midway  between the olecranon and the acromion) and 2) a cuff 
bladder length th at covers 80% to 100% of the circumference of the arm. 
Orthostatic vital signs will be obtained for all subjects pending cooperation of subjects. A set of 
3 measurements will be obtained at baseline only, separated byintervals of 10 minutes. 
Thereafter, only 1orthostatic vital sign measurement will be taken at all subsequent visits. The 
method for obtaining orthostatic vital signs will be as follows: subject will be supine for 
5minutes prior to measurement, and stan ding for 2 minutes prior to measurement.
Physical Examination
Physical examinations and anthropometric measurements ,including weight, height, and pubertal 
stage according to Tanner’s classification ,37will be performed at the times specified in the Time 
and Events Schedule.
Height will be assessed using a wall-mounted stadiometer . Height will be read to the nearest 
0.1 cm; measures are to be repeat ed at least 3 times . Based on previous measurements and 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
65
Approved, Date: 3 November 2017clinical judgment, the healthcare professional should discard any extreme results and make 
additional measurements until 3 approximately  consistent measurements are obtained. All 
3final measurements will be recorded in the CRF ; all measurements will be recorded into the 
source documents .To obtain accurate measures, shoes and hair adornments should be 
removed and the child should be positioned with heels, buttocks ,and back of head against 
the stadiom eter.
The healthcare professionals who measure height at each visit must be trained in the 
standardized procedure. If possible, the same individual and the same equipment should 
collect all height measurements at each study  site, to help ensure consisten cy of 
measurements. 
All study  site personnel performing the height assessment must be blinded to study  treatment 
assignment and the rest of the subjects’ data to avoid/minimize bias. A blinded study  nurse or 
other staff will measure the height of the subject and record it in the source documents ,or 
provide it to the unblinded study  coordinator for entry  into the source documents. The 
unblinded study  coordinator will then enter this data, along with other visit data, into the 
CRF. The location for the height measurement data should be kept separate from the rest of 
the study  data, and procedures must be in place to ensure maintenance of the blind .
Body weight will be measured using digital electronic or beam balan ce scale to the nearest 
0.1kg.Prior to weight measurements, the scale should be set to zero to avoid drift in 
equipment functioning . Subjects will be weighed in examination gowns or in lightweight 
clothing and without shoes . If possible, weight measurements should be taken at the same 
time of day after the bladder is emptied so subjects are alway s evaluated inthe same 
physiologic state.
Tanner staging of subjects ofage 8 years and above will be conducted by a qualified 
pediatric endocrinologist or by  a phy sician trained in the method .27
Any abnormalities present at baseline, or subsequent changes, will be documented in the 
appropriate sections of the eCRF. Any  clinicall y significant abnormalities persisting at the end of 
the study  will be followed by the investigator until resolution or until reaching a clinicall y stable 
endpoint.
Neurologic Examination
Neurologic examinations (including mental status, cranial nerves , moto r exam ination [muscle 
tone, strength, deep tendon reflexes ],cerebellar functions, and gait) will be performed by the 
investigators at all visits except Month 2 .
Any abnormalities present at baseline, or subsequent changes from baseline, will be documented
in the appropriate sections of the eCRF. Any clinically  significant abnormalities persisting at the 
end of the study  will be followed by  the investigator until resolution or until reaching a clinicall y 
stable endpoint.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
66
Approved, Date: 3 November 2017Bone Mineralization
Monitoring chan ges in bone mineralization will include: DEXA scans of the posterior -anterior 
lumbar spine (L1-L4) and total body  less head area BMD and bone mineral content (BMC ),and 
serum biochemical parameters of bone metabolism ,including serum levels of alkaline 
phosphatase, calcium, phosphorus, parath yroid hormone (intact) , 25-hydroxy -vitamin D, 
1,25-dihydroxy-vitamin D, and IGF-1. Biochemical assessments will be obtained at screening , 
Month 6, and Month 12/early withdrawal .DEXA scans (without sedation) will be obtained at 
baseline, Month 6, and Month 12/early  withdrawal .For all scans, up to 3 DEXA scan attempts 
will be performed all on the same day with the goal of obtaining 2complete, movement -free 
scans, recognizing that it might not be possible to obtain 2 adequate scans in some younger 
children.
All scans will be centrally  analyzed; central analy sis will be performed by one highly  trained 
technologist at the DEXA reading center with International Societ y for Clinical Densitometry 
(ISCD) certification, a licens e to operate a DEXA scanner, and 3 to 5 years of experience with 
whole body  and spine scans. In addition, the baseline and M12 scans will be read locally  to 
determine eligibility  for randomization and for the Post -Study  Follow -Up phase .
If any subject shows a clinically  important reduction (change in Z-score of -0.5 or greater) at 
6months or 12 months , the central reader will reassess the scan for quality and to determine the 
presence of any artifacts, and will provide recommendations based on the Z-score and BMD.
Abnormalities will be reported to parents and primary -care physicians, and appropriate referrals 
for further evaluation will be made b y the investigator ,if needed.
Short -term precision testing will be performed for DEXA measurements according to standard 
protocols. The same DEXA machine will be used at each site for all subjects and all 
measurements; only clinical sites using recent -generation Hologic systems (Discovery  and 
Delphi systems) or General Electric Lunar systems will participate in the study ; the GE/Lunar 
systems will only be used for subjects ≥5 years of age. The same technician should acquire all 
scans for any particular subject. All technicians should be certified by the ISCD or have similar 
competency  training with specific knowl edge of the DEXA system, including a degree program 
in radiologic technology .Technicians must also pass a written competency  test and undergo 
specific training for this study , either online or in person, for scanning of young children. Further 
details regarding the DEXA measurements, including the reference databases to be used, will be 
provided in the DEXA Manual for this study .
Both the technicians administering the DEXA scans and the central reader will be blinded to the 
treatment group.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
67
Approved, Date: 3 November 2017Physical Activi ty Evaluation
Information regarding physical activity  will be obtained at screening from the HAES (see 
Attachment 1for an example) . Parents/caregivers will be asked how many hours their childre n 
spent in a 24-hour day in 1 of 4 categories of activity /inactivity  to assess physical activity  levels 
on the basis of the standardized and validated activity  questionnaire. The total number of hours 
each subject spends in each category  will beprocessed to determine the activity  score on a scale 
of -100 (100% inactive) to +100 (100% active). A value of 0 indicates that the subject spent 
12hoursof the day  active and an equal number of hours inactive.22
Renal Stone Evaluation 
Renal ultrasounds (at screening , Month 6, and Month 12/early withdrawal ; without sedation and 
after a 3-hour period during which only water, juice, or electroly te solution will be permitted, as 
clinically  indicated) will be performed under blinded conditions (after randomization) by a 
qualified radiologist or nephrologist at each site with age-appropriate inducers. The ultrasounds 
will be read/interpreted centrall y(local reading at the screening visit is acceptable to determine 
eligibility  for randomization ; both the local and central readers will be blinded to the study  
treatment group ). If possible, exam ination s should be done by the same individual at any given 
site. 
Subjects with definite renal stones, nephrocalcinosis, or hydronephrosis at screening will be 
excluded from the study . Other abnormalities will be followed in subsequent examinations, 
which may occur more frequentl y at the discretion of the investigator in collaboration with the 
sponsor ’smedical monitor . Abnormalities will be reported to parents and primary -care 
physicians, and appropriate referrals will be made by  the investigator if needed. 
Cognitive, Developmental ,and Behavioral Assessments
Cognitive, d evelopmental ,and behavioral assessments will be conducted as follows:
Cogstate Battery (2practice session s, 1at screening and 1 baseline prior to the baseline 
assessment ; assess edat baseline, Month 6, and Month 12/early  withdrawal ):
For subjects 6 to 15 years of age, the Detection Test, Identification Test, One Card 
Learning Test, One Back Test, and Groton Maze Learning Test will be administered.
For cooperative subjects 4 to 5 years of age, the Detection Test and the Identification 
Test will be administered.
Language function test (Animal Fluency  NEPSY -II(A Developmental NEuroPSYchological 
Assessment) Test -subjects 6 to 15 years of age; 1 practice session at screening; assessed at 
baseline, Month 6, and Month 12/ early  withdrawal ) 
Vineland Adaptive Behavior Scale (to be completed by a parent or guardian for subjects 2 to 
5 years of age, assessed at baseline, M onth 3, Month 6, and Month 12/ early withdrawal )
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
68
Approved, Date: 3 November 2017Child Behavior Checklist (CBCL )-Parent version (Achenbach System of Empirically  Based 
Assessment [ASEBA ])(assessed at baseline, Month 3, Month 6, and Month 12/early 
withdrawal )
Preschool version -subjects 2 to 5 y ears of age
School -age version -subjects 6 to 15 y ears of age
Note: For subjects who turn 6 years of age during the study , the Vineland Adaptive Behavior 
Scale ,the preschool version of the CBCL , and only the Detection Test and Identification Test of 
the Cog state Battery will continue to be administered throughout the study .
Cognitive Assessments
The Cogstate Computerized Test Battery15,26,30requires less than 30 minutes to administer, and 
will be administered by non-expert (non-psychologist) study site personnel trained in the 
Cogstate administration method . All tests will be managed and scored centrally  by Cog state. The 
Battery  includes tests that assess information processing speed and fine motor skills ,attention, 
learning and memory , working memory , and executive functions. The tests were designed for 
multiple assessments over a short time period, with virtually  no practice effects in adults and 
children. The pediatric version of the card tests (Detection Test, Identification Test, One Card 
Learning Test, and One Back Test) use cards with age-appropriate designs (ie, colors, shapes, 
and numbers) rather than using cards from a French playingcard deck. However, the paradigms 
are the same.
The Detection Test is a measure of information processing speed and fine motor skills, and 
uses a well -validated simple reaction time paradigm with card stimuli. I n this test, the play ing 
cards are all red and black. The subject is asked to press the Yes key as soon as the card in 
the center of the screen flips over.
The Identification Test is a measure of visual attention and uses a well-validated choice 
reaction time paradigm with card stimuli. In this test, the playing cards are all either red or 
black. The subject is asked whether the card currentl y being presented in the center of the 
screen is red. The subject responds by pressing the Yes key when the card is red and the No 
key when it is black.
The One Card Learning Test is a measure of visual recognition memory and uses a well-
validated pattern separation paradigm using card stimuli. In this test, the cards are similar to 
those found in a deck of playing cards. The subject is asked whether the card currently  being 
presented in the center of the screen was seen previously  in this test. The subject responds by 
pressing the Yes or No key. Because no card has been presented yet, the first response is 
alway s No.
The One Back Test is a measure of working memor y and uses a well-validated n-back
paradigm using card stimuli. In this test, the cards are similar to those found in a deck of 
playing cards. The subject is asked whether the card currentl y being presented is the same as 
the one presented immediately  previously . The subject responds by pressing the Yes or No 
key. Because no card has been presented y et, the first response is alway s No.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
69
Approved, Date: 3 November 2017The Groton Maze Learning Test is a measure of problem solving and reasoning and uses a 
well-validated maze learning paradig m. In this test, the subject is shown a grid of boxes on a 
computer screen. A pathway  is hidden among these possible locations. Each box represents 
move locations, and the grid refers to the box array (eg, 10 × 10). Subjects are required to 
find the hidden pathway  guided by search rules. Feedback is given with visual and auditory 
cues (green check marks and red crosses) to indicate whether the selected box is correct or 
incorrect. There are a specific number of well-matched alternative pathway s available. The 
software records each move as an error or as a correct move. 
The Cogstate pediatric normative database consists of cognitive tests from over 55,000 healthy 
children. The majority  of the data are from select test scales (One Card Learning Test, One Back
Test, Detection Test, Identification Test) in 10-to 18-year-old children, but there are data on the 
Groton Maze Learning Test in younger children. Furthermore, the Cogstate tests have been 
shown to have demonstrated utility  in pediatric clinical studies in oncology , and in the treatment 
of disorders such as attention -deficit/hy peractivity  disorder, HIV, neurodevelopmental disorders, 
and sickle cell disease.
The semantic item “Animal s”from the Word Generation subtest of the NEPSY -II (A 
Developmental NEuroPSYchological Assessment) will be included in this study .This test 
measures verbal productivity  through the ability  to generate words within specific categories and 
is a commonly  used and standardized measure of language and executiv e functioning in children 
and adolescents. This will be administered by  study  site personnel who are trained according to a 
study -specific rater training plan. The test will be scored by the site rater and the data will be 
transferred to Cogstate .
Developm ental As sessments in Subjects 2 to 5Yearsof Age
The Vineland Adaptive Behavior Scale will be administered for subjects 2 to 5years of age, to 
assess developmental level and adaptive functioning . For very young children, the behaviors 
assessed are closel y correlated with developmental milestones.
The Vineland Adaptive Behavior Scale , version IIfocuses on behaviors needed to operate inan
age-appropriate manner inthe individual’s environment. It is age-specific and provides an 
assessment of function in the domains of communication, daily  living, socialization, and motor 
skills, as well as a composite scale. The Vineland scores have a mean of 100 and a standard 
deviation of 15 ,based o n a normative population sample.6,36
The interview will becompleted by the parent/guardian and will be scored by a trained rater at 
screening, at Month 3, Month 6, and Month 12/early  withdrawal .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
70
Approved, Date: 3 November 2017Behavioral Assessments
The CBCL is a widel yused method of identify ing problem behavior in children.1,2It is a 
component in the ASEBA . It is a detailed, specific measure of competencies, adaptive 
functi oning, and behavioral/emotional problems in children ,split into competencies and 
problems. The CBCL  has been shown to have good reliability  and validity ,2and has been used in 
many  pediatric populations with different disorders, including epileps y.5,13,34
Problems are identified by a respondent who knows the child well, usually  a parent. There are 
two versions of the CBCL -Parent version . The preschool checklist (CBCL/1½ -5) is intended for 
use with children 18 months to 5 y earsof age (seeAttachment 6for an example) .The school -age 
version (CBCL/6 -18) is for children 6 to 18 y ears of age (see Attachment 7for an example).
The checklists consist of a number of statement s about the child's behavior, eg,"Acts too young 
for his/her age. "Responses a re recorded on a Likert scale: 0= not true, 1=somewhat or sometimes 
true, 2=very  true or often true. The preschool checklist contains 99 questions and the school -age 
checklist contains 112 questions.
Similar questions are grouped into a number of syndromes, eg,Aggressive behavior, and their 
scores are summed to produce a score for that s yndrome. Some sy ndromes are further summed to 
provide scores for Internalizing (Anxious/Depressed, Withdrawn/Depressed, and Somatic 
Complaints) and Externalizing problem scales (Rule -Breaking Behavior and Aggressive 
Behavior). A total score from all questions is also derived. For each syndrome, problem scale ,
and the total score, tables are given that determine whether the score represents normal, 
borderline, or clinical beha vior. These categorizations are based on quantiles from a normative 
sample.
Suicidality
The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and will be 
administered at every  visit, to assess suicidal ideation , intent, and behavior.31The scale will be 
administered by study personnel (either non-expert, eg, study  coordinator, or clinical expert, eg, 
MD or PhD psychologist) , asking questions of the subjects (preferable, if cooperative) or 
parents/caregivers for subjects who are not cooperative . If possible, the same individual should 
evaluate the subject at all visits. The assessment will be administered for subjects 6 to 15 y ears of 
age and will not be administered for subjects 2 to 5 years of age.Examples of the scales are 
provided in Attachment 8(Baseline) and Attachment 9(Since Last Visit).
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
71
Approved, Date: 3 November 201710. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Completion
Asubject will be considered to have completed the study  if he or she has completed 1 year of 
open -label treatment. Subjects who prematurely  discontinue study  treatment for any reason 
before completion of the1-year open -label treatment phase will not be considered to have 
completed the study .Subjects who require a concomitant AED (s)after initiating treatment with 
study  drug and continue in the study  until Month 12 will also not be considered to have 
completed the study .
10.2. Withdrawal From the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent
The investigator orsponsor believes (eg, that for safet y or tolerability  reasons such as an 
adverse event) it is in the best interest of the subject to discontinue treatment.
Death
Other reasons
If a female subject becomes pregnant during the study , she must be discontinued from the 
study  and the pregnancy  followed to term, if applicable.
During the study ,subjects will also be withdrawn if:
Subject develops status epilepticus not controlled by  a single rescue agent .
At the discretion of the investigator, subject develops any new seizure types or any clinically 
relevant safet y issue.
Subject requires greater than a 10-day course of medications that may impact bone 
metabolism, including intravenous or oral steroids, furosemide, growth hormone, NSAIDs, 
antacids, or calcium/ vitamin D supplements.
Subject develops nephrocalcinosis (diagnosed in any way) or develops a significant clinical 
adverse event (eg, serious event, treatment -limiting event, or other consideration) diagnosed 
as being related to a new kidney  stone. Ultrasound results that suggest an asymptomatic 
kidney  stone will not necessarily  serve as a reason for withdrawal from the study .
The investigator believes the subject to be at significant risk of suicidal or violent behavior.
If a subject discontinues treatment before the end of the open -label treatment phase, the 
end-of-study assessment s should be obtained.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
72
Approved, Date: 3 November 2017Ifa subject is lost to follow -up, every  reasonable effort must be made by  the study  site personnel 
to contact the subjec t and determine the reason for discontinuation/withdrawal. The measures 
taken to follow -upmust be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the CRF and in the source document. Study  drug assigned to the withdrawn 
subject may  not be assigned to another subject. Subjects who withdraw will not be replaced.
11. STATISTICA L METHODS
Statistical analy sis will be done by the sponsor or under the authority  of the sponsor. A general 
description of the statistical methods to be used to analy ze the study  data is outlined below. 
Specific details will be provided in the Statistical Analy sis Plan.
11.1. Subject Information
All subjects who are randomized will be included in the anal ysis population. 
11.2. Sample Siz e Determination
A total of 282randomized subjects, 141 in each treatment group, will be recruited to the study . 
The sample size takes into account a 1-year dropout rate of 29%, which is a conservative 
estimate based on the dropout rates observed in a previous monotherapy  study in the 6-to 
15-year-oldage group ,Study TOPMAT -EPMN -106, including a dropout rate of 22% in the 
study  overall (both double -blind and open -label phases) and a dropout rate of 35% for the 
double -blind phase .The sample size was estimated in order to achieve a sufficient precision for 
the estimates of the treatment effect on the key endpoints. The precision of the confidence 
interval (CI) estimates for the key  safet y parameters are shown below:
Annual change in BMD (L1-L4) Z-score: In the Bone Mineral Density  in Childhood Study  
(BMDCS), mean annual change in BMD (L1-L4) Z-score in 6-to 15-year-old health y 
subjects was, as expected, minimal (0.01 -0.07).35The standard deviation (SD) varied from 
0.3 to 0.48 across sex and age groups.35Assuming an S D of 0.4, with 100completed subjects 
per group, the 95% CI for the treatment difference will have a precision of 0.12.
Annual change in height Z-score in the 2-to 9-year-old age group: In the monotherap y 
epilepsy  study TOPMAT -EPMN -106, the observed chang efrom baseline in mean height 
Z-score at 1 year among the 2-to 9-year-old subjects treated with topiramate 400 mg/day 
was -0.18, with an SD of 0.28.40Assuming that 53% of the subjects will be recruited in the 
2-to 9-year-old age group, ie, 53completed subjects per treatment group, the 95% CI for the 
treatment difference will have a precision of 0.11.
Incidence of kidney stone formation: In the studies TOPMAT -PEP-3001 and 
TOPMAT -PEP-1002 in infants (1 month to 2 years of age), a 7% incidence of kidney  stones 
was observed during the 1-year topiramate adjunctive treatment period.11,38A sample size of 
100completed subjects per treatment group will provide a 95% CI (Wilson score CI) for the 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
73
Approved, Date: 3 November 2017treatment difference with a width of 0.12, assuming that the incidence of kidney  stone 
formation is 7% and near zero in the topiramate group and the levetiracetam group, 
respectivel y.
Change in weight Z-score in the 2-to 15-year-old age group :In the monotherapy  epileps y 
study  TOPMAT -EPMN -106, a -0.59 decrease from baseline in weight Z-score, with an SD 
of 0.43, was observed after 1 y ear of treatment with topiramate 400 mg/day. Assuming an SD 
of 0.43, a sample size of 100completed subjects per treatment group will provide a 95% CI 
with a precision of 0.12.
11.3. Pharmacokinetic Analyses 
Data will be listed for all subjects with available plasma concentrations per treatment group . 
All concentrations below the l owest quantifia ble concentration or m issing data will be labeled as 
such in the concentration data presentation . Concentrations below the lowest quantifiable 
concentration will be treated as zero in the summary  statistics. All subjects and samples excluded 
from the anal ysis will be clearl y documented in the study  report.
For each treatment group, descriptive statistics, including arithmetic mean, SD, coefficient of 
variation, geometric mean, median, minimum, and maximum will be calculated for the
topiramate or levetiracetam plasma concentrations at each sampling time .
Topiramate and levetiracetam p lasma concentrations will be provided as listings .
11.4. Safety  Analyses
The key  safet y endpoints will include:
Percent ageof subjects with kidney  stones 
Change from baseline in weight Z -score over time
The following height analy ses will be conducted for prepubertal subjects (2 to 9 years of 
age), subjects 10 to 15 years of age , and subjects 2 to 15 years of age :
oHeight at 1 y ear postbaseline
oHeight change from baseline over time
oHeight Z -score at 1 year postbaseline
oChange from baseline in height Z -score over time
oHeight velocity  at 1 y ear postbaseline
oHeight velocity  Z-score at 1 y ear postbaseline
oPercentage of outlier subjects with height Z-score decrease of >0.5, >1.0, and 
>2.0 over time
The following BMD and BMC endpoints:
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
74
Approved, Date: 3 November 2017oBMD and BMC over time 
oBMD and BMC change from baseline over time
oZ-score for BMD and BMC over time
oChange from baseline in Z -score for BMD and BMC over time
oPercent change from baseline in BMD and BMC over time
oPercentage of outlier subjects with BMD Z -score decrease of >0.5, >1.0, and >2.0 
over time
Change from baseline in biochemical markers of bone mineralization including: serum levels 
of alkaline phosphatase, calcium, phosphorus, parathy roid hormone (intact), 25-hydroxy-
vitamin D, 1,25 -dihyroxy vitamin D, and IGF -1
Change from baseline in serum and urine laboratory  tests, eg, bicarbonate, ammonia, renal 
function tests, and LFTs
Change from baseline in bone age
Z-scores for the DEXA scans will be calculated locally  at baseline and at M12 to determine 
eligibility  for the study and the Post-Study  Follow -Up phase, and centrally  for all statistical 
analyses. The Z -score calculation will take the DEXA machine and the subject’s age, sex, height, 
and ethnicit y into consideration . The reference databases for calculating the Z-scores are 
provided in the DEXA Manual for this study .
Longitudinal endpoints will be analy zed using a mixed -model repeated measures (MMRM) 
analysis. The MMRM model will include treatment group, age group, visit, treatment -by-visit 
interaction, baseline measure, and baseline -by-visit interaction. An unstructured covariance will 
be used. Other appropriate covariance structures will be explored as needed. Confidence 
intervals with 95% confidence for the estimate d treatment differences will be provided at each 
time point as appropriate. For proportion endpoints, 95% confidence intervals will be provided 
for the treatment difference. Each of the endpoints will also be summarized by  age group.
Seizure counts , cognitive, developmental level ,and behavioral assessments will be summarized 
by treatment group and age group .The incidence of suicide -related thoughts and behaviors as 
determined b y the C -SSRS will be summarized by  treatment group and age group.
For the cognitive assessments, standardized change from baseline scores will be calculated by 
computing the change for each postdose assessment score from the baseline assessment score, 
relative to the expected within -subject standard deviations for each Cogstate task. For the tasks 
for which lower scores indicate improvement (eg, Detection Test and Identification Test), the 
score will bemultiplied by (-1), so that negative standardiz ed scores represent a decline in 
cognitive performance consistently  across all ta sks. 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
75
Approved, Date: 3 November 2017A meaningful decline in cognitio n has been defined as a standardiz ed change of less than -1.65 
from the baseline assessment. These calculations will indicate meaningful decline at the subject 
level. For each individ ual score assessment, standardiz ed change scores that meet the definition 
of a meaningful decline will be identified using a binary  flag, where 1 repres ents a meaningful 
decline from b aseline and 0 otherwise. 
Group -based summary  data (frequency  distribution of the binary  flags) will also be presented by 
computing the proportion of subjects who meet the criteria for meaningful decline at each 
postdose assessment.
In addition to the above endpoints, other safety -related endpoints may be included in the 
analyses and summarized if deemed necess ary.
Adverse Events
The verbatim terms used in the CRF by investigators to identify  adverse events will be coded 
using the Medical Dictionary  for Regulatory  Activities (MedDRA). All reported adverse events 
with onset during the treatment phase (ie, treatment -emergent adverse events , and adverse events 
that have worsened since baseline ) will be included in the analysis. For each adverse event, the 
percentage of subjects who experience at least 1occurrence of the given event will be 
summarized by  treatment group and b y age group.
Summaries , listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event.
Adverse events of clinical interest for topir amate are: effects on liver function; metabolic 
acidosis; effects on growth and maturation ;vision abnormalities ;oligohidrosis with 
hyperthermia and rash; hyperammonemia and encephalopath y;kidney  stones ;cogniti ve 
disorders ;and suicidality .
Adverse even ts of clinical interest for levetiracetam are as listed previously ,notabl y somnolence, 
asthenia, and behavior disturbances (especially  hostility and nervousness ).
Subjects with adverse events of special interest may be counted or listed .
Clinical Laborato ry Tests
Laboratory  data will be summarized by type of laboratory  test. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data. Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and at each scheduled time point. Changes from baseline results will be presented in pre-versus 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
76
Approved, Date: 3 November 2017posttreatment cross -tabulations (with classes for below, within, and above normal ranges). A 
listing of subjects with any laboratory  results outside the reference ranges will be provided. A 
listing of subjects with any  markedl y abnormal laboratory  results will also be provide d. 
Vital Signs
Descriptive statistics of temperature, heart rate, respiratory  rate,and blood pressure (systolic and 
diastolic) values and changes from baseline will be summarized at each scheduled time point. 
The percentage of subjects with values beyondclinically  important limits (using age-appropriate 
ranges) will be summarized.
Physical Examination /Neurologic Examination
Descriptive statistics of changes from baseline will be summarized at each scheduled time point.
11.5. Data Monitoring Committee
Anextern al, independent DMC will be established to review safet y data on at least a semiannual 
basis (or more frequentl y,if necessary ) and ensure the continuing safet y of the subjects enrolled 
in this study .After the review, the DMC will make recommendations regarding the continuation 
of the study . The details will be provided in a separate DMC charter.
The DMC will include experts from pediatric subspecialties and one statistician. The DMC 
responsibilities, authorities, and procedures will be documented in its c harter.
12. ADVERSE EVENT REPORT ING
Timely , accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicin al (investigational or non-investigational) product, whether or not 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
77
Approved, Date: 3 November 2017related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [I CH])
This includes any  occurrence that is new in ons et or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the informed 
consent /assent form (refer to Section 12.3.1 , All Adverse Events ,for time of last adverse event 
recording).
Serious Adverse Event
A serious adverse event based onICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dosage :
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or signi ficant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations , such asimportant medical events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above.
These should usually  be considered se rious.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
Anadverse event is considered unlisted ifthe nature or severity  is not consistent with the 
applicable product reference safet y information. For topiramate , the expectedness of an adverse 
event will be determined by whether or not it is listed in the Investigator's Brochure.33For 
levetiracetam , the expectedness of an adverse event will be determined by whether or not it is 
listed in the package insert.24
Adverse Event A ssociated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel yby the definitions listed in Sect ion12.1.2 .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
78
Approved, Date: 3 November 201712.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explana tion, eg,
concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely , eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by an alternative explanation, eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated ,causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe :Extreme distress ,causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit yof events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor medicinal product that may require expedited reporting 
and/or safet y evaluation include, but are not limited to:
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
79
Approved, Date: 3 November 2017Overdose of a sponsor medicinal product
Suspecte d abuse/misuse of a sponsor medicinal product
Inadvertent or accidental exposure to a sponsor medicinal product
Medication error involving a sponsor product (with or without subject/patient exposure to the 
sponsor medicinal product, eg, name confusion)
Special reporting situations should be recorded in the CRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the CRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations , whether serious or non-serious, will be 
reported from the time a signed and dated informed consent form is obtained until completion of 
thesubject's last study -related procedure (which may include contact for follow -up of safety).
Serious adverse events, including those spontaneously  reported to the investigator within 30 days
after the last dose of study  drug, must be reported using the Serious Adverse Event Form. The 
sponsor will evaluate any safety information that is spontaneously  reported by an investigator 
beyond the time frame specified in the protocol.
All adverse events, regardless of seriousness, severity , or presumed relationship to study  therapy , 
must be recorded using medical terminology  in the source document and the CRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respiratory  infection "). Investigators must record in the CRF their opinion concerning the 
relationship of the adverse event to study  therapy . All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes respo nsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all serious adverse events that are unlisted (unexpected) and associated 
with the use of the study  drug. The investigator (or sponsor where required) must report these 
events to the appropriate Independent Ethics Committee/I nstitutional Review Board (IEC/IRB) 
that approved the protocol unless otherwise required an d documented by  the IEC/I RB. 
For all studies with an outpatient phase, including open -label studies, subjects or 
parents/caregivers must be provided with a "wallet (study )card"and instructed to carry this card 
with them for the duration of the study , indicating the following:
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
80
Approved, Date: 3 November 2017Study  number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name and 24 -hour contact telephone number
Local sponsor's name and 24 -hour telephone number (for medical staf f only)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse events occurring during the study must be reported to the appropriate sponsor 
contact person b y study-site personnel within 24 hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax) .
All serious adverse events that have not resolved by the end of the study , or that have not 
resolved upon discontinuation of the subject 's participation in the study , must be followed until 
any of the following occurs:
The event resolves .
The event stabilizes .
The event returns to baseline, if a baseline value /status is available .
The event can be attributed to agents other than the study  drug or to factors unrelated to study 
conduct .
It becomes unlikel y that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demons tration of 
due diligence with follow -up ef forts) .
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject 's participation in a clinical study  must be reported as a 
serious adverse event , except hospitalizations for the following:
Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the CRF) 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
81
Approved, Date: 3 November 2017The cause of death of a subject in a study  within 30 days of the last dose of study  drug, whether 
or not the event is expected or associated with the investigational agent, is considered a serious 
adverse event.
12.3.3. Pregnancy
All initial reports of pregnancy  must be reported to the sponsor by the study -site personnel
within 24 hours of their knowledge of the event using the appropriat e pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, stillbirth, congenital anomal y) 
are considered serious adverse events and must be reported using the Serious Adverse Event 
Form. Any subject who becomes pregnant during the study  must be promptly  withdrawn from 
the study anddiscontinue further study  treatment.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed on the Contact Information 
page(s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMPLA INT HA NDLING
A product qualit y complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliability  of a product, inc luding its labeling or package integrity . A PQC may have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by regulatory  agencies worldwide. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1. Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event.
If the defect is combined with a serious adverse event, the investigational staff must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor .
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
82
Approved, Date: 3 November 201713.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug s
TOPAMAX®tablets and sprinkle capsules will be supplied for topiramate; KEPPRA®tablets and 
solution will be supplied for levetiracetam.
The topiramate tablets supplied for this study  aredebossed, round, coated tablets in the following 
strengths and colors: 25 mgwhite or cream , 50 mg light yellow, 100 mg yellow. The tablets are 
imprinted as follows:
25 mg -“OMN” on one side, “25” on the other
50 mg -“OMN” on one side , “50” on the other
100 mg -“OMN” on one side , “100” on the other
Topiramate sprinkle capsules areprovided as small, white to off-white spheres in gelatin capsules 
consist ing of white bodies with clear caps. The capsules are printed with black pharmaceutical ink 
as follows:
25 mg -“TOP” on the cap and “25 mg” on the capsule body
Refer to the topiramate prescribing information for a list of excipients.38
Levetiracetam tablets are provided as oblong -shaped, scored, film-coated tablets in the following 
strengths and colors: 250 mg blue, 500 mg yellow, 750 mg orange. The tablets are imprinted as 
follows:
250 mg -"ucb 250" on one side
500 mg -"ucb 500" on one side
750 mg -"ucb 750" on one side
Levetiracetam oral solution is a clear, colorless, grape -flavored liquid (100 mg/mL) . 
Refer to the levetiracetam prescribing information for a list of excipients.24
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
83
Approved, Date: 3 November 201714.2. Packaging
Topiramate tablets and sprinkle capsules will be packaged in high-densit y polyethylene bottles. 
Levetiracetam tablets will be supplied in blister cards packed in cartons ; levetirace tam 
(100 mg/mL) oral solution will be provided in glassbottles.
All study  drugs willbe dispensed in child -resistant packaging.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
14.4. Preparation, Handling, and Storage
Allstudy  drug should be stored and handled per the labelled storage conditions. Both formulations 
should be stored in tightly  closed containers and protected from moisture. Topiramate drug product 
formulations are not sterile. While topiramate sprinkle capsules are designed for use by subjects 
who require that the administered drug be dispe nsed with food, neither this formulation nor tablets 
are intended for storage in food mixtures ,as this practice may create the risk of bacterial 
contamination. This particular risk is relevant to subjects whose comorbidities make them 
susceptible to infections (systemic or enteral) by pathogens capable of growing in food mixtures 
such as enteric orinfant formulas. To prevent the possibility  for bacterial contamination, the 
topiramate sprinkle capsules drug/ food mixture should be used immediately  and not stored for later 
use.
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . The dispensing of study  drug to the subject, and the 
return of study  drug from the subject (if applicable), must be documented on the drug 
accountability  form. Subjects or their legally acceptable representative swhere applicable, must 
be instructed to return all original containers, whether empty  or containing study  drug. The 
subjects must return unused study  drug to the site .
Study  drug must be handled in strict accorda nce with the protocol and the container label ,and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug, and study  drug returned by the subject, must be 
available forverification by the sponsor 's site monitor during on-site monitoring visits. The 
return to the sponsor of unused study  drug will be documented on the drug return form. When 
the site is an authorized destruction unit and study  drug supplies are destroy ed on site, this must 
also be documented on the drug return fo rm.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
84
Approved, Date: 3 November 2017Potentially  hazardous materials ,such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes. 
Study  drug should be dispensed under the supervision of the investigator ora qualified member 
of the investigational staff, or by  a ho spital/clinic pharmacist. Study  drug will be supplied only  to 
subjects participating in the study . Returned study drug must not be dispensed again, even to the 
same subject. Whenever a subject brings his or her study  drug to the site for pill count, this i s not 
seen as a return of supplies. Study  drug may not be relabeled or reassigned for use by other 
subjects. The investigator agrees neither to dispense the study  drug from, nor store it at, any site 
other than the stud y sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Topiramate Investigator 'sBrochure
Topiramate Prescribing Information
Levetiracetam Prescribing Information
Laboratory  manual
IWRS manual
Electronic data capture ( eDC)manual
Blinding Plan for TOPMATEPY4067
DEXA Manual for TOPMATEPY4067
CDC growth charts
Subject take -home records
Seizure d iaries
Subject recruitment materials
Subject information materials
Sample scale ,instructions and workbook (if applicable) forthe following outcome
assessments :Tanner scale ; CBCL ; HAES; Vineland Adaptive Behavior Scale, version II;
C-SSRS, NEPSY -II
Worksheet for inadequacy of current epileps y treatment
Preprinted labels for blood samples 
Computers ,software , and thumb drives for the Cog state battery
Refrigerated centrifuge, if not available locally
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
85
Approved, Date: 3 November 201716. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
This study  is a postmarketing requirement that is being conducted to evaluate long-term safet y 
issues associated with topiramate monotherapy  in children 2 to 15years of age with newlyor 
recentl y diagnosed epilepsy . Of particular concern is the potential for chronic metabolic acidosis 
and the potential impact on growth, bone mineralizat ion, and kidney  stone formation. The study  
is designed to assess these issues in comparison with levetiracetam monotherapy .The study  is 
designed as a randomized, active -controlled, open -label study ; however, to eliminate bias, after 
randomization the key safet y outcomes (DEXA scan, renal ultrasound, and height) will be 
obtained in a blinded fashion.
Ethical concerns include the enrollment of pediatric subjects and the requirement for them to 
taper off their current AED. Performing this study  in children isjustified because it remains 
unclear how long term AED may impact normal bone mineralization and development. Overall, 
an extensive clinical database that included children from age 1 month and above in different 
clinical settings has not demonstrated bone-related adverse clinical outcomes ,but more 
quantitative and sy stemic safet y data are desirable in this population. The concern of tapering off 
an existing AED is mitigated by the requirement that investigators document the inadequacy  of 
the subject’s cu rrent AED treatment.
Levetiracetam is an appropriate comparator because it has demonstrated efficacy  and safety  in a 
number of investigator -initiated studies when used as monotherap y in dosage s similar to those 
used in the current study . It also has relati vely low toxicity , and specifically  a lack of significant 
concerns for risks for kidney  stones or possible deleterious effects on bone or growth. Other 
AEDs that might be considered as a comparator beside levetiracetam include carbamazepine, 
lamotrigine, or valproic acid. However, there are possible concerns with all of these AEDs. 
There are many publications in the literature that suggest carbamazepine may decrease BMD , 
increase serum alkaline phosphatase and decrease serum calcium and phosphorus, which might 
suggest problems with bone development. Lamotrigine has potentially  serious toxicity  especially 
serious rash (eg, Stevens -Johnson syndrome or toxic epidermal necrol ysis) and there are various 
publications that suggest that valproic acid may also have deleterious effects on decreasing 
BMD .
A 1-year study  duration is justified based on the following:
The American Academy  Pediatrics Clinical Report Bone Densitometry  in children and 
adolescents states that the recommended interval between repeat DEXA scans depend son 
progression of bone disorder, with a minimal interval between scans of6months, but often 
1year or more may be appropriate to allow measurable change to occur.3The Position 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
86
Approved, Date: 3 November 2017statement on DEXA scans in children and adolescents from ISCD statesthat in pediatric 
patients, repeat scans should generall y be obtained within 1 to 2 years for clinical purposes 
and in some settings, such as a patient in a research study  and/or receiving a therapeutic 
skeletal agent, every  6 months.18The shorter 6-month interval may reveal trends in skeletal 
losses and gains, reflecting variations in bone turnover from either a chronic disease or 
intervention, but ones not yet clinically  significant. The ISCD suggests aminimum 
monitoring time interval of 6months for repeating B MD measurement .4
Abnormaliti es in height have been detected during 1 year of treatment in children treated 
with topiramate monotherap y. Topiramate as monotherapy  for newl y or recentl y diagnosed 
POS has been evaluated in 3 double -blind Phase 3 studies, each of which included subjects 
between the ages of 6 and 15years of ageat enrollment.33One of these 3 studies included 
post-baseline height or BMI data and also included an open-label extension phase.9During 
thecombined double -blind and open -label extension, there was a small percentage of 
children who met height criteria for growth delay .
Renal stones as documented by renal ultrasound have been demonstrated within a 1-year 
treatment duration with topiramate . Results from the open -label extension study  performed in 
284 infants with epilepsy  1 to 24 months of age treated with topiramate for 1 yearshowed 
that 18 of 284 subjects (6.3%) had nephrolithiasis detected by sonogram approximately  4 to 
5months into the study .11
Additional ethical concerns relate to consent/assent and ensuring that ethical principles related to 
pediatric subjects as vulnerable subjects arein effect, primarily  to ensure that total allowable 
blood volumes are not exceeded during study  conduct.
Potential subjects and their guardian swill be fully informed of the risks and requirements of the 
study  and, during the study ,they will be given any new information that may affect their decision 
to continue participation. They  will be told that their consent /assent to participate in the study  is 
voluntary  and may be withdrawn at any time with no reason given and without penalty  or loss of 
benefits to which they would otherwise be entitled. Enrollment will only be allowed if 
parents/legall y accept able representatives orsubjects are fully able to understand the risks, 
benefits, and potential adverse events of the study , and provide their consent /assent voluntaril y. 
When referring to the signing of the informed consent form, the terms legal guardia n and legally 
acceptable representative refer to the legall y appointed guardian of the child with authority  to 
authorize participation in research. For each subject, his or her parent(s) (preferabl y both parents, 
if available) or a legall y acceptable repre sentative(s), as required by local regulations, must give 
written consent (permission) according to local requirements after the nature of the study  has 
been fully  explained and before the performance of any study -related assessments. Assent must 
be obtain ed from children (minors) capable of understanding the nature of the study , typicall y 
subjects 7 years of age and older, depending on the institutional policies. For the purposes of this 
study , all references to subjects who have provided consent/assent refers to the subjects (assent 
as applicable) and his or her parent(s) or the subject's legal guardian(s) or legally  acceptable 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
87
Approved, Date: 3 November 2017representative(s) who have provided consent according to this process. Minors who assent to a 
study  and later withdraw their assen t should not be maintained in the study  against their will, 
even if their parents still want them to participate.
The total blood volume to be collected during the study  is less than 3 mL/kg body  weight per 
8-week period (approximatel y 11.0mLor less at each visit), consistent with the guidelines for 
total allowable blood volumes drawn from pediatric subjects from multiple sources ,including NIH 
IRB, US Department of Health and Human Services, Alliance Laboratory  Services ,and Harvard's 
Massachusetts General Hospital (Boston, Massachusetts) .23
Although a subject could be exposed to as many as 18 DEXA scans over the 12-month course of 
the study , the additional amount of radiation is less than the yearly natural background radiation in 
the United States (3 mSV), and involves minimal risk. Further details, including the radiation dose 
by machine, scan, and age, areprovid ed in the DEXA Manual for this study.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the clinical study  is performed in accordance 
with the protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable 
regulatory  and country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the clinical study  data are c redible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents:
Final protocol and, if app licable, amendments
Sponsor -approved informed consent form and assent forms (and any other written materials 
to be provided to the subjects)
Investigator 's Brochure (or equivalent information) and amendments /addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
88
Approved, Date: 3 November 2017Investigator 's curriculum vitae or equivalent information (unless not required, as documented 
by the IEC/IRB)
Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study  will be undertaken only after the IEC/ IRB has given full approval of the final 
protocol, amendments (if any), the informed consent form, assent forms, applicable recruiting 
materials, and subject compensation programs, and the sponsor has received a copy of this 
approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriat e:
Protocol amendments
Revision(s) to informed consent form , assent forms, and any other written materials to be 
provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator 's Brochure and amendments /addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least ann ually)
Reports of adverse events that are serious, unlisted /unexpected , and associated with the 
investigational drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Annual Safet y Report and L ine Listings, where applicable
Any other requir ements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data,or study  conduct) , the amendment and applicable informed 
consent /assent form revisions must be submitted promptly  to the IEC/IRB for review and 
approval before implementation of the change(s).
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
89
Approved, Date: 3 November 2017At least once a year, the IEC/IRB will be asked to review and reapprove this clinical study . The 
reapproval should be documented in writing (excluding the ones that are purel y administrative, 
with no consequences for subjects, data ,or study conduct) .
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Consen t
Parents (or a legall yacceptable representative) and pediatric subjects must give written consent
and assent, respectively ,according to local requirements ,after the nature of the study  has been 
fully  explained. Assent must be obtained from children (minors) capable of understanding the 
nature of the study , typically  subjects 7 years of age and older , depending on the institutional 
policies, as described below . The consent and assent form smust be signed before performance of 
any study-related activity. The consent form and assent form sthat are used must be approved by 
both the sponsor and by the reviewing IEC/I RBand be in a language that the parents or legall y 
acceptable representative and subject can read and understand . The informed consent and assen t 
should be in accordance with principles that originated in the Declaration of Helsinki, current 
ICH and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the investigational 
staff must explain to potential subjects and their parents or legally acceptable representatives the 
aims, methods, reasonably  anticipated benefits, and potential hazards of the study ,and any 
discomfort participation in the study  may  entail . Subjects will be informed that their participation 
is voluntary  and that they may withdraw consent to participate at any time. They  will be 
informed that choosing not to participate will not affectthe care the subject will receive for the 
treatment of his or her disease. Subjects will be told that alternative treatments are available if 
they refuse to take part and that such refusal will not prejudice future treatment. Finally , they  will 
be told that the investigator will maintain a subject identification register for the purposes of 
long-term follow -upif needed and that their records may be accessed by health authorities and 
authorized sponsor staff without violating the confidentiality  of the subject, to the extent 
permitted by the applicable law(s) or regulations. By signing the informed consent and assent
form sthe subject and parents orlegall yacceptable representative is authorizing such access , and 
agrees to allow his or her study  physician to recontact the subject for the purpose of obtaining 
consent and assent for additional safety  evaluations, if needed .
The subject and parents orlegall yacceptable representative will be given sufficient time to read 
the informed consent form and the oppo rtunity to ask questions. After this explanation and 
before entry  into the study , consent and assent should be appropriatel y recorded by means of 
either the subject's or his or her legall yacceptable representative's personally  dated signature. 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
90
Approved, Date: 3 November 2017After havin g obtained the consent, a copy of the informed consent form must be given to the 
subject.
If the subject and parents or legall yacceptable representative is unable to read or write, an 
impartial witness should be present for the entire informed consent process (which includes 
reading and explaining all written information) and should personally  date and sign the informed 
consent and assent form safter the oral consent of the subject and parents or legall yacceptable 
representative is obtained.
Children (min ors) or subjects who are unable to comprehend the information provided can be 
enrolled only after obtaining consent from parents or a legally acceptable representative. Assent 
must be obtained from children (minors) capable of understanding the nature of the study , 
typicall y subjects 7years of age and older , depending on the institutional policies. W ritten assent 
should be obtained from subjects who are able to write. A separate assent form written in 
language the subject can understand should be developed for adolescents. After having obtained 
the assent, a copy of the assent form must be given to the subject, and to the subject's parent 
and/or legall yacceptable representative.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulat ions. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibili ties require access to personal data agree to 
keep the identit y of study subjects confidential.
The informed consent and assent obtained from the subject or parent (or his or her legally
acceptable representative) includes explicit consent for the processi ng of personal data and for 
the investigator to allow direct access to his or her original medical records for study -related 
monitoring, audit, IEC/IRB review, and regulatory  inspection. This consent also addresses the 
transfer of the data to other entitie s and to other countries.
The subject or parent has the right to request through the investigator access to his or her 
personal data and the right to request rectification of any data that are not correct or complete. 
Reasonable steps will be taken to respond to such a request, taking into consideration the nature 
of the request, the conditions of the study , and the applicable laws and regulations.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
91
Approved, Date: 3 November 2017Exploratory  research is not conducted under standards appropriate for the return of data to 
subjects . In addit ion, the sponsor cannot make decisions as to the significance of any findings 
resulting from exploratory  research. Therefore, exploratory  research data will not be returned to 
subjects or investigators, unless required by  law. Privacy  and confidentiality  of data generated in 
the future on stored samples will be protected by the same standards applicable to all other 
clinical data.
16.2.5. Country Selection
This study  will only be conducted in those countries where the 2 study  drugs are commercially 
available for th e treatment of epilepsy .
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment
by the sponsor . All protocol amendments must be issued by  the sponsor, and signed and dat ed by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, inwhich case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor or its designee. When the change(s) involves only logistic or administrative aspects of 
the study , the I RB (and IEC where required) only  needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page (s)provided separatel y). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the CRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure an d the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approv al/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiat ed until all local regulatory  
requirements are met.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
92
Approved, Date: 3 November 201717.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
investigational site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of the dated and signed ,written IEC/IRB approval of the protocol, amendments, 
informed consent form, assent forms, any recruiting materials, and if applicable, subjec t 
compensation programs. This approval must clearly  identify  the specific protocol by  title and 
number and must be signed by  the chairman or authorized designee.
Name and address of the IEC/IRB ,including a current list of the IEC/IRB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/IRB, a general statement may be substituted for this list.If an investigator or a 
member of the investigational staff is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the vote/opinion 
of the study .
Regulatory  authority  approval or notificati on, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all clinical subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy of 
current laboratory  normal ranges for these tests , if applicable
Local laboratory  documentation demonstrating competence and test reliability  
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file. To ensure subject confidentiality , no copy  will be made. All 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
93
Approved, Date: 3 November 2017reports and communications relating to the study will identify  subjects by dumm y initials and 
assigned number only.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the CRF: subject identification, eligibility , and study  identification; study  discussion 
and date of informed consent and assent ; dates of visits; results of safety  and efficacy  parameters 
as required by the protocol; record of all adverse events and follow -up of adverse events; 
concomitant medication; drug receipt/dispensing/return records; study drug administration 
information ; and date of study  completion and reason for early discontinuation of study  drug or 
withdrawal from the study , if applicable.
In addition, the author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a study  subject should be 
consistent with that commonly  recorded at the site as a basis for standard medical care. Specific 
details required as source data for the study  will be reviewed with the investigator before the 
study  and will be described in the monitoring guidelines (or other equivalent document).
The following data will be recorded directly  in the source documents and then entered into the 
CRF : 
Race
Blood pressure and heart rate
Height –A blinded study  nurse or other staff will measure the height of the subject and 
record it in the source documents ,or provide it to the unblinded study  coordinator for entry 
into the source documents. The unblinded study  coordinator will then enter this data, along 
with other visit data, into the CRF .
Weight 
Details of ph ysical examination
Subject -and investigator -completed scales and assessments designated by the sponsor below 
will be recorded separately  from the CRF and will be considered source data:
Vineland Adaptive Behavior Scale
CBCL  -Parent version (preschool and school -age versions)
Seizure d iary
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
94
Approved, Date: 3 November 2017C-SSRS
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format. 
Electronic data capture will be used for this study . The study  data will be transcribed by study 
personnel from the source documents onto an eCRF , and transmitted in a secure manner to the 
sponsor withi n the timeframe agreed upon between the sponsor and the site. The electronic file 
will be considered to be the CRF.
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the subject 's source documentation. All data relating to the 
study  must be recorded in CRFs prepared by the sponsor . Data must be entered into CRFs in 
English. Designated site personnel must complete the CRF as soon as possible after a subject 
visit, and the forms should be available for review at the next scheduled monitoring visit.
Every  effort should be made to ensure that all subjective measure ments (eg, pain scale 
information or other questionnaires) to be recorded in the CRF are completed by the same 
individual who made the initial baseline determinations. The investigator must verify  that all data 
entries in the CRF s are accurate and correct.
All CRF entries, corrections, and alterations must be made by the investigator or other authorized 
study -site personnel. If necessary , queries will be generated in the eDC tool.The investigator or 
an authorized member of the investigational staff must adjust the CRF (if applicable) and 
complete the query .
If correc tions to a CRF are needed after the initial entry  into the CRF, this can be done in 
3different way s:
Site personnel can make corrections in the eDC tool at their own initiative or as a response to 
an auto query  (generated by  the eDC tool) .
Site manager ca n generate a query  for resolution by  the investigational staf f.
Clinical data manager can generate a query  for resolution by  the investigational staf f.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
associated personnel before the study , periodic monitoring visits by the sponsor, and direct 
transmission of DEXA, and clinical laboratory  data from a central laboratory  into the sponsor 's 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
95
Approved, Date: 3 November 2017database. Written instructions will be provided for collection, preparation, and shipment of 
samples. 
Guidelines for CRF completion will be provided and reviewed with study personnel before the 
start of the study .The sponsor will review CRFs for accuracy  and completeness during on-site 
monitoring visits and after transmission to the sponsor; any discrepancies will be resolved with 
the investigator or designee, as appropriate. After upload of the data into the clinical study
database they  will be verified for accuracy and consistency  with the data sources .
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  requirement(s).
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investiga tor retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator must permit access to such reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  sitevisit log that will be kept at the site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the CRFs with the hospital or clinic records (source 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
96
Approved, Date: 3 November 2017documents). The natur e and location of all source documents will be identified to ensure that all 
sources of original data required to complete the CRF are known to the sponsor and 
investigational staff and are accessible for verification by the sponsor site contact. If electr onic 
records are maintained at the investigational site, the method of verification must be discussed 
with the investigational staff. 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data record ed in the CRF are consistent with the original source data. Findings 
from this review of CRFs and source documents will be discussed with the investigational staff. 
The sponsor expects that, during monitoring visits, the relevant investigational staff will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study to provide feedback on the study conduct.
17.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last study  assessment forthe last subject 
participating in the study. The final data from the investigational site will be sent to the sponsor
(or designee) after completion of the final subject assessment at that site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the investigational site or terminate the study  at any time
for any reason at the sole discretion of the sponsor .Investigational sites will be closed upon 
study  completion. An investigational site is considered closed when all required documents and 
study  supplies have been collected and a site closure visit has been performed.
The investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of an investigational site by the sponsor or investigator may  include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor 's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the inv estigator
Discontinuation of further drug development
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
97
Approved, Date: 3 November 201717.10. On-Site A udits
Representatives of the sponsor 's clinical quality  assurance department may visit the site at any 
time during or after completion of the study  to conduct an audit of the study  in complian ce with 
regulatory  guidelines and compan y policy . These audits will require access to all study  records, 
including source documents, for inspection and comparison with the CRFs. Subject privacy 
must, however, be respected. The investigator and staff are responsible for being present and 
available for consultation during routinel y scheduled site audit visits conducted by  the sponsor or 
its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if they have been 
contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of In formation and Publication
All information, including but not limited to information regarding topiramate or the sponsor 's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation informa tion) supplied by the sponsor to the investigator and not 
previously  published, and any  data generated as a result of this study , areconsidered confidential 
and remain the sole property  of the sponsor. The investigator agrees to maintain this information 
in confidence and use this information only  to accomplish this study , and will not use it for other 
purposes without the sponsor 's prior written consent.
The investigator understands that the information developed in the clinical study  will be used by 
the sponsor in connection with the continued development of topiramate , and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain CRF data from all investigational sites that participate in the study and data from 
DEXA, and clinical laboratory  tests, which will be direct lytransmi tted from a central laboratory
into the sponsor's database . Recruitment performance or specific expertise related to the nature 
and the key assessment parameters of the study  will beused to determine a coordinating 
investigator for the study .Any work created in connection with performance of the study  and 
contained in the data that can benefit from copyright protection (except any publication by the 
investigator as provided for below) shall be the propert y of the sponsor as author and owner of 
copy right in such work. 
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
98
Approved, Date: 3 November 2017The sponsor shall have the right to publish such data and information without approval from the 
investigator. If an investigator wishes to publish information from the study ,a copy of the 
manuscript must be provided to the sponsor for review at least 60days before submission for 
publication or presentation. Expedited reviews will be arranged for abstracts, poster 
presentations, or other materials. If requested by the sponsor in writing, the investigator will 
withhold such publication for up to an additional 60days to allow for filing of a patent 
application. In the event that issues arise regarding scientific integrit y or regulatory  compliance, 
the sponsor will review these issues with the investigator. The sponsor will not mandate 
modifications to scientific content and does not have the right to suppress information. For
multicenter study  designs and substudy  approaches, secondary  results generall y should not be 
publi shed before the primary  endpoints of a study  have been published. Similarly , investigators 
will recognize the integrity  of a multicenter study by not submitting for publi cation data derived 
from the individual site until the combined results from the compl eted study have been submitted 
for publication , within 12months of the availability  of the final data (tables, listings, graphs) , or 
the sponsor confirms there will be no multicenter study  publication. Authorship of publications 
resulting from this study will be based on the guidelines on authorship, such as those described 
in the ICMJE Recommendations for the Conduct, Reporting, Editing and Publication of 
Scholarly  Work in Medical Journals, which state that the named authors must have made a 
significant contribution to the conception or design of the work; or the acquisition,  analysis, or 
interpretation of the data for the work; and drafted the work or revised it critically  for important 
intellectual content; and given final approval of the version to be published; and agreed to be 
accountable for all aspects of the work in ensuring that questions related to the accuracy  or 
integrit y of an y part of the work are appropriatel y investigated and resolved.
Registration of Clinical Studies and Disclosure of Resu lts
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
99
Approved, Date: 3 November 2017REFERENCES
1. Achenbach TM, Rescorla LA. Manual for the ASEBA Preschool Form s and Profiles. 1991;Burlington, VT: 
University of Vermont Dep artment of Psychiatry.
2. Achenbach TM, Rescorla LA. Manual for the ASEBA School -Age Forms and Profiles. 1991;Burlington, VT: 
University of Vermont, Research Center for Children, Youth, and Families.
3. Bachrach LK, Sills IN; Section on Endocrinology. Clinical report —bone densitometry in children and 
adolescents. Pediatrics. 2011;127(1):189 -194.
4. Bishop N, Braillon P, Burnham J, et al. Dual -energy X-ray absorptiometry assessment in children and 
adolescents with diseases that may affect the skeleton: the 2007 ISCD Pediatric Official Positions. J Clin 
Densitom. 2008;11(1):29 -42.
5. Caplan R, Sagun J, Siddarth P, et al. Social competence in pediatric epilepsy: Insights on underlying 
mechanisms. Epilepsy Behav. 2005;6:218 -228.
6. Ciochetti DV, Sparrow  SS, Carter A. Deve lopm ent and validation of the Vineland Adaptive Behavior 
screening instruments. 1991;San Francisco, CA: American Psychological Association.
7. Clinical Study Report TOPMAT -EPMN -104. Topiram ate monotherapy clinical trial in subjects with recently 
diagnosed pa rtial onset seizures. RWJPRI (22 Apr 1999).
8. Clinical Study Report TOPMAT -EPMN -105. Topam ax (Topiramate) monotherapy comparison trial to 
standard monotherapy in the treatment of newly diagnosed epilepsy. RWJPRI (26 Oct 2000).
9. Clinical Study Report TOPMAT -EPMN -106. A random ized, double blind, parallel group, monotherapy study 
to com pare the safety and efficacy of two doses of topiramate in the treatment of newly diagnosed or recurrent 
epilepsy. J&JPRD (20 Aug 2002).
10. Clinical Study Report TOPMAT -MIG -3006. A randomized, double -blind, placebo -controlled study to 
evaluate the efficacy and safety of topiram ate for the prophylaxis of migraine in pediatric subjects 12 to 17 
years of age. J&JPRD (20 Aug 2007).
11. Clinical Study Report TOPMAT -PEP-1002 and TOPMAT -PEP-3001. Long -term safety of topiramate 
administered as the oral liquid and sprinkle capsule formulations as an adjunct to concurrent anticonvulsant 
therapy in infants (aged 1 to 24 months, inclusive) with refractory partial -onset seizures (Interim Report Based
on Available Data as of 15 June 2007). J&JPRD (14 Jan 2008).
12. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for 
revised classification of the epilepsies and epileptic syndromes. Epilepsia. 1989;30:389 -399.
13. Connolly AM, Northcott E, Cairns DR, et al. Quality of life of children with benign rolandic epilepsy. Ped 
Neurol. 2006;35:240 -245.
14. Drug Metabolism Research Report DM97328. Topiramate metabolite profiling and identification in infant 
subjects.RWJPRI. (20 Jan 1998).
15. Falleti MG, Maruff P, Collie A, Darby  DG. Practice effects associated with the repeated assessment of 
cognitive function using the Cogstate Battery at 10-minute, one week and one month test-retest intervals. J 
Clin Exp Neuropsychol. 2006;28(7):1095 -1112.
16. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE Official Report A practical clinical definition of epilepsy. 
Epilepsia. 2014;55(4):475 -482.
17. Girgis IG, Nandy  P, Nye JS, et al. Pharmacokinetic –pharm acody namic assessmen t of topiramate dosing 
regimens for children with epilepsy 2 to <10 years of age. Epilepsia. 2010;51:1954 –1962.
18. Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy X-ray absorptiometry interpretation and 
reporting in children and adolescents: The 2007 ISCD Pediatric Official Positions. J Clin Densitometry: 
Assessment of Skeletal Health. 2008;11:43 -58.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
100
Approved, Date: 3 November 201719. Greer FR. Defining vitamin D deficiency in children: beyond 25-OH vitamin D serum concentrations. 
Pediatrics. 2009;124(5):1471 -3.
20. Greulich W, Pyle S. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd edition. (1959) 
Stanford, CA: Stanford University Press.
21. Grosso S, Cordelli DM, Franzoni E, et al. Efficacy and safety of levetiracetam in infants and young children 
with refractory epi lepsy. Seizure. 2007;16:345 —350.
22. Hay JA. Development and testing of the Habitual Activity Estimation Scale. In Armstrong N, Welsman J, 
Kirby B (eds). Children and Exercise. XIX: Prom oting Health and Well -being. XIXth International 
Symposium of Pediatric W ork Physiology, Exeter, London: E&FN Spon, 1997;II:125 –129.
23. How ie SR. Blood sample volumes in child health research: review  of safe limits. Bull World Health Organ. 
2011;89(1):46 -53.
24. Keppra® (levetiracetam) Package Insert. UCB, Inc. Apr 2009.
25. Kuczmarski RJ, Ogden CL, Grummer -Strawn LM, et al. CDC growth charts: United States. Adv Data. 
2000;314:1 -27.
26. Maruff P, Thom as E, Cysique L, et al. Validity of the Cogstate brief battery: relationship to standardized tests 
and sensitivity to cognitive impairm ent inmild traumatic brain injury, schizophrenia, and AIDS dementia 
complex. Arch Clin Neuropsychol. 2009;24(2):165 -178.
27. Morris NM, Udry  JR. Validation of a self-administered instrument to assess stage of adolescent developm ent. 
J Youth Adolesc. 1980;9:271 -280.
28. Nonclinical Safety Study Report TOX6898. Oral toxicity study in juvenile rats. CIT Study No. 29067 RSR. 
J&JPRD (22 Dec 2006).
29. Opp J, Tuxhorn I, May T, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label 
study in Germany. Seizure. 2005;14:476 -484.
30. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the Cogstate 
schizophrenia battery and the measurement and treatment Research to improve cognition in Schizophrenia 
(MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 
2009;31(7): 848 -859. doi:10.1080/13803390802592458 .
31. Posner K, Oquendo M, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide 
Assessment (C-CASA): Classification of suicidal events in the FDA’s pediatric suicidal risk analysis of 
antidepressants. Am J Psychiatry. 2007;164:1035 -1043.
32. Rosenfeld WE, Doose, DR, Walker SA, Baldassarre JS, Reife RA. A study of topiramate pharmacokinetics 
and tolerability in children wi th epilepsy. Pediatr Neurol. 1999;20:339 -344.
33. RWJ -17021 -000 (topiramate) Investigator's Brochure Edition 15. J anssen R&D (15 March 2017 ).
34. Sabaz M, Cairns DR, Bleasel AF, et al. The health -related quality of life of childhood epilepsy syndromes. J 
Paediat r Child Health. 2003;39:690 -696.
35. Shepherd JA, Wang L, Fan B, et al. Optimal monitoring time interval between DXA measures in children. J 
Bone Miner Res. 2011;26:2745 -2752.
36. Sparrow  SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales: Interview  Edition Survey Forms 
Manual. Circle Pines, MN. American Guidance Service 1984.
37. Tanner JM. Grow th at Adolescence, 2nd ed. (1962). London, England Oxford: Blackw ell Scientific. 
38. TOPAMAX® (topiramate) Prescribing Information. Janssen Pharmaceuticals, Inc., Jul 2011.
39. Topiramate Integrated Summary of Safety. Topiramate as monotherapy for pediatric and adult subjects with 
newly diagnosed epilepsy. J&JPRD (30 Sep 2002).
40. Topiramate Pediatric Monotherapy sNDA Integrated Summary of Safety. J&JPRD (9 Dec 2009).
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
101
Approved, Date: 3 November 201741. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate 
use. Expert Opinion Drug Safety. 2007;6(5):547 -557.
42. Vitamin D fact sheet for health professionals. http://ods.od.nih.gov/factsheets/VitaminD -HealthProfe ssional. 
Accessed 08 Jun 2015 .
43. von Stuelpnagel C, Holthausen H, Kluger G. Long-term use of levetiracetam in patients with severe 
childhood -onset epilepsy. Eur J Paed Neur. 2007;11:341 –345.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
102
Approved, Date: 3 November 2017ATTACHMENTS
Attachment 1: Habitual A ctivity Estimation Scale

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
103
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
104
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
105
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
106
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
107
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
108
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
109
Approved, Date: 3 November 2017Attachment 2: Titration Schedules for Topiramate and Levetiracetam
Topiramate Monotherapy Titration Schedule for Subjects 2 to <10 Years of Age
Table 1: Topiramate Monotherapy Titration Schedule for Subjects 2 to <10 Years of Age –Body  Weight up to 
11kg (Maximum Recommended Maintenance Dosage 250 mg/day)
Total Daily Dosage 
(mg)Morning Dose (mg) Evening Dose (mg)
Week 1 25 0 25
Week 2 50 25 25
Week 3 75 25 50
Week 4 100 50 50
Week 5 125 50 75
Week 6 150 75 75
Week 7 200 100 100
Week 8 250 100 150
Table 2: Topiramate Monotherapy Titration Schedule for Subjects 2 to <10 Years of Age –Body  Weight 12 to 
22kg (Maximum Recommended Maintenance Dosage 300 mg/day)
Total Daily Dosage 
(mg)Morning Dose (mg) Evening Dose (mg)
Week 1 25 0 25
Week 2 50 25 25
Week 3 75 25 50
Week 4 100 50 50
Week 5 150 75 75
Week 6 200 100 100
Week 7 250 125 125
Week 8 300 150 150
Table 3: Topiramate Monotherapy Titration Schedule for Subjects 2 to <10 Years of Age –Body Weight 23 to 
38kg (Maximum Recommended Maintenance Dosage 350 mg/day)
Total Daily Dosage 
(mg)Morning Dose (mg) Evening Dose (mg)
Week 1 25 0 25
Week 2 50 25 25
Week 3 75 25 50
Week 4 100 50 50
Week 5 200 100 100
Week 6 250 125 125
Week 7 300 150 150
Week 8 350 175 175
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
110
Approved, Date: 3 November 2017Topiramate Monotherapy Titration Schedule for Subjects 10 to 15 Years of Age
Table 4: Topiramate Monotherapy Titration Schedule for Subjects 10 to 
15Years of Age
Morning Dose (mg) Evening Dose (mg)
Week 1 25 25 
Week 2 50 50 
Week 3 75 75 
Week 4 100 100 
Week 5 150 150 
Week 6 200 200 
Levetiracetam Weight -Based Titration Dosing Guide (Oral Solution, 100 mg/mL) for Subjects With 
a Body Weight ≤20 kg
Table 5: Levetiracetam Weight -Based Titration Dosing Guide (Oral Solution; 100 mg/mL) for Subjects With a 
Body  Weight ≤20 kg –Weeks 1 to 2 (20 mg/kg/day)
Body  Weight (kg) Total Daily Dos age 
(mg)Morning Dose (mg) Evening Dose (mg) Dosage Regimen
10 200 100 100 1.0 mL BID
11 220 110 110 1.1 mL BID
12 240 120 120 1.2 mL BID
13 260 130 130 1.3 mL BID
14 280 140 140 1.4 mL BID
15 300 150 150 1.5 mL BID
16 320 160 160 1.6 mL BID
17 340 170 170 1.7 mL BID
18 360 180 180 1.8 mL BID
19 380 190 190 1.9 mL BID
20 400 200 200 2.0 mL BID
Table 6: Levetiracetam Weight -Based Titration Dosing Guide (Oral Solution; 100 mg/mL) for Subjects With a 
Body  Weight ≤20 kg –Weeks 3 to 4 (40 mg/kg/day)
Body  Weight (kg) Total Daily Dos age 
(mg)Morning Dose (mg) Evening Dose (mg) Dosage Regimen
10 400 200 200 2.0 mL BID
11 440 220 220 2.2 mL BID
12 480 240 240 2.4 mL BID
13 520 260 260 2.6 mL BID
14 560 280 280 2.8 mL BID
15 600 300 300 3.0 mL BID
16 640 320 320 3.2 mL BID
17 680 340 340 3.4 mL BID
18 720 360 360 3.6 mL BID
19 760 380 380 3.8 mL BID
20 800 400 400 4.0 mL BID
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
111
Approved, Date: 3 November 2017Table 7: Levetiracetam Weight -Based Titration Dosing Guide (Oral Solution; 100 mg/mL) for Subjects With a 
Body  Weight ≤20 kg –Weeks 5 to 8 and Maintenance (60 mg/kg/day)
Body  Weight (kg) Total Daily Dos age 
(mg)Morning Dose (mg) Evening Dose (mg) Dosage Regimen
10 600 300 300 3.0 mL BID
11 660 330 330 3.3 mL BID
12 720 360 360 3.6 mL BID
13 780 390 390 3.9 mL BID
14 840 420 420 4.2 mL BID
15 900 450 450 4.5 mL BID
16 960 480 480 4.8 mL BID
17 1,020 510 510 5.1 mL BID
18 1,080 540 540 5.4 mL BID
19 1,140 570 570 5.7 mL BID
20 1,200 600 600 6.0 mL BID
Levetiracetam Weight -Based Titration Dosing Guide (Tablets) for Subjects With a Body Weight 
>20 kg
Table 8: Levetiracetam Weight -Based Titration Dosing Guide (Tablets) for Subjects With a Body Weight >20 kg 
Morning Dose (mg) Evening Dose (mg)
20.1 to 40 kg >40 kg 20.1 to 40 kg >40 kg
Week 1 250 500 250 500
Week 2 250 500 250 500
Week 3 500 500 500 1,000
Week 4 500 500 500 1,000
Week 5 750 1,000 750 1,500
Week 6 750 1,000 750 1,500
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
112
Approved, Date: 3 November 2017Attachment 3: Pharmacokinetic Collection and Handling Procedure
Materials and Labeling
The central laboratory will provide the investigational site with blood collection tubes, storage tubes, preprinted 
labels (or tubes labeled with preprinted labels), and related supplies for the collection and shipment of PKsamples. 
Labels should be attac hed to the storage tubes at least 12 hours before being frozen to ensure proper adherence.
Use of alternative materials will not result in a protocol amendment if preapproved by the Bioanalysis Scientist.
Detailed information regarding the collection and storage containers will be provided in the laboratory manual from 
the central laboratory.
Preparation of Plasma Pharmacokinetic Samples for Topiramate
Collect 1mL of blood into the appropriate K 2-EDTA -containing collection tube (eg, Vacutainer) at each time 
point.
Record the exact date and time of sampling in the CRF or laboratory requisition form, as appropriate.
Gently invert the tubes 8 to 10 times to afford mixing, before processing.
Centrifuge blood samples at room temperature within 1 hour(s) of co llection at 1,300 g for 10 minutes, unless 
otherwise specified by the supplier, to yield approximately 0.4 mL of plasma from each 1 mL whole blood 
sample.
Transfer all separated plasma immediately with a clean, disposable glass or polyethylene pipette (use 1 new 
pipette per sample) to a pre -labeled storage tube (3.6 -mL NUNC Cryotube , Cat. No. 366524 or 379189).
Store plasma samples in an upright position in a freezer, at a set temperature of –20C until transfer to the central 
laboratory.
The time betw eenblood collection and freezing the plasma should not exceed 2 hours.
Ship specimens to the central laboratory according to the instructions provided.
Questions regarding handling the plasma PKspecimens should be addressed to the contact person for the 
sponsor.
Alternative procedures w ill not result in a protocol amendment if approved by the Bioanalysis Scientist.
Preparation of Plasma Pharmacokinetic Samples for Levetiracetam
Collect 1mL of blood into the appropriate K 3-EDTA -containing collection tube (e g, Vacutainer) at each time 
point.
Record the exact date and time of sampling in the CRF or laboratory requisition form, as appropriate.
Gently invert the tubes 8 to 10 times to afford mixing, before processing.
Centrifuge blood samples at room temperatur e within 1 hour(s) of collection at 1,300 g for 10 minutes, unless 
otherwise specified by the supplier, to yield approximately 0.4 mL of plasma from each 1 mL whole blood 
sample.
Transfer all separated plasma immediately with a clean, disposable glass or p olyethylene pipette (use 1 new 
pipette per sample) to a pre -labeled storage tube (3.6 -mL NUNC Cryotube , Cat. No. 366524 or 379189).
Store plasma samples in an upright position in a freezer, at a set temperature of –20C until transfer to the central 
laboratory.
The time betw een blood collection and freezing the plasma should not exceed 2 hours.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
113
Approved, Date: 3 November 2017Ship specimens to the central laboratory according to the instructions provided.
Questions regarding handling the plasma PKspecimens should be addressed to th e contact person for the 
sponsor.
Alternative procedures w ill not result in a protocol amendment if approved by the Bioanalysis Scientist.
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
114
Approved, Date: 3 November 2017Attachment 4: Labeling Instructions for Pharmacokinetic Samples
STRUCTURE OF THE LABEL:
1. Each label has 2 identical parts. 
2. The backing of the label and the label itself are 
perforated.
STEP 1: Remove part 1 of the label and 
completely attach it to the Vacutainer, 
lengthwise . Centrifuge the Vacutainer.
STEP 2: Remove part 2 of the label and attach it to the 
empty plasma storage tube. The label must be attached to 
the tube lengthwise. Labels should be attached to the 
storage tubes at least 12 hours before being frozen to 
ensure proper adherence. You are now  able to match the 
alphanumeric code, subject identification, and time point 
on the plasma collecting tube with the corresponding 
information on the Vacutainer. After the tubes are 
matched, the plasma may be transferred from the 
Vacutainer to the plasma storage tube.
STEP 3: Freeze the sample in an upright position. 
Pack and ship the samples as instructed in the protocol.

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
115
Approved, Date: 3 November 2017Attachment 5: Shipment of Pharmacokinetic Samples
All PKsamples will be sent to the central laboratory at the intervals agreed upon. The laboratory manual from the 
central laboratory provides details regarding packaging and shipment of the samples. The follow ing general 
guidelines should be considered:
For all international shipments, World Courier w ill be used. For domestic shipments, a domestic courier, as 
recommended by the central laboratory, w ill be used.
Notify central laboratory and courier at least 24 hours in advance of the planned shipment. Provide th e courier 
with the appropriate account number to be used, if applicable.
Place the frozen samples for each subject in the appropriate containers, as specified in the central laboratory 
manual.
Pack the frozen samples in sufficient quantity of dry ice, to m aintain a frozen state for at least 3 days.
Avoid direct contact betw een sam ple bags and dry ice, by separating them with a dry ice resistant material (eg, 
newspaper).
For all biological samples, follow  the International Air Transport Association (IATA) regulations for shipment.
Ensure that the total package weight does not exceed 27.2 kg (60 lb).
Label the package with the study number and all other information required by the central laboratory.
Include a return address (which includes the investigator’ s nam e) on the outside of each shipping container.
Com ply with all courier regulations for the shipment of biological specimens (include all paperw ork).
Retain all documents indicating date, time, and signature(s) of person(s) making the shipment, in the s tudy files.
Samples should be shipped via overnight delivery only on Monday through Wednesday, excluding holidays. As 
soon as shipment day and air bill number(s) are available, the site will call, fax, or e -mail the central laboratory. The 
call, fax, or e -mail must specify the study number, the number of PKsamples, and the time of shipment pick -up.
Samples must be sent to the name and address indicated in the central laboratory manual.
NOTE: If there are changes regarding the courier or location to which samples are shipped during the course of the 
clinical study, written notification will be provided to the investigator and will not require (a) protocol 
amendment(s).
RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
116
Approved, Date: 3 November 2017Attachment 6: CBCL -Preschool

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
117
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
118
Approved, Date: 3 November 2017Attachment 7: CBCL School A ge

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
119
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
120
Approved, Date: 3 November 2017Attachment 8: Columbia Suicide Severity Scale: Baseline Version

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
121
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
122
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
123
Approved, Date: 3 November 2017Attachment 9: Columbia Suicide Severity Scale: Since Last Visit Version

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
124
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
125
Approved, Date: 3 November 2017

RWJ -17021 -000(topiramate)
Clinical Protocol TOPMATEPY4067 Amendment INT -6
126
Approved, Date: 3 November 2017INVESTIGA TOR AGREEME NT
LAST P AGE
PPD